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Introduction 
 
Cardiovascular disease (CVD) is common in Chronic Kidney Diseased (CKD) patients and 
considered to be one of the most common causes of death. However the pathogenic mechanisms linking 
CKD with CVD remain poorly understood and thus, therapy is unsatisfactory. Both inflammation, 
abnormal lipid metabolism and bone mineral metabolism abnormalities are thought to play a role. Among 
different inflammatory factors, chemokine (C-X-C) ligand 16 (CXCL16) is a small cytokine belonging to 
the CXC chemokine family that has been linked to lipid metabolism and to vascular disease. Proprotein 
convertase subtilisin/kexin type 9 (PCSK9) is a circulating protein that regulates serum cholesterol levels. 
Subclinical vascular disease may be studied by a variety of techniques, including ultrasonographic 
assessment of pulse wave velocity (PWV) and pulse wave analysis (PWA). Arterial PWV is utilized to 
detect the arterial stiffness. 
 
Hypothesis 
 
The study of biomarkers and the pulse wave assessment will provide insights into the pathogenesis 
and monitoring of CVD in diabetic CKD patients that may eventually lead to improve outcomes. 
 
Objectives 
 
The general objective of this thesis is to characterize potential markers of vascular injury in patients 
with CKD which help understand the pathogenesis of vascular injury in CKD in order to develop novel 
therapeutic approaches, as well as to develop novel monitoring instruments. 
1. To study the distribution of plasma values and the correlates of novel plasma biomarkers in 
diabetic non-dialysis CKD patients. 
2. To study the prevalence and correlates of vascular injury as assessed by pulse wave 
assessment in hypertensive and CKD patients. 
 
 
Patients and Methods 
 
Patients attending the CKD, diabetic kidney disease (DKD) and hypertension clinics not on dialysis 
were studied. This cross-sectional observational study assessed baseline data from the following two 
prospective cohorts of patients. 
· A “biomarker” cohort included 134 diabetic patients with CKD. In these patients the novel 
plasma biomarkers CXCL16 and PCSK9 were assessed.  
· A “Pulse Wave Assessment” cohort included 191 individuals. Of these, 153 were CKD 
patients and 38 non-CKD patients with hypertension or high cardiovascular (CV) risk. In 
these patients pulse wave assessment was performed. 
Both cohorts had in common 54 CKD patients, for whom both pulse wave assessment and 
biomarkers data were available. 
 
Results 
 
1. Biomarker cohort 
 
PCSK9 
The mean±standard deviation (SD) of plasma PCSK9 levels were 309.8±113.9 ng/ml. In 
multivariate models, the only parameters that remained independently significantly positively correlated 
with plasma PCSK9 were the therapy with fibrate alone or fibrate with statin, serum total iron binding 
capacity (TIBC), Log renin and phosphaturia. In general, the multivariate models explain very little of the 
PCSK9 variability. The best R squared obtained was 0.20. 
 
CXCL16 
The mean±SD of plasma CXCL16 levels were 4.0±0.9 ng/ml. Several multivariate models showed 
that estimated glomerular filtration rate (eGFR) and serum albumin remained independently significantly 
negatively correlated with plasma CXCL16, while urinary albumin creatinine ratio (UACR) and serum 
alkaline phosphatase were independently positively correlated with plasma CXCL16. The best R squared 
obtained was 0.34. 
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2. Pulse Wave Assessment cohort 
 
Mean PWV 
The mean±SD of the PWV were 10.9±3.1 m/sec. Different multivariate models showed that 
advanced age, systolic BP, DM, serum uric acid, UACR and resin calcium therapy were independently 
positively correlated with the mean PWV. The best R squared obtained was 0.33. 
 
Delta above upper limit of normal PWV (Delta PWV)  
The mean±SD of the Delta PWV were 0.8±1.6 m/sec. In the multivariate analysis, systolic BP, 
active smoking and resin calcium therapy remained independently positively correlated with delta PWV, 
while age, urinary potassium and beta blocker therapy were independently negatively correlated with 
delta PWV. The multivariate model explain a little of the delta PWV variability with R squared of 0.27. 
 
Subendocardial viability ratio (SEVR; or Buckberg Index) 
In the cohort of diabetic or hypertensive patients, the mean±SD of the SEVR were 141±30 %. In the 
multivariate analysis, age, beta blocker therapy and log 25 hydroxyvitamin D {25(OH)D} independently 
positively correlated with SEVR, while female gender, pulse pressure, mean PWV and proton pump 
inhibitor therapy were independently negatively correlated with SEVR. The multivariate model with the 
highest R squared was 0.39. 
 
Conclusions 
 
The present thesis allows drawing the following conclusions: 
 
1. Plasma PCSK9 values in diabetic CKD patients are very variable and the factors underlying this 
variability are unclear. The use of lipid lowering therapies containing fibrates is associated with higher 
plasma PCSK9. However, PCSK9 did not correlate with features of vascular injury.  
 
2. Plasma CXCL16 values in diabetic CKD patients increased with renal function deterioration and 
albuminuria and correlate with parameters of bone mineral metabolism, but not with features of vascular 
injury.  
 
3. Arterial stiffness was very prevalent in CKD patients. Among modifiable factors associated with 
arterial stiffness we found serum uric acid, albuminuria and potassium metabolism. 
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Introducción 
 
La enfermedad cardiovascular (ECV) es común en la enfermedad renal crónica (ERC) y se considera 
una de las causas más comunes de muerte. Sin embargo, los mecanismos patogénicos que vinculan la 
ERC con la ECV son poco conocidos y, por tanto, el tratamiento no es satisfactorio. Se cree que tanto la 
inflamación como alteraciones del metabolismo metabolismo lipídico y óseo-mineral desempeñan un 
papel importante. Entre los diferentes factores inflamatorios, la quimiocina CXC ligando 16 (CXCL16) se 
ha relacionado con el metabolismo lipídico y con la enfermedad vascular. La proproteína convertasa 
subtilisina/kexina tipo 9 (PCSK9 ) es una proteína circulante que regula los niveles de colesterol en suero. 
La enfermedad vascular subclínica se puede estudiar por varias técnicas, incluyendo la evaluación 
ultrasonográfica de la velocidad de la onda del pulso (VOP) y el análisis de la onda del pulso. La VOP se 
utiliza para detectar la rigidez arterial. 
 
Hipótesis 
 
El estudio de biomarcadores y la evaluación de la onda de pulso proporcionarán información sobre la 
patogenia y la monitorización de las enfermedades cardiovasculares en los pacientes con ERC diabéticos 
que eventualmente puede conducir a mejorar su pronóstico.  
 
Objetivos 
 
El objetivo general de esta tesis es caracterizar posibles marcadores de lesión vascular en pacientes 
con ERC que ayuden a entender la patogenia de la lesión vascular en la ERC con el fin de desarrollar 
nuevos enfoques terapéuticos, así como desarrollar nuevos instrumentos de monitorización. 
1. Estudiar la distribución de los valores plasmáticos y los correlatos de biomarcadores plasmáticos 
novedosas en pacientes con ERC no dializados diabéticos. 
2. Estudiar la prevalencia y los correlatos de la lesión vascular según la evaluación de la onda del 
pulso en pacientes hipertensos y con ERC. 
 
Pacientes y Métodos 
 
Se estudiaron pacientes de las consultas de ERC, enfermedad renal diabética e hipertensión. En este 
estudio transversal observacional se evaluaron datos basales de dos cohortes prospectivas de pacientes. 
• Una cohorte "biomarcadores" incluyó 134 pacientes diabéticos con ERC. En estos pacientes se 
evaluaron los biomarcadores plasmáticos CXCL16 y PCSK9.  
• Una cohorte "evaluación de la onda de pulso" incluyó 191 individuos. De ellos, 153 eran 
pacientes con ERC y 38 pacientes sin ERC con hipertensión o de alto riesgo cardiovascular. En estos 
pacientes se realizó la evaluación de la onda de pulso. 
Ambas cohortes tenían en común 54 pacientes, de los que disponemos tanto de la evaluación de la 
onda de pulso como de datos de biomarcadores. 
 
Resultados 
 
1 . Cohorte de biomarcadores 
 
PCSK9 
La media±desviación estándar (SD) de los niveles de PCSK9 fue 310±114 ng/ml. En los modelos 
multivariados, los únicos parámetros que se correlacionaron de forma positiva e independiente con 
PCSK9 fueron la terapia con fibratos solos o fibratos con estatinas, la trasferrina (TIBC), renina y 
fosfaturia. En general, los modelos multivariados explican muy poco de la variabilidad de PCSK9. La 
mejor R cuadrado obtenida fue de 0,20. 
 
CXCL16 
La media±SD de los niveles de plasma CXCL16 fue 4,0±0,9 ng/ml. Varios modelos multivariados 
mostraron que la tasa de filtración glomerular y la albúmina sérica se correlacionan negativamente de 
forma independiente y significativa con CXCL16, mientras que el índice albúmina creatinina urinaria 
(UACR) y la fosfatasa alcalina en suero se correlacionaron positivamente con CXCL16. La mejor R 
cuadrado obtenida fue de 0,34. 
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2 . Cohorte de evaluación de onda del pulso 
 
Velocidad de la onda del pulso  
La media±SD de la VOP fue 10,9±3,1 m/sec. Diferentes modelos multivariados mostraron que la 
edad avanzada, la presión arterial sistólica, la diabetes mellitus, el ácido úrico en suero, UACR y el 
tratamiento con resincalcio se correlacionaron positivamente de forma independiente con la VOP. La 
mejor R cuadrado obtenida fue de 0,33. 
 
Delta por encima del límite superior de la normalidad de VOP (Delta VOP) 
La media±SD de la Delta VOP fue 0,8±1,6 m/sec. En el análisis multivariado, la presión arterial 
sistólica, el tabaquismo y el resincalcio se correlacionaron de forma independiente y positiva con la Delta 
VOP, mientras que la edad, potasio urinario y beta bloqueantes se correlacionaron de forma 
independiente y negativa con la Delta VOP. El modelo multivariado explica un poco de la variabilidad de 
la Delta VOP con R cuadrado de 0,27. 
 
Coeficiente de viabilidad subendocárdica (SEVR) [Índice Buckberg] 
En la cohorte de pacientes diabéticos o hipertensos, la media ± SD de la SEVR fue 141±30%. En el 
análisis multivariado, la edad, la terapia con beta bloqueantes y la 25 hidroxivitamina D {25(OH)D} se 
correlacionaron de forma independiente y positiva con SEVR , mientras que el sexo femenino, la presión 
del pulso, la VOP y la terapia con inhibidores de la bomba de protones se correlacionaron de forma 
independiente y negativa con SEVR. El modelo multivariado con el mayor R cuadrado fue 0,39. 
 
Conclusiones 
 
La presente tesis permite extraer las siguientes conclusiones: 
 
1. Los valores de PCSK9 plasmáticos en pacientes con ERC diabéticos son muy variables y los 
factores que subyacen a esta variabilidad no están claros. El uso de terapia hipolipemiante con fibratos se 
asocia con niveles de PCSK9 más altos. Sin embargo, PCSK9 no se relacionó con patología 
cardiovascular. 
 
 
2. Los valores de CXCL16 plasmáticos en pacientes diabéticos con ERC aumentan con el deterioro 
de la función renal y la albuminuria, y se correlacionaron con parámetros del metabolismo mineral óseo, 
pero no con patología cardiovascular.  
 
 
3. La rigidez arterial es muy frecuente en los pacientes con ERC. Entre los factores modificables 
asociados con la rigidez arterial se encuentran la uricemia, albuminuria y el metabolismo de potasio. 
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1. Chronic Kidney Disease (CKD) 
 
CKD is a worldwide public health problem with an increasing incidence and prevalence, poor 
outcomes, and high cost. In the United States, at the end of 2011, 615,899 dialysis and transplant patients 
were receiving treatment for end-stage renal disease (ESRD); a 3.2% increase from 2010 (Figure 1) [1]. 
Outcomes of CKD include not only kidney failure but also complications of decreased kidney function 
and CVD. Current evidence suggests that some of these adverse outcomes can be prevented or delayed by 
early detection and treatment [2]. Unfortunately, CKD is underdiagnosed and undertreated, in part, until 
recently, as a result of lack of agreement on a definition and classification of its stages of progression. 
 
 
 
 
Figure 1: Adjusted prevalent rates of ESRD and annual percent change in the United States 
  
Kidney Disease Outcome Quality Initiative (KDOQI) guidelines 1) define CKD and classify its 
stages, regardless of underlying cause, 2) evaluate laboratory measurements for the clinical assessment of 
kidney disease, 3) associate the level of kidney function with complications of CKD, and 4) stratify the 
risk for loss of kidney function and development of CVD.  
CKD is defined as kidney damage or eGFR below 60 ml/min/1.73 m2 or other evidence of kidney 
injury for 3 months or more irrespective of the cause. KDOQI guidelines have classified CKD into 5 
stages (Table 1) [3].  
 
Table 1: CKD stages 
 
 
 
 
More recent Kidney Disease Improving Global Outcomes (KDIGO) guideline defined CKD as 
abnormalities of kidney structure or function, present for more than 3 months, with implications for health 
and CKD is classified based on cause, GFR category, and albuminuria category (CGA) (Table 2) [4]. 
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Table 2: Recent KDIGO CKD staging and prognosis 
 
Persistent albuminuria categories 
Description and range 
A1 A2 A3 
Normal to 
mildly 
increased 
Moderately 
increased 
Severely 
increased 
 
< 30 mg/g 
< 3 mg/mmol 
30-300 mg/g 
3-30 mg/mmol 
> 300 mg/g 
> 30 mg/mmol 
G1 Normal or high > 90    
G2 Mildly decreased 60-89    
G3a Mildly to moderately decreased 45-59    
G3b Moderately to severely decreased 30-44    
G4 Severely decreased 15-29    
G
FR
 c
at
eg
or
ie
s (
m
l/m
in
/1
.7
3m
2 )
 
D
es
cr
ip
tio
n 
an
d 
ra
ng
e 
G5 Kidney failure <15    
 
Green: low risk (if no other markers of kidney disease, no CKD); Yellow: moderately increased risk; 
Orange: high risk; Red: very high risk 
 
Factors affecting initiation and progression of CKD 
CKD is likely to be a multi-hit process. Risk factors for CKD include susceptibility, initiation, and 
progression factors. Susceptibility factors predispose to CKD, whereas initiation factors directly trigger 
kidney damage. Progression factors are associated with worsening of already established kidney damage. 
The aim of identifying susceptibility and initiation factors for CKD is to define individuals at high risk for 
development of CKD; with progression factors, the aim is to define individuals at high risk for worsening 
CKD and subsequent loss of kidney function (Table 3) [5]. Once it is established, CKD progression is 
influenced by a number of modifiable and nonmodifiable risk factors [6]. 
 
Table 3: Summary of risk factors associated with the initiation and progression of CKD 
 
Initiation Factors Progression Factors 
· Systemic Hypertension 
· Diabetes Mellitus 
· Cardiovascular Disease 
· Dyslipidemia 
· Obesity / Metabolic Syndrome 
· Hyperuricemia 
· Smoking 
· Low socioeconomic status 
· Nephrotoxic exposure: 
non-steroidal anti-inflammatory drugs 
(NSAIDS), analgesics, traditional herbal 
use, heavy metal exposure (such as lead) 
· Older age 
· Gender (male) 
· Race / Ethnicity 
· Genetic predisposition 
· Poor blood pressure control 
· Poor glycemia control 
· Proteinuria 
· Cardiovascular disease 
· Dyslipidemia 
· Smoking 
· Obesity / Metabolic Syndrome 
· Hyperuricemia 
· Low socioeconomic status 
· Alcohol consumption 
· Nephrotoxins; NSAIDS, Radiocontrast material 
· Acute Kidney Injury 
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         Nonmodifiable progression risk factors 
Age: The prevalence of CKD rises dramatically with age. Based on the results of the National 
Health and Nutrition Examination Survey 1999-2004 (NHANES), more than one third of those aged 70 
or older have moderate or severe CKD defined as an eGFR <60 ml/min/1.73 m2 [7]. While all stages of 
CKD are more common at older ages, it is the prevalence of moderate CKD (eGFR 30-59 ml/min/1.73 
m2) that increases most dramatically with advancing age. 
 
Gender: The progression rate of many renal diseases is affected by sex [8]. A meta-analysis of more 
than 11000 patients from 68 different studies, demonstrated that renal disease in women with polycystic 
kidney disease, IgA nephropathy, membranous glomerulopathy, and ‘CKD of unknown aetiology’ 
progresses at a slower rate than it does in blood pressure (BP)- and lipid levels-matched men with these 
diseases [9]. Two additional population-based studies showed that men were associated with a worse 
CKD progression than women [10, 11]. 
 
Race: In the United States, for all causes of ESRD, African Americans have a faster rate of 
progression than Caucasians. The incidence and prevalence of diabetic and hypertensive CKD are higher 
in African and Hispanic Americans compared with Caucasians [12]. 
 
Genetics: Studies of linkage and association analyses with candidate gene approaches have 
demonstrated that genetic factors play a crucial role in CKD and ESRD. Recent technologic 
advancements in genome-wide association studies are likely to uncover new CKD susceptibility genes 
[13].  
 
Modifiable progression risk factors 
Hypertension: Systemic hypertension is an important cause, consequence, and presenting feature of 
CKD. It is thought to be one of the leading causes of ESRD worldwide [14]. Experimental and 
epidemiologic studies have shown that sustained hypertension is indeed a significant contributor to the 
progression of CKD [15]. It is believed that the transmission of systemic hypertension into the glomerular 
capillary beds and the resulting glomerular hypertension contribute to the progression of 
glomerulosclerosis. 
 
Lipids: Dyslipidemia may contribute to glomerulosclerosis and tubulointerstitial fibrosis. A number 
of studies of diabetic and non-diabetic nephropathies have confirmed by multivariate analysis that 
dyslipidemia is a risk factor for a faster rate of CKD progression [15]. 
 
Proteinuria: A large number of studies in patients with diabetic and non-diabetic glomerular and 
nonglomerular diseases confirmed, by multivariate analysis, that heavy proteinuria is associated with a 
faster rate of CKD progression [16, 17]. Furthermore, reduction of proteinuria by diet, angiotensin-
converting enzyme inhibitor (ACEI), or angiotensin receptor blocker (ARB) predicts a better outcome 
[17]. The extent of reduction in proteinuria is often proportional to the benefit accrued by such 
intervention on CKD progression.  
 
Albuminuria, CKD, and CVD: Urinary albumin excretion rate (UAER) is independently 
associated with the presence and severity of CVD in the general population [18]. Even low-grade 
albuminuria (below the current microalbuminuria threshold UACR <30 mg/g) in middle-aged non-
diabetic and non-hypertensive individuals is associated with increased CV risk. Diffuse endothelial and 
vascular dysfunction may be the common pathway linking albuminuria to the manifestations and 
prognosis of CKD and CVD. Albuminuria has been linked in a number of studies to underlying systemic 
atherosclerosis, diffuse vascular stiffness, and maladaptive vascular remodeling [19, 20]. 
CKD is now defined as a CV risk equivalent, and patients with moderate to severe CKD are taken to 
be in the “highest risk group” for development of CVD [16, 17]. Patients with CVD are also at a higher 
risk for development of CKD. Overall, these observations may, in part, be explained by the fact that CVD 
and CKD share many risk factors, including obesity, metabolic syndrome, hypertension, diabetes mellitus 
(DM), dyslipidemia, and smoking. In addition, CVD may have direct hemodynamic effects on the 
kidneys that may promote initiation and progression of CKD, including decreased kidney perfusion in 
heart failure and atherosclerosis of the renal arteries, with subsequent ischemic nephropathy. Evidence is 
linking faster rate of CKD progression to severe atherosclerotic disease [21]. 
 
Renin-Angiotensin-Aldosterone System (RAAS): The links between systemic hypertension, 
proteinuria/albuminuria, and CVD may be mediated in part by changes in the RAAS in CKD. A number 
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of experimental and clinical data have implicated the RAAS in the pathogenesis of hypertension, 
proteinuria, and renal fibrosis throughout the course of CKD. Consequently, interventions aimed at 
inhibition of the RAAS have been proved to be extremely effective in slowing the progression of CKD 
[22]. 
 
Glycemia: Randomized clinical trials have demonstrated that tight diabetes control can potentially 
slow the rate of progression of diabetic microvascular complications, including diabetic nephropathy in 
both type 1 and type 2 DM [23]. 
 
Inflammation and CKD: Cross-sectional studies show that patients with CKD have a pronounced 
inflammatory phenotype, including an elevated serum concentration of inflammatory markers, such as C-
reactive protein (CRP) and interleukin (IL)-6, and decreased serum albumin levels [24, 25]. A 
retrospective analysis of data from 9,250 adults enrolled in NHANES II confirmed systemic inflammation 
as an independent risk factor for future development of CKD [26].  
  
Obesity: Several studies have linked obesity, and the associated metabolic syndrome, with 
increased risk of CKD. Anecdotal reports suggest that weight reduction reduces obesity-related renal 
hemodynamic changes as well as CKD-associated proteinuria, and increased weight gain is associated 
with its progression [27]. 
 
Smoking: Smoking has been shown to increase the risk of albuminuria as well as that of 
progression of CKD. Possible mechanisms whereby cigarette smoking may contribute to kidney damage 
include sympathetic nervous system activation, hypertension, endothelial injury, and potential direct 
tubulotoxicity [28]. 
 
Uric Acid: Hyperuricemia has been associated with systemic hypertension, CVD, and CKD [29]. 
Hyperuricemia may cause hypertension and renal injury through crystal-independent pathways, notably a 
stimulation of the RAAS. However, not all observational studies confirm the association between uric 
acid and CKD progression. An observation from the United States suggested that in patients with CKD, 
hyperuricemia appears to be an independent risk factor for all-cause and CVD mortality but not for 
kidney failure [30]. Nevertheless treating hyperuricemia slowed progression of CKD in an open label 
randomized controlled trial from Spain [31]. 
 
2. Diabetic kidney disease (DKD) 
 
           Around 10% of the population of Western countries is diabetic. The current obesity epidemic is 
expected to increase the incidence of type 2 DM, which accounts for 90% of DM cases. In the United 
States, 40% of adults with DM have some degree of CKD [32]. Prevalence of DKD increased from 1988 
to 2008 in proportion to the prevalence of DM, from 2.2% in NHANES III to 3.3% in NHANES 2005-
2008. Among persons with DM, prevalence of DKD was stable despite increased use of glucose-lowering 
medications and RAAS inhibitors [33]. DKD is characterized by proteinuria and progressive loss of renal 
function leading to ESRD requiring renal replacement therapy. The pathological substrate of DKD is a 
progressive loss of parenchymal renal cells, inflammation and extracellular matrix accumulation. DKD 
remains the most frequent cause of ESRD in developed countries. This means that current 
nephroprotective strategies, based on targeting the RAAS are insufficient to stop progression of the 
disease in a sizable number of DM patients. Only a comprehensive understanding of the molecular basis 
for renal injury initiation and progression will allow the rational design of novel, more successful 
therapeutic strategies [34]. 
 
The expanding spectrum of DKD: non-albuminuric renal insufficiency 
Microalbuminuria (UAER between 30 and 300 mg/day or mg/g creatinine) is considered the earliest 
clinical marker of DKD. Microalbuminuria precedes the development of macroalbuminuria (UAER > 300 
mg/day or mg/g creatinine). The onset of macroalbuminuria is usually followed by a slowly progressive 
decline in GFR and ESRD [35]. Albuminuria occurs secondary to podocyte injury (podocytopathy) [36]. 
DM causes hypertrophy of podocytes, and initial relative and subsequent absolute podocytopenia due to 
initial increase in glomerular volume and later detachment or apoptosis of podocytes [37]. 
Normoalbuminuric patients are not completely protected from DKD, which may develop insidiously and 
progress silently to renal failure [38]. Around 25 to 35% of diabetic patients with impaired GFR have no 
increased albuminuria [39, 40]. In NHANES III, among adults with type 2 DM and CKD, only 45% and 
19% had microalbuminuria and macroalbuminuria, respectively. The population estimate of adults with 
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type 2 DM and CKD in the absence of diabetic retinopathy or albuminuria was approximately 0.3 million. 
In type 1 DM patients enrolled in the Epidemiology of Diabetes Interventions and Complications 
(EDIC)/Diabetes Control and Complications Trial (DCCT) studies the cumulative incidence of stage 3 
CKD (eGFR <60 ml/min/1.73 m2) was 11.4% over 14-19 years. Of patients developing stage 3 CKD 24% 
had albuminuria <30 mg/24h at all prior evaluations, 16% had developed microalbuminuria (30-300 
mg/24 h) and 61% had macroalbuminuria (>300 mg/24 h) before they reached stage 3 CKD [39]. In the 
EDIC study ten-year cumulative incidences of progression to macroalbuminuria, impaired GFR, ESRD, 
and regression to normoalbuminuria were 28%, 15%, 4%, and 40%, respectively. After the development 
of persistent microalbuminuria, intensive glycemic control, lower BP, and a more favorable lipid profile 
are associated with improved outcomes [35]. The rate of loss of GFR is lower in patients with stable 
microalbuminuria or regression to normal albuminuria compared to patients who progressed to 
macroalbuminuria [39]. The factors responsible for GFR loss in non-proteinuric DKD patients have not 
been identified [41, 42]. Intrarenal vascular disease may contribute. However, non-proteinuric DKD also 
occurs in type 1 DM patients who are generally younger and less likely to have high intrarenal vascular 
resistance [43]. Genetic backgrounds may prevent development of proteinuria in face of DKD. Low-grade 
chronic inflammation may also contribute to DKD [44-46]. Elevated serum inflammatory markers are 
associated with decline of GFR in nonproteinuric DKD patient, independent of UAER [47].  
 
The conundrum of DKD management 
Current treatment strategies for DKD include lifestyle improvements (cessation of smoking and 
dietary modifications), glycemic control, cholesterol management and reduction of BP [32]. The 2012 
update of American Diabetes Association (ADA) guidelines [48] recommends optimization of glycemic 
and BP control to reduce the risk of progression of DKD as the cornerstone of the treatment (A evidence). 
Lowering HbA1C to below or around 7% has been shown to reduce microvascular and neuropathic 
complications of type 1 and type 2 DM. Postprandial glucose may be targeted if HbA1C goals are not met 
despite reaching preprandial glucose goals. Glycemic management of type 2 DM has been recently 
reviewed [49] and focused on drug therapy aimed at preventing, slowing or regressing DKD beyond 
glycemic control. Hypertension is common in diabetic patients, even in the absence of DKD. The 
recommended BP target in diabetic patients is 125/75 mmHg to prevent both DKD progression and CV 
events [48]. ACEIs or ARBs are the elective drugs to treat hypertension in DKD (evidence A). Other 
drugs to control BP (diuretics, calcium channel blockers, beta-blockers or alpha-blockers) may be used 
for adequate BP control in diabetic patients under RAAS inhibitors [50]. 
 
RAAS targeting: ACEI, ARB, renin inhibitors and mineralocorticoid receptors blockers are 
designed to block the RAAS system. ACEIs and ARBs have been most studied in the setting of 
hypertension in diabetes. In diabetic patients with micro- or macroalbuminuria, either ACEIs or ARBs 
decreased urinary protein excretion in a dose-dependent manner and should be given at the maximum 
dose which could be tolerated [51, 52]. There are no adequate comparisons of ACEIs vs. ARBs. However 
in clinical trials, ACEIs delay the progression of nephropathy in patients with type 1 DM, hypertension, 
and any degree of albuminuria [53], both ACEIs and ARBs delay the progression to macroalbuminuria in 
patients with type 2 DM, hypertension, and microalbuminuria, and ARBs delay the progression of 
nephropathy in patients with type 2 DM, hypertension, macroalbuminuria, and renal insufficiency 
(eGFR<60 ml/min/1.73m2) [48, 54, 55]. 
A further concept is DKD prevention in normotensive, normoalbuminuric patients [56]. The role of 
RAAS blockade to prevent the appearance of microalbuminuria in normotensive, normoalbuminuric 
patients is not well defined. Perindopril delayed the increase in albuminuria in 89 normotensive 
normoalbuminuric type 1 DM patients [57]. In 156 normotensive, normoalbuminuric patients with type 2 
DM, ACEI reduced transition to microalbuminuria from 19% placebo to 6.5% enalapril in 6 years of 
follow-up [58]. EUCLID (EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes) 
reported a non-significant reduction in incidence of increased albuminuria in 530 normotensive patients 
with type 1 DM [59]. The DIRECT-Renal investigators studied 5231 diabetics and concluded that 
candesartan had no effect on the primary prevention of increased urinary albumin excretion during 4.7 
years in normoalbuminuric, normotensive patients with type 1 DM or normoalbuminuric patients with 
type 2 DM who were either normotensive or hypertensive [60]. The RASS investigators studied 288 
normotensive, normoalbuminuric type I diabetics with renal biopsies and concluded that there were no 
structural or functional benefits to the kidney from blockade of the RAAS with either an ACEI or ARB 
[61]. 
While targeting the RAAS, it is important to monitor serum creatinine and potassium since there is a 
risk of hyperkalemia or impairment of renal function. Targeting the system sets off compensatory 
mechanisms that may increase angiotensin II, aldosterone or renin and may account for delayed increases 
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in albuminuria following an initial decrement. Thus, hyperplasia of the renin-secreting juxtaglomerular 
apparatus has been described in experimental animals and in humans [62]. It has been hypothesized that 
partial RAAS blockade lies behind the failure to prevent progression in some DKD patients. In this 
regard, dual blockade of the RAAS has been proposed to overcome compensatory mechanisms. However, 
dual or triple blockade of the RAAS increases the risk of adverse events such as hyperkalemia or 
hypotension, especially in older patients [63]. 
 
Combined RAAS blockade: Combination of different drugs targeting the RAAS decreases 
albuminuria more than just one drug [64, 65]. However safety concerns have been raised by a number of 
studies, including ONTARGET (Ongoing Telmisartan Alone and in combination with Ramipril Global 
Endpoint Trial) and ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using CV and Renal Disease 
Endpoints) and the efficacy to impact long-term renal function has not yet been demonstrated. 
COOPERATE is a key trial exploring the ACEI/ARB combination in non-diabetic kidney disease that 
showed protection from progression of CKD in 3 years. However it was withdrawn after serious concerns 
about the authenticity of the results were raised [66]. A 2006 meta-analysis on the combination of ACEIs 
and ARBs in renal disease disclosed reduction of proteinuria and renoprotection in patients with 
proteinuric CKD [67]. However the benefits of double blockade of RAAS were greater in patients with 
non-diabetic renal disease than in DKD despite similar BP control. 
The ONTARGET trial studied patients older than 55 years that had diabetes with organ damage and 
vascular disease. Subjects were treated with telmisartan, ramipril or the combination for a median of 56 
months. Double blockade resulted in lower BP and proteinuria, but the incidence of hyperkalemia and the 
incidence of renal replacement (dialysis, transplantation) or death were increased [63]. The VA 
NEPHRON-D (Veterans Affairs Nephropathy in Diabetes study) trial did not evidence advantages of 
lisinopril/losartan over losartan alone regarding CKD progression in terms of reduction of eGFR, in a 
total of 1850 patients with overt proteinuria [68].  
The direct renin inhibitor aliskiren is Food and Drug Administration (FDA) approved as an anti-
hypertensive medication. Aliskiren on top of optimal antihypertensive treatment including an ARB 
reduced urinary albumin excretion 20% in microalbuminuric type 2 DM patients in the Aliskiren in the 
evaluation of proteinuria in diabetes (AVOID) trial [69, 70]. However, a metanalysis raised concerns on 
the excess occurrence of hyperkalemia in patients enrolled in clinical trials [71]. The ALTITUDE trial 
was terminated because patients randomized to aliskiren experienced a higher incidence of kidney 
impairment, hypotension and hyperkalemia. ALTITUDE randomized 8606 high risk type 2 DM patients 
to receive aliskiren or placebo added to recommended cardio-renal protective treatment including ACEIs 
or ARBs, but not both [72]. Primary outcome measures included CV events as well as ESRD and 
doubling of serum creatinine. 
Aldosterone has direct effects promoting inflammation and fibrosis. Despite no changes in blood 
glucose levels or BP, spironolactone significantly decreased urinary albumin excretion when used alone 
[73]. Spironolactone also has an additive effect on proteinuria when used in combination with an ACEI or 
an ARB in both type 1 and type 2 DM [74]. Co-administration of the aldosterone antagonist eplerenone 
with an ACEI in type 2 DM decreased UAER compared to the placebo group. There was a significant 
increase in hyperkalemia episodes with the higher (100 mg/d), but not the lower (50 mg/d) eplerenone 
dose [75]. However, the effect on long-term preservation of renal function by aldosterone targeting has 
not been addressed. 
In April 2014, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European 
Medicines Agency (EMA) has advised that combining different classes of medicines that act on RAAS 
should not be recommended, and in particular that patients with DKD should not be given an ARB with 
an ACE-inhibitor. Where such combination (dual blockade) is considered absolutely necessary, it must be 
carried out under specialist supervision with close monitoring of kidney function, fluid and salt balance 
and blood pressure. (This would include the licensed use of the ARBs candesartan or valsartan as add-on 
therapy to ACE-inhibitors in patients with heart failure who require such a combination.) The 
combination of aliskiren with an ARB or ACE-inhibitor is strictly contraindicated in those with kidney 
impairment or diabetes (EMA/196502/2014) [76]. 
 
Beyond the RAAS: Given the limitations of RAAS blockade, attempts have been made to improve 
the outcome of DKD using different add-on strategies. Recent clinical trials have targeted albuminuria or 
GFR by adding to conventional ARB- or ACEI-based therapy drugs such as vitamin D receptor (VDR) 
activators, bardoxolone, endothelin receptor antagonists, pirfenidone, pyridoxamine, sulodexide, 
pentoxifylline or ruboxistaurin [77-84].  
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3. Cardiovascular Risk in Diabetic CKD 
 
Cardiac diseases are independently associated with a deterioration of renal function and worsening 
of existing kidney disease. On the other hand, CKD is an independent risk factor for increased CV 
morbidity and mortality [85]. CV and total mortalities are 10- to 100-fold higher in ESRD patients than in 
age-matched controls. Indeed, the risk of CV death of a 30-year-old ESRD patient is similar to that of an 
80-year-old in the general population [86, 87]. Thus, ESRD may be considered an accelerated aging 
syndrome. CVD in CKD has a complex pathogeneses, and traditional risk factors are not able to fully 
explain its high incidence and prevalence [88] and interventions that have been successful in the general 
population have failed to increase survival in ESRD patients [89, 90]. 
Both albuminuria and GFR are believed to be risk factors for CV events. There are limited data as to 
whether these two factors are associated with adverse outcomes independently not only of other known 
CV risk factors but also of each other in patients with type 2 DM [91]. The Action in Diabetes and 
Vascular Disease: Preterax and Diamicron MR Controlled Evaluation (ADVANCE) study [92] showed 
that high albuminuria and low GFR are independent risk factors for CV events among patients with type 2 
DM. However, the two main clinical features associated with DKD, diabetic retinopathy and albuminuria, 
were detected in only 7.1 and 29.3% of patients, respectively [93] and 62% of patients with a GFR <60 
mL/min did not have concurrent albuminuria [92]. 
The Nephropathy In Diabetes-Type 2 (NID-2) study [94] was originally designed to investigate the 
prevalence of CV risk factors, their management and the achievement of international guideline targets in 
a large population of type 2 DM patients with a clinical diagnosis of classical diabetic nephropathy 
defined by the concomitance of albuminuria and severe diabetic retinopathy, followed up in the tertiary 
care setting. The cross-sectional phase of the NID-2 study pointed out that patients with diabetic 
nephropathy are characterized by clusters of risk factors, not at target, compatible with a high CV risk 
profile [94]. 
 
Cardiovascular disease in diabetic patients with macroalbuminuria 
The role of macroalbuminuria in CVD has been outlined in the post-hoc analyses of the Irbesartan 
Diabetic Nephropathy Trial (IDNT) and the Reduction of End points in NIDDM with the Angiotensin II 
Antagonist Losartan (RENAAL) studies. The IDNT enrolled subjects with type 2 DM, hypertension, and 
macroalbuminuria [54]. Irbesartan proved to be superior to amlodipine or placebo with respect to 
renoprotection but no difference was detected between treatment groups on the secondary outcome of CV 
events. A post hoc analysis performed to assess the relationship between baseline UACR and the CV 
composite (CV death, nonfatal myocardial infarction, hospitalization for heart failure, stroke, amputation, 
and coronary and peripheral revascularization) revealed in a multivariate analysis that albuminuria is an 
independent risk factor for CV events with a 1.3-fold increased relative risk for each natural log increase 
of 1 U in UACR [95]. 
Similar results were noted in the RENAAL study whereby losartan was superior to placebo with 
regards to renoprotection in type 2 diabetic, hypertensive patients with macroalbuminuria. However 
losartan conferred no statistically significant benefit on the secondary CV outcomes, although de novo 
heart failure was less frequently noted in the losartan group [96]. Nevertheless, in a post-hoc analysis of 
RENAAL, baseline albuminuria was again shown to be a predictor of both the prespecified composite CV 
end point (composite of myocardial infarction, stroke, first hospitalization for heart failure or unstable 
angina, coronary or peripheral revascularization, or CV death) as well as of heart failure alone. With 
subjects stratified into 3 groups on the basis of baseline UACR, comparison of the highest tertile with the 
lowest revealed an adjusted hazard ratio of 1.92 for the composite CV end point and 2.70 for heart failure. 
In multivariate analysis, baseline albuminuria was the strongest independent predictor of both outcomes. 
In addition, the change in UACR from baseline to 6 months was the only dynamic correlate of adverse 
CV outcomes. A 50% reduction in baseline albuminuria translated into an 18% reduction in the 
composite CV end point and a 27% reduction in the risk of heart failure. It has thus been suggested that 
albuminuria serve as an indicator of therapeutic response. 
 
Cardiovascular disease in diabetic patients with microalbuminuria 
Microalbuminuria also correlates with adverse CV events. In type 2 DM microalbuminuria was the 
strongest predictor of adverse CV outcomes with an odds ratio of 10.02 [97]. In addition, in the Heart 
Outcomes Prevention Evaluation (HOPE) study, a baseline UACR >20 mg/g (present in 33% of the 
diabetic cohort and in 15%of the non-diabetic cohort) increased the adjusted relative risk of CV events 
(1.83), all-cause death (2.09), and hospitalization for congestive heart failure (3.23). In addition, the 
impact of microalbuminuria on the primary composite outcome of CV death, myocardial infarction, or 
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stroke was significant in both diabetic (relative risk 1.97) and non-diabetic (relative risk 1.61) subjects 
[98].  
 
Cardiovascular disease in diabetic patients with low GFR 
Declining renal function plays an important role in CVD in diabetic patients, as demonstrated in the 
Valsartan in Acute Myocardial Infarction (VALIANT) trial; a multicentre double-blind randomized 
controlled trial which randomly assigned patients to receive captopril, valsartan, or both. GFR was 
estimated using the 4-component Modification of Diet in Renal Disease (MDRD) equation. The 
likelihood of experiencing the primary end-point of all-cause mortality was higher in patients with than 
without DM for each level of renal function. In patients with DM, a decrease in eGFR of 10 units was 
associated with a hazards ratio of 1.09 (95% confidence interval (CI) 1.06 to 1.12, p <0.001) for risk of 
fatal and nonfatal CV outcomes independent of treatment assignment [99]. The importance of renal 
impairment in predicting outcome following myocardial infarction in diabetic patients was also 
investigated and shown that the combination of renal impairment and DM was associated with a 
particularly high risk of myocardial infarction and death/ myocardial infarction following a non-ST 
elevation myocardial infarction, suggesting that attention to preserving renal function may be of particular 
benefit for reducing CV risk in diabetic patients [100]. 
 
DKD and peripheral arterial occlusive disease 
Peripheral arterial occlusive disease (PAOD) is a major cause of morbidity. PAOD carries a 
particularly poor prognosis in DM [101, 102]. DKD has been reported to be associated with PAOD in 
both type 1 and type 2 DM subjects [103]. Both albuminuria and declining GFR are probably associated 
with increased risk. PAOD is more prevalent in type 2 DM patients with increased UACR [104, 105]. It is 
likely that microalbuminuria reflects widespread vascular damage. In addition, a reduction in GFR is 
associated with PAOD in both non-diabetic [106] and diabetic patients [104, 105]. Albuminuria and 
declining renal function are also independent predictors of the occurrence of PAOD in non-Caucasian 
populations in both genders [107]. Interestingly, in a type 2 DM populations with proliferative diabetic 
retinopathy declining renal function was an independent predictors of PAOD, whilst microalbuminuria 
was not [108, 109].  
In type 2 DM patients with normal ankle-brachial indices (ABIs), eGFR correlated positively with 
flow volume and negatively with ankle-brachial PWV and with resistive index in patients with 
albuminuria but not in those with normoalbuminuria [110]. This suggests an association between 
nephropathy and impaired lower limb circulation secondary to higher arterial stiffness and increased 
vascular resistance in type 2 DM. In Japanese type 2 DM patients with normal ABIs the major risk factors 
for reduced flow volume were age, hypertension, and DKD [111]. These results suggest that DKD may 
plays a role in the early stages of PAOD in diabetes by altering vascular resistance and arterial stiffness.  
 
Cardiovascular consequences of DKD 
Disturbed renal function in DKD leads to a multitude of adverse CV effects (Figure 2) [109]. 
Increased BP together with accelerated large vessel disease and increased arterial stiffening and 
calcification lead to increased afterload whilst hypervolemia and anemia lead to increased preload with 
consequent adverse effects on the heart. These cardiac abnormalities are further augmented by the local 
activation of the RAAS and endothelin system, amongst others. The RAAS plays a role in the activation 
of the sympathetic nervous system, the dysregulation of endothelial function and progression of 
atherosclerosis, and inhibition of the fibrinolytic system, while direct profibrotic actions of angiotensin II 
and aldosterone in the kidney and heart promote end-organ injury [112]. 
 
High blood pressure predisposes CVD, CKD and predates the onset of DKD. However high BP is 
also a consequence of renal disease, thereby initiating a vicious cycle resulting in progression of CKD as 
well as in CKD being causally related to increased CV risk [113]. 
 
Left ventricular hypertrophy (LVH) is an important risk factor for adverse CV outcomes in 
patients with CKD and in type 2 DM subjects with and without DKD [114]. In addition, LVH increases 
with progression of nephropathy [115, 116]. Multiple factors may contribute to LVH, including high BP, 
vascular stiffening, anemia, CV autonomic neuropathy, uremia toxins and albuminuria [117, 118]. 
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Figure 2: Cardiovascular Consequences of DKD 
 
Left ventricular (LV) diastolic dysfunction is another adverse cardiac effect. DKD is a significant 
predictor of LV diastolic dysfunction in CKD subjects, independent of other influencing factors such as 
age, BP, renal function, anemia and LVH. LV diastolic dysfunction is characterized by elevated LV end-
diastolic pressure or left arterial pressure, ultimately leading to LV systolic dysfunction and overt heart 
failure symptoms [119].  
 
Mitral annular calcification predicts atrial fibrillation, stroke and CV disease morbidity and 
mortality. In the Framingham Heart Study, the combination of both CKD and mitral annular calcification 
was associated with a three-fold increased risk of death compared with those without CKD or mitral 
annular calcification (p<0.01), following adjustment for age and gender. However, no significant 
association was found between CKD and either aortic sclerosis or aortic annular calcification [120]. 
 
Ischemic heart disease is strongly associated with DKD. Patients with both ESRD and DM carry 
an increased risk of coronary atherosclerosis. In addition to coronary atherosclerosis, abnormalities in 
myocardial blood flow and in coronary flow reserve could be responsible for CV morbidity in DKD. In 
the presence of end-organ damage caused by DM, abnormalities in coronary physiology may be seen in 
the absence of overt epicardial coronary artery disease [121].  
 
In addition to arterial changes, reduction in capillary density interferes with oxygen delivery in 
CKD. In uremic subjects with LVH, there is a significant decrease in capillary density, leading to an 
increase in inter-capillary distance, and potentially compromising the blood and oxygen supply of the 
myocardium under conditions of increased demand, thus rendering the myocardium more prone to 
ischemic injury [122].  
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Potential pathogenic mechanisms 
Various mechanisms account for the CV dysfunction present in renal disease, as outlined below. 
 
Endothelial cell dysfunction: The vascular endothelium is a versatile multifunctional tissue having 
many synthetic and metabolic properties (Figure 3) [109].  
 
 
 
 
 
Figure 3: Endothelial Cell Properties and Functions 
 
Endothelial cell dysfunction seems to be central in the genesis of many different aspects of CV 
dysfunction in subjects with DKD, such as increased PWV [123] and decreased flow-mediated dilation 
(FMD) of the brachial artery [124]. The various factors leading to endothelial cell dysfunction have been 
outlined in (Figure 4) [125]. Endothelium-dependent vascular dysfunction, as assessed using FMD, 
correlates with proteinuria in type 2 DM subjects with early DKD. Interestingly, no correlation was found 
between proteinuria and nitroglycerine-mediated dilation (NMD) of the brachial artery. This suggests that 
the bioavailability of nitric oxide (NO) is decreased, but that the vessels remain responsive to NO in 
DKD. Proteinuria might lead to endothelial dysfunction via increasing serum levels of the nitric oxide 
synthase (NOS) inhibitor asymmetrical dimethylarginine (ADMA), together with loss of vasoprotective 
circulating proteins such as adiponectin and fetuin [124]. 
 
 
 
 
Figure 4: Factors inducing endothelial dysfunction and its role in the pathogenesis of cardiovascular 
disease events 
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ADMA is an endogenous competitive NOS inhibitor that can be metabolized by dimethylarginine 
dimethylaminohydrolase (DDAH) or excreted by the kidneys. ADMA is increased in patients with 
increased CV risk [126] and predicts future CV events [127]. Accumulation of ADMA in CKD could 
promote atherosclerosis and is related to macrovascular disease in patients with type 1 or type 2 DM and 
macroalbuminuria [128]. In type 2 DM patients with albuminuria, increased ADMA was also linked to 
declining GFR and subclinical inflammation, as assessed using high sensitivity C-reactive protein 
(hsCRP) [129]. 
In addition to its direct inhibitory effect on endothelial NOS, ADMA may cause endothelial 
dysfunction via other mechanisms. These include increased superoxide production by activation of 
NADPH-oxidase (nicotinamide adenine dinucleotide phosphate-oxidase), thereby interfering with NO 
bioavailability; activation the local RAAS, thus contributing to the development of arteriolar dysfunction 
and increased tone; and a decrease in the number of circulating endothelial progenitor cells (EPCs), 
possibly interfering with vascular repair mechanisms [130]. 
Insulin resistance also plays an important role in endothelial dysfunction. Insulin resistance has been 
associated with renal disease in both types 1 [131] and type 2 [132] DM, thereby offering another 
possible explanation of the association between CV disease and DKD.  
Endothelial cell injury has recently been linked to increased shear stress [133]. The latter is known 
to be associated with high BP. 
Plasma levels of the soluble RAGE are strongly associated with CVD in patients with DKD [134]. 
RAGE induces the production of adhesion molecules and inflammatory cytokines, thus promoting 
endothelial and renal dysfunction, low grade inflammation and vascular remodeling. Through these 
mechanisms, RAGE may contribute to both DKD and CV disease. 
Elevated levels of uric acid have been associated with inflammation, oxidative stress, insulin 
resistance, dysglycemia, endothelial dysfunction, vascular stiffness, cardiac diastolic dysfunction, renal 
hyperfiltration and proteinuria [135]. Uric acid decreases NO production [136]. Experimental 
hyperuricemia causes afferent renal arteriolopathy and tubulo-interstitial fibrosis in the kidney by 
activating the RAAS [137]. Uric acid also activates cytoplasmic phospholipase A2 and NF-κB [138] and 
increases inflammation [139]. Lowering uric acid reduces tubulointerstitial fibrosis both in the 5/6th 
nephrectomised model [140] and in diabetic nephropathy [141]. Additionally, withdrawing uric acid—
lowering therapy increases urinary transforming growth factor beta 1 (TGFβ-1) in hyperuricemic patients 
with CKD [142]. The putative mechanisms by which increased serum uric acid may contribute to CKD 
onset and progression are illustrated in (Figure 5) [135]. 
 
 
 
 
 
Figure 5: Putative mechanisms by which elevated serum uric acid level may contribute to CKD 
development, progression and atherosclerosis 
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Activation of the RAAS in DKD results in endothelial dysfunction. When angiotensin II activates 
the AT1 receptor, it stimulates the generation of reactive oxygen species by NAD(P)H oxidase and other 
enzyme systems, leading to upregulation of inflammatory mediators, which include cytokines, 
chemokines, adhesion molecules, and plasminogen activator inhibitor 1, and superoxide scavenging of 
NO. These events promote endothelial dysfunction, vascular remodeling and the progression of 
atherosclerosis [143].  
Hyperhomocysteinemia may also play a role in endothelial dysfunction. Elevated plasma 
homocysteine levels are associated with albuminuria in both type 1 [144] and type 2 DM [145]. The 
increased susceptibility of diabetic subjects to hyperhomocysteinemia may be secondary to an 
acceleration of glucose-induced oxidative stress on endothelial cells [144]. This hypothesis is supported 
by animal studies showing that homocysteine-induced endothelial dysfunction occurs much more readily 
in the presence of diabetes than in its absence [146]. However, in clinical trials treatment of 
hyperhomocysteinemia did not improve outcomes. 
 
Endothelial progenitor cells (EPCs): Bone marrow-derived EPCs in peripheral circulation 
contribute to re-endothelialization of injured vessels as well as to neovascularization of ischemic lesions 
and therefore play a key role in maintaining the integrity of the vascular system. Various factors influence 
the number and function of EPCs. Mild-to-moderate renal dysfunction accompanying stable angina has 
been shown to be associated with EPC depletion, irrespective of angiographic coronary artery disease 
extent. This may exacerbate an imbalance between endothelial injury and EPC-mediated repair, thus 
contributing to high CV risk in coronary artery disease coexisting with renal insufficiency. In addition, 
the number of EPCs is decreased in both patients with type 1 and type 2 DM [130].  
 
Inflammation: CKD results in a chronic, low-grade inflammatory process that becomes evident 
even in the early stages of the disease. Circulating levels of inflammatory markers, such as CRP and 
interleukin-6 (IL-6), are elevated in CKD patients. There is a relationship between inflammatory 
activation of peripheral blood mononuclear cells and UACR in type 2 DM. Increased inflammation could 
thus play a role in accelerated atherosclerosis and increased CV risk associated with DKD [147].  
 
Advanced glycosylation end-products (AGEs): AGEs are products of non-enzymatic glycation 
and oxidation of proteins and lipids that are increased in situations with hyperglycemia and oxidative 
stress such as DM. The kidney plays an important role in clearance and metabolism of AGEs. In CKD, 
AGE concentrations increase, partly by an increase in oxidative and carbonyl stress. AGEs and their 
receptors are thought to play an important role in the pathophysiology of DKD and vascular injury [148, 
149].  
 
Lipoprotein abnormalities: Lipoprotein abnormalities also play a role. DKD is characterized by 
low high-density lipoprotein (HDL)-concentrations and elevated intermediate-density lipoprotein (IDL), 
both of which contribute to an increased CV risk. Elevated serum creatinine has a greater impact than 
albuminuria on abnormalities in IDL and HDL [150]. In addition, in diabetic patients, serum lipoprotein 
(a) concentration is associated with albuminuria, further contributing to the elevated CV risk [151]. 
 
Adhesion molecules: Elevated plasma concentrations of soluble adhesion molecule concentrations 
in patients with DKD could be markers of atherosclerosis and increased CV risk. Thus, plasma 
concentration of soluble intercellular adhesion molecule-1 (sICAM-1) is elevated in type 1 DM patients 
with microalbuminuria and also the concentrations of sICAM-1 are elevated in patients with 
macroalbuminuria and normal serum creatinine [152]. 
 
Hyperfibrinogenaemia: Hyperfibrinogenaemia is a CV risk factor. Fibrinogen was higher in 
albuminuric type 2 DM subjects than in type 2 DM normoalbuminuric patients [153]. 
 
Cardiac autonomic neuropathy: In type 2 DM patients, cardiac autonomic neuropathy and DKD 
were independently associated with asymptomatic coronary artery disease [154]. In type 1 DM patients 
with nephropathy, cardiac autonomic neuropathy assessed as heart-rate variation during deep breathing 
was an independent risk factor for CV morbidity and mortality [155]. In addition, autonomic neuropathy 
may be associated with increased central arterial stiffness [156].The mechanisms of increase CV 
morbidity and mortality by cardiac autonomic neuropathy are still under debate. Suggested mechanisms 
include impaired central control of respiration in patients with cardiac autonomic neuropathy [157]; 
exercise intolerance with a reduced response in heart rate and BP and decreased cardiac output during 
exercise; and possibly QT prolongation [158, 159]. 
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Other possible links between cardiovascular disease and DKD 
Several additional hypotheses have been proposed to explain the link between the CKD and CVD 
[122]. Local factors may play a role in the cross-talk between the kidney and the CV system. It was 
hypothesized that enzymes involved in the proteoglycan metabolism are the primary cause of albuminuria 
and the associated complications [160]. However, there is little evidence supporting this hypothesis. An 
alternative hypothesis is a common glycocalyx defect in the glomerulus and in the systemic circulation. 
The endothelial glycocalyx plays a significant role in the genesis of vascular disease and controls vascular 
permeability [161, 162]. 
Accumulation of toxins may also link reduced renal function and endothelial dysfunction [122]. 
This may be a consequence of accumulation of the toxins that are normally excreted via the kidneys or 
the reduced kidney dependent catabolism of molecules such as ADMA or catecholamines. 
Systemic factors may also play a role; such as enhanced sympathetic activity at an early stage of 
renal disease when whole-kidney GFR is still normal. Increased sympathetic afferent signals originating 
from the damaged kidney may contribute to increased incidence of sudden death and mortality secondary 
to ischemia in renal patients. However, the triggering intrarenal mechanisms have not yet been identified 
[122]. 
Genetic influences probably also play a role. The P12A and C161T polymorphisms of the 
peroxisome proliferator activated receptor gamma (PPAR-γ) gene are important predictors of CVD in 
patients with DKD [163]. Another interesting polymorphism is the leucine 7 to proline 7 (Leu7Pro), 
located in the signal peptide of the human preproneuropeptide Y [164]. In the Finnish Diabetic 
Nephropathy (FinnDiane) Study, the Leu7Pro substitution was independently associated with HbA1c, 
proteinuria, and coronary heart disease in multivariate analysis, suggesting that it may contribute to the 
genetic susceptibility to DKD and CVD in type 1 DM patients. 
Short stature is associated with increased mortality in diabetic and non-diabetic subjects with ESRD 
[165]. Short stature has been linked to nephropathy in both type 1 [166] and type 2 DM [167]. This may 
be due to common genetic and/or environmental factors predisposing to short stature, DKD and CVD. In 
addition to genetic influences, the hypothesis of “nephron underdosing” suggests that aberrant fetal 
programming secondary to genetic factors, malnutrition, and other insults in utero leads to the formation 
of fewer glomeruli [168]. Future ESRD is predicted by baseline BP [169]. Congenital variability in 
filtration surface area may contribute to the varying susceptibility of patients exposed to potentially 
injurious renal stimuli to eventually manifest chronic nephropathy, as well as the different susceptibility 
of subsets of type 1 and type 2 DM to develop overt glomerulopathy. Kidney transplantation in 5/6 
nephrectomized animals protects against albuminuria and rise in BP [170]. In humans, single kidney GFR 
declines more rapidly in uninephric individuals compared to binephric ones [171]. The role of fetal 
programming on the occurrence of renal and CVD needs further study. 
 
 
4. Assessment of cardiovascular risk in Diabetic CKD 
 
The analysis of the plasma levels of novel mediators in DKD patients may provide insights into 
pathogenesis and eventually facilitate tools for risk stratification and for the design of novel therapeutic 
strategies. In this regard, novel prognostic biomarkers of mortality in CKD and ESRD have allowed the 
identification of potential key processes in CVD mortality [172]. Although simplified, this approach helps 
to build a conceptual framework of the pathogenesis of CVD in CKD and understand the interconnections 
between biological processes [173]. We have chosen a representative of inflammatory mediators, 
Chemokine (C-X-C Motif) Ligand 16 (CXCL16) and another from the regulators of lipid metabolism, 
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), for further studies in DKD patients. 
 
Chemokine (C-X-C Motif) Ligand 16 (CXCL16) 
 
Chemokines are divided into four major subfamilies, C, CC, CXC, and CX3C, based on the number 
and spacing of conserved cysteines. Biological activities of chemokines have been most clearly defined in 
leukocytes, where chemokines coordinate development, differentiation, anatomic distribution, trafficking, 
and effector functions and thereby regulate innate and adaptive immune responses [174]. CXCL16 
belongs to the CXC chemokine family.  
 
CXCL16 is a chemokine and cell membrane receptor 
CXCL16 is synthesized as a transmembrane molecule [175]. CXCL16 has an atypical structure, 
being larger (254 amino acids) than other chemokines, and being composed of an extracellular N-terminal 
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chemokine domain, a glycosylated mucin-like stalk, a transmembrane domain, and a short cytoplasmic 
tail containing a potential tyrosine phosphorylation site that may bind SH2 [176, 177]. The presence of a 
transmembrane domain is unusual for a chemokine, and allows CXCL16 to be expressed as a cell surface 
bound molecule, as well as a soluble chemokine [178]. CXCL16 interacts with the CXC-chemokine 
receptor CXCR6, also known as Bonzo [179]. CXCL16 was originally described as a scavenger receptor 
for phosphatidylserine and oxidized low-density lipoprotein (oxLDL) and termed SR-PSOX [180]. 
Expression of CXCL16 is induced by the inflammatory cytokines; interferon gamma (IFNγ) and tumor 
necrosis factor alpha (TNFa) [179]. CXCL16 has been implicated in the pathogenesis of vascular, kidney 
and lung injury [181, 182]. 
Upon cleavage of the mucin-like stalk, the CXCL16 chemokine is released and functions as a 
chemoattractant for CXCR6+ T, NK, NKT (Natural Killer T cell), B, and dendritic cells [176, 177, 183, 
184]. Cleavage is mediated by A Disintegrin and metalloproteinase domain-containing protein 10 
(ADAM10), a member of the disintegrin and metalloproteinase domain family of enzymes [185, 186]. 
Because CXCL16 functions as a chemokine, a scavenger receptor, and an adhesion molecule, it may be 
involved in several phases of the immune response from antigen recognition to migration of immune cells 
into inflammatory foci, including atherosclerotic plaque [187]. 
 
CXCL16 as a new biomarker of kidney injury 
While much is known from animal-based studies, little is known about CXCL16 in human subjects. 
Urinary CXCL16 levels are significantly higher in active systemic lupus erythematosis (SLE) patients 
with renal disease than in active SLE patients without renal disease [179]. Serum CXCL16 levels were 
significantly increased in CKD and gout subjects and were independently associated with a change of 
renal function [188, 189]. Taken together, these findings suggest that CXCL16 may be a marker of renal 
disease. No significant differences in serum CXCL16 levels between healthy and type 2 DM subjects 
were found. However, CXCL16 levels were higher in DKD patients than in CKD patients without 
diabetes [189]. CXCL16 levels were independently associated with renal function in DKD and not with 
diabetes itself. Circulating CXCL16 levels were negatively correlated with eGFR and blood albumin, and 
positively correlated with creatinine and proteinuria in DKD subjects after adjustment for age, gender and 
BMI suggesting that elevated CXCL16 levels are closely related to glomerular injury and declining renal 
function in DKD patients [190]. 
However, the mechanism responsible for the elevation of CXCL16 concentration and its role in the 
pathophysiology of DKD is not fully understood. CXCL16 expression in subjects with DKD may be 
related to the abnormalities of cholesterol metabolism. Thus, elevation of CXCL16 was associated with 
higher levels of oxLDL were found in streptozotocin-induced diabetic mice [191], increased glomerular 
CXCL16 expression was also accompanied by high levels of oxLDL in patients with glomerular kidney 
diseases [192]. 
CXCL16 plays a major role in the uptake of oxLDL by podocytes but not by mesangial and tubular 
renal cells. Abnormalities of podocyte structure and function play a major role in the onset of albuminuria 
both in diabetic and non-diabetic nephropathy [193]. The podocyte dysfunction-oxLDL-CXCL16 axis 
may play a role in DKD.  
 
CXCL16 as a biomarker for CV risk 
Atherogenesis is thought to involve inflammatory responses to oxLDL and its free oxidized lipid 
constituents, which accumulate in the arterial intima [194]. These responses include local release of 
chemokines that collaborate with cytokines and adhesion molecules to promote infiltration of leukocytes 
into vascular subendothelium [195, 196]. In contrast to this paradigm, genetic evidence has suggested that 
the chemokine CXCL16 may have atheroprotective factor actions [182], through unknown mechanisms 
that may be related to its scavenger receptor functions. 
CXCL16 is undetectable in normal aorta, but is expressed in mouse and human coronary and carotid 
atherosclerotic lesions, colocalizing with lipid-laden intimal macrophages and smooth muscle cells [187, 
197]. Studies evaluating soluble CXCL16 as a potential biomarker of coronary artery disease have been 
inconsistent [198, 199]. A polymorphic variant of CXCL16 named CXCL16-A181V was associated with 
increased coronary artery stenosis in post-infarction patients [200]. Genetic inactivation of CXCL16 in 
hyperlipidemic LDL receptor (LDLR) knockout (KO) mice (ldlr-/-) results in accelerated atherosclerosis 
due to enhanced macrophage recruitment to the aortic arch [182]. Although the CXCL16-CXCR6 
relationship is considered monogamous, CXCR6 inactivation in atherosclerosis-prone apolipoprotein E 
(ApoE) KO mice (apoE-/-) decreased susceptibility to atherosclerosis, and was accompanied by reduced 
homing of lymphocytes into the aorta. These data suggest that CXCR6 is a proatherogenic chemokine 
receptor [201]. 
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Lipid-induced down-regulation of surface ADAM10 favors the scavenger role of cell surface 
CXCL16. However, the mechanism through which atherogenic lipids down-regulate ADAM10 remains 
unclear. Thus, although CXCL16 exists in two different forms, soluble and membrane bound, the 
atherogenic environment may dictate preference of a single configuration that may determine the role of 
CXCL16 in atherosclerotic lesions. When expressed in a membrane-tethered form, CXCL16 could 
conceivably support cell-cell adhesion [202], which could play a role in plaque evolution. Consistent with 
this, transmembrane CXCL16 functions as a proadhesive chemokine promoting adhesion of primary 
cells, predominantly T cells to fibroblastic reticular cells in the lymph node [203], to the follicle-
associated epithelial cells covering Peyer’s patches [204] and to the vascular endothelium [205], 
suggesting that the CXCR6-CXCL16 axis may contribute critically in the formation of primary and 
secondary T cell responses. 
Cellular cholesterol efflux constitutes a potent physiological protective system against 
atherosclerosis [206, 207]; however, the involvement of many players in the metabolic pathway of HDL 
makes this system a difficult therapeutic target. A link between CXCL16, HDL, and macrophage 
cholesterol efflux has been established, and provided the first experimental support at the molecular and 
cellular level using primary human cells relevant to atherosclerotic plaque for the scavenger mechanism 
of atheroprotection mediated by CXCL16 [208]. 
The ability to reflect upstream inflammatory activity is an important criterion for an ideal biomarker 
in CVD. Because of the link between several inflammatory mediators and the cleavage of the membrane-
bound to the soluble form of CXCL16, it has been suggested that soluble CXCL16 could serve as a 
reliable marker of inflammation. The high stability of CXCL16 (eg, little circadian variation, minor 
influence of food intake, and little variation after freeze and thaw cycle) further support a potential role of 
CXCL16 as a biomarker in clinical samples [209]. 
Onset of acute coronary syndrome appears to involve the rupture or erosion of atheromatous plaques 
with abundant infiltration of inflammatory cells, such as monocytes/macrophages and T-lymphocytes. In 
addition, OxLDL appears to play a role in the formation of erosion- or rupture-prone vulnerable plaques 
by enlarging the lipid core, thinning of the fibrous cap, and evoking proinflammatory responses, which 
result from foam cell transformation of macrophages, apoptosis of vascular endothelial and smooth 
muscle cells and macrophages, production and activation of matrix metalloproteinases and induced 
expression of chemokines and endothelial-leukocyte adhesion molecules [210]. The association between 
circulating CXCL16 levels obtained within 24 hours after admission and time to death was assessed in 
1351 patients with a diagnosis of unstable angina, non ST-segment elevation myocardial infarction, or 
ST-segment elevation myocardial infarction. During a median follow-up time of 81 months, high 
CXCL16 levels were prognostically unfavorable. After adjustment for conventional risk markers, 
logarithmically transformed CXCL16 level remained a strong independent indicator of long-term 
mortality (hazard ratio 1.21; 95% CI 1.09 to 1.36 per 1 SD increase in CXCL16; P<0.01) and congestive 
heart failure development (hazard ratio 1.25; 95% CI 1.05 to 1.48; p=0.01). In a subsample of 714 
patients, after further adjustment for troponin T, hsCRP, pro–B-type natriuretic peptide, and LV ejection 
fraction, CXCL16 still provided significant additional prognostic information on mortality (hazard ratio 
1.21; 95% CI 1.02 to 1.42 per 1 SD increase in CXCL16; p=0.02) [209]. These findings support a pro-
atherogenic effect of CXCL16 in human coronary artery disease [209]. Increased circulating chemokines, 
including CXCL16 have been reported during acute myocardial infarction and might give prognostic 
information about future ischemic events [211]. However decreased or increased CXCL16 levels in both 
stable and unstable angina was reported in different studies [199, 212, 213]. Soluble CXCL16 induces 
inflammatory responses in vascular smooth muscle cells and peripheral-blood mononuclear cells. With 
relevance to plaque destabilization, soluble CXCL16 enhances matrix metalloproteinase activity [198, 
214]. Also, CXCL16 may have constitutive functions, such as promotion of cell survival and normal 
leukocyte recruitment. Thus although too much CXCL16 may be harmful, too little may not necessarily 
be beneficial. 
 
Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) 
 
PCSK9 was first described in 2003 as neural apoptosis-regulated convertase-1 [215] and was 
renamed PCSK9 after it was found to be a member of the PCSK family of pre-protein convertases [216]. 
 
PCSK9 function 
PCSK9 is the third gene [in addition to LDLR and apolipoprotein B (ApoB)] to cause autosomal 
dominant hypercholesterolemia [215]. Autosomal dominant PCSK9 activating mutations account for 1% 
of cases of familial hypercholesterolemia. Single nucleotide polymorphisms (SNPs) or mutations are 
associated with asymptomatic slightly reduced LDL-cholesterol levels, but only one patient with 
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homozygous PCSK9 deficiency has been described. This patient is hypocholesterolemic, with a 
lipoprotein phenotype of hypobetalipoproteinemia, and is reportedly fit and well [217]. A patient with a 
dominant negative phenotype and hypobetalipoproteinaemia has also been described [218] although most 
mutations show co-dominant (additive) effects. 
PCSK9 is a 692 amino acids protein, which regulates LDLR expression [219]. LDLR represents the 
main route of elimination of PCSK9 and a reciprocal regulation controls serum PCSK9 levels, hepatic 
LDLR expression, and serum LDL levels [220]. PCSK9 subcellular expression profile follows that of the 
LDLR [219]. Thus, PCSK9 is highly expressed in hepatocytes, enterocytes, brain [216] and in other cells 
including macrophages [216, 221]. PCSK9 has a highly self-specific auto-catalytic protease domain 
involved in degradation of the LDLR [216, 221] though this is not required to reduce LDLR expression 
[222, 223]. In general, autosomal dominant activating mutations in PCSK9 cause familial 
hypercholesterolemia by reducing LDLR expression. By contrast, inactivating mutations upregulate 
LDLR expression and are associated with reduced plasma LDL-cholesterol. Two inactivating stop 
mutations common in African-Americans account for the lower LDL-cholesterol levels found in this 
group [224]. In the Atherosclerosis Risk in Communities (ARIC) study, the YI42X mutation present in 
0.8% or the C679X mutation present in 1.8% resulted in 28% lower LDL-cholesterol and reduced risk of 
CVD from 9.7 to 1.2%, that is, by 88% over the 15-year period of follow up [224]. However, while most 
inactivating PCSK9 mutations are co-dominant (i.e., additive in effect), a few are dominant [218]. PCSK9 
contributes to cholesterol levels in familial hypercholesterolemia. Patients with familial 
hypercholesterolemia with lower untreated LDL-cholesterol had lower PCSK9 levels (152 ng/ml) 
compared with unaffected controls (177 ng/ml) and also patients with high LDL-cholesterol familial 
hypercholesterolemia (186 ng/ml) [225]. Consistent with these findings, subjects carrying loss-of-
function mutations (Y142X and C679X) exhibited a 28% reduction of plasma LDL-cholesterol levels and 
an 88% decrease in the risk of coronary heart disease in a 15-year follow-up survey [224]. The human 
genetic data are in agreement with the observations in mice. Plasma cholesterol levels are approximately 
50% lower in PCSK9 KO mice owing to increased clearance of lipoproteins from plasma [226]. No 
apparent physiological or behavioral abnormality was observed in KO mice or humans carrying 
compound heterozygous loss-of-function mutations [226, 227]. Mice with PCSK9 deficiency are 
hypocholesterolemic, hyperglycemic, hypoinsulinaemic and had abnormal pancreatic islets [228] but this 
full phenotype does not seem to occur in man. 
PCSK9 activity is related to fasting, postprandial lipid metabolism [229] and affected by insulin 
regulation of the sterol regulatory element binding protein 1c (SREBP-1c) [230]. PCSK9 is secreted by 
enterocytes in the ileum and by hepatocytes in plasma in response to eating [231, 232]. One hypothesis is 
that PCSK9 transiently down regulates LDLR on the liver so that triglyceride-rich lipoproteins are not 
subject to first pass clearance and metabolism but are allowed to enter the general circulation. 
Consequently, triglyceride-rich lipoproteins are available for the action of lipoprotein lipase to release 
free fatty acids for uptake by muscle and adipose tissue. Once circulating PCSK9 has been cleared, 
hepatic LDLR is upregulated and triglyceride-rich lipoproteins and later LDL are cleared from the 
circulation. This action of PCSK9 is not the only mechanism that downregulates LDLR as similar actions 
have been shown for the Idol protein that acts in a reciprocal manner to PCSK9 and can be affected by 
statins and is controlled by liver-X receptor (LXR)-mediated pathways [233]. The extracellular pathway 
of PCSK9 to regulation of LDLR function oversimplifies the actual regulatory contribution. In addition, 
intracellular PCSK9 is present both in the liver and in enterocytes and also regulates local LDLR 
expression, yet the function and control of this pathway and how it relates to the extracellular pathway are 
unclear [234]. PCSK9 may also directly affect atherogenesis. PCSK9 secreted after overexpression by 
smooth muscle cells, upregulates macrophage LDLR expression [221]. Cross-breeding experiments in 
mice have investigated the role of PCSK9 in atherosclerosis [235]. These involved mating C57BL/6 wild-
type (WT), apoE-deficient and LDLR-deficient mice with PCSK9 deficient, WT or overexpressing mice. 
Following 12-months Western diet PCSK9 KO mice accumulated fourfold less aortic cholesterylesters 
than WT mice, whereas PCSK9 overexpressing mice exhibited high aortic cholesterylesters and severe 
aortic lesions. The experiment was repeated in apoE deficient mice. After 6 months of regular diet, 
PCSK9 KO/ApoE KO mice showed a 39% reduction in atherosclerosis and aortic cholesterylesters 
accumulation compared with PCSK9 WT/ ApoE KO mice, while PCSK9 overexpressing/ApoE KO mice 
showed a 137% increase. No influence of PCSK9 expression was observed in LDLR KO mice, 
suggesting that PCSK9 modulates atherosclerosis mainly via the LDLR.  
Commercially available enzyme-linked immunosorbent assays (ELISA) have been used to better 
understand PCSK9 function and biomarker potential, while activity assays are complex [236]. In cross-
sectional studies associations of PCSK9 mass and activity have been described with levels of androgens, 
estrogens, insulin and growth hormone [229, 237] but other as yet unstudied hormones may affect PCSK9 
activity. Sex steroids can induce changes in PCSK9 activity, and these are suspected to be responsible for 
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the increase in LDL-cholesterol during puberty in boys and following the menopause in women [229, 
237]. PCSK9 shows a diurnal activity that parallels cholesterol synthesis as measured by lathosterol 
levels, and this rhythm is abolished by statin or bile acid sequestrant therapy [238].  
 
PCSK9 and the Kidney 
Heavy glomerular proteinuria, a hallmark of nephrotic syndrome, is associated with severe 
hyperlipidemia and lipiduria. Hypercholesterolemia, increased plasma LDL, impaired LDL and HDL 
clearance, and depressed maturation of HDL are common features of dyslipidemia in nephrotic syndrome 
[239]. These abnormalities are due to acquired hepatic LDLR and HDL docking receptor (SRB1; 
scavenger receptor class B1) deficiencies as well as urinary excretion and reduced plasma concentration 
and enzymatic activity of lecithin cholesterol acyltransferase (LCAT) [240]. In addition plasma 
concentrations of triglycerides, very low-density lipoprotein (VLDL), and IDL are increased, and 
triglyceride content of various lipoproteins is elevated [241]. Nephrotic syndrome results in impaired 
clearance of triglyceride-rich lipoproteins, VLDL, chylomicrons, and their remnants [239]. The latter is 
caused by down-regulations of the primary pathways of triglyceride-rich lipoprotein clearance including 
lipoprotein lipase [242] and VLDL receptor [243] in the muscle and adipose tissues and of hepatic 
triglyceride lipase [244]. In addition, increased hepatic production of fatty acids and triglycerides has 
been demonstrated in various models of nephrotic syndrome [245]. 
Plasma PCSK9 concentration was higher in patients with nephrotic syndrome (n=15, 15±5 ng/mL) 
and peritoneal dialysis (13±1 ng/mL) than in healthy controls (9±0.6 ng/mL) and hemodialysis (7.0±0.5 
ng/mL) patients. Plasma PCSK9 level was directly related to total and LDL cholesterol concentrations in 
the study population. Higher plasma PCSK9 concentration may contribute to elevation of LDL levels by 
promoting LDLR deficiency in nephrotic syndrome and peritoneal dialysis [246]. Upregulation of PCSK9 
and inducible degrader of the LDL receptor (IDOL) was also observed in experimental nephrotic 
syndrome [247]. 
In another study serum PCSK9, total cholesterol, LDL-cholesterol and HDL-cholesterol levels were 
significantly lower in hemodialysis than in control individuals. In hemodialysis patients not on statins 
PCSK9, total cholesterol and LDL- cholesterol levels were lower than in control subjects and PCSK9 
levels correlated with total cholesterol, LDL-cholesterol and triglyceride levels. In hemodialysis patients 
on statins PCSK9 levels were not significantly different from the non-CKD group and did not correlate 
with total or LDL-cholesterol levels. These data suggest that the regulation of LDL-cholesterol by PCSK9 
remains intact in hemodialysis patients [248]. 
 
PCSK9 and cardiovascular risk 
Dyslipidemia is one of the most significant risk factors for CVD, accounting for 50% of the 
population-attributable risk for myocardial infarction [249] and 25% of the population-attributable risk 
for stroke [250]. The effective management of dyslipidemia is therefore essential for the reduction of CV 
risk.  
Nonsense PCSK9 mutations are associated with a 20-40% reduction in mean LDL cholesterol [251, 
252]. In the ARIC study during a 15-year-follow-up period, the 10 percent of black subjects who did not 
have a nonsense PCSK9 mutation experienced a coronary event. In contrast, only 1% of subjects with a 
non-sense mutation of PCSK9 developed CVD [224]. The calculated hazard ratio for coronary heart 
disease among carriers as compared with noncarriers, after adjustment for age and sex, was 0.11. The 
incidence was still significantly low also after taking into consideration the BP and diabetes. 
Autosomal dominant hypercholesterolemia patients with gain of function PCSK9 mutations had 
significantly higher serum total cholesterol concentrations and appeared to be more resistant to statin 
therapy compared to heterozygous familial hypercholesterolemia patients with known mutations in 
LDLR. Ischemic heart disease occurred earlier in patients with PCSK9 mutations than in patients with 
LDLR mutations. The reason underlying this severe phenotype associated with the PCSK9 D374Y 
mutation is not yet understood and has been suggested to be related to a possible positive role of PCSK9 
on apoB secretion [253]. PCSK9 increases apoB secretion is independent of the LDLR. PCSK9 binding 
to apoB may protect apoB from the intracellular degradation [254]. 
Thus, putative gain or loss of function mutants correlate with increased or reduced plasma LDL 
levels and CV risk, respectively. A genome-wide association study observed a linkage between a SNP at 
a locus near PCSK9 with early-onset myocardial infarction [255].  
Accordingly, PCSK9 could represent a safe and effective pharmacological target to increase 
clearance of LDL cholesterol and to reduce the risk of coronary heart disease. Recent clinical trials 
showed that anti-PCSK9 monoclonal antibodies that block the interaction between PCSK9 and LDLR and 
inhibit the PCSK9-mediated LDLR degradation considerably reduce LDL-C levels by up to 65% when 
given alone and by up to 72% in patients already receiving statin therapy [256]. PCSK9 binding to LDLR 
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can be blocked by >80% using anti-PCSK9 polyclonal antibodies [257]. Different clinical trials in phase 
I-II which are studying new lipid-lowering therapies based on PCSK9-neutralizing antibodies [258-262]. 
 
PCSK9 and Experimental Atherosclerosis and Diabetes Mellitus 
Although the regulatory pathways and enzymes involved in cholesterol homeostasis in mice are 
dramatically different than humans, mice studies have provided some relevant information [221]. PCSK9 
null and transgenic mice crossed with LDLR-/-mice show similar plasma cholesterol levels and plaque 
size compared to LDLR−/− mice. These data indicated that the effect of PCSK9 on cholesterol 
homeostasis and atherosclerotic plaque development is almost entirely dependent by the presence of 
LDLR [263].  
PCSK9 is present in human atherosclerotic plaques may locally regulate the expression of LDLR in 
macrophages [221]. Of interest, resistin, a small protein secreted by macrophages in humans and 
adipocytes in rodents [264], induces PCSK9 expression in hepatocytes and reduces LDLR levels [265], 
suggesting that resistin-mediated upregulation of PCSK9 may contribute to the dyslipidemia commonly 
observed in obesity and DM. 
 PCSK9 expression is also dependent by the action of insulin through the activation of SREBP-1c 
[230]. In diabetic rats PCSK9 expression was significantly decreased [266]. In hyperinsulinemic obese 
mice, PCSK9 was also decreased and has been shown to regulate LDLR, via the mammalian target of 
rapamycin complex 1 (mTORC1) kinase activity [267]. In the same model, the transcriptional factor 
hepatocyte nuclear factor 1α (HNF1α) regulated PCSK9 levels [267]. These data are consistent with 
previous work demonstrating that the HNF1 binding site adjacent to sterol responsive element (SRE) is 
the critical regulatory sequence motif, and HNF1α is the predominant working partner for SREBP-2 in 
the regulation of PCSK9 gene [268]. Taken together, PCSK9 expression appears to be deregulated under 
different pathological conditions such as DM and obesity, and is potentially involved in the associated 
dyslipidemia. 
 
Assessment of cardiovascular risk using the pulse wave 
 
Vascular stiffness increases left ventricular afterload and decreases coronary perfusion leading to 
CVD. Increased vascular stiffness, as measured by pulse wave velocity (PWV), is associated with 
increased CV and all-cause mortality in dialysis patients [269]. Indeed, arterial stiffness has been used as 
an end-point in interventional studies in CKD patients [270]. 
 
Aortic (Carotid Femoral) Pulse Wave Velocity (CF-PWV) 
Large arteries are not simple tube conduction structures. They moderate systolic pressure increases 
and maintain sufficient diastolic level to guarantee myocardial perfusion.  Under disease conditions these 
arteries lose their natural elasticity leading to high systolic and low diastolic BP levels, which determine 
high pulse pressure. Arterial stiffness is now considered an increasingly important biomarker in the 
evaluation of CV risk and the detection of incipient vascular damage associated with hypertension and/or 
atherosclerosis. Arterial stiffness is an independent predictor of CV mortality in the elderly, hypertensive, 
diabetics, and patients with CKD as well as in the general population [271-274]. As an example, a 
prospective, observational cohort study examined the impact of aortic stiffness on CV mortality among 
265 ESRD patients on hemodialysis, including 50 diabetic patients. At baseline, the diabetic ESRD 
patients had significantly higher aortic PWV than the nondiabetic patients. During a mean follow-up 
period of 63 months, 81 deaths, including 36 CV deaths, were recorded. All-cause or CV mortality rates 
were higher in the diabetic as compared with the nondiabetic patients and also in those with higher aortic 
PWV than those with lower aortic PWV. In a multivariate model including 13 covariates, aortic PWV 
remained a significant predictor for CV and overall mortality but not for non-CV mortality. Thus, the 
increased aortic stiffness of the ESRD patients with DM was associated with higher all-cause and CV 
mortality rates [275]. The guidelines of the European Societies of Hypertension and Cardiology (2007-
2009) have postulated arterial stiffness assessment, measurement of the carotid plaque and ankle brachial 
index (ABI) as markers of vascular status. Any alteration of these measurements may define a state of 
vasculopathy that significantly increases the evaluation of risk [276]. There are several methods to 
estimate arterial stiffness (Table 4) [277]. 
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Table 4: Devices and methods used to determine arterial stiffness 
 
 Mechanotransducer 
Tonometer 
Echotracking Pulse Wave Velocity 
Doppler 
Echotracking 
Local stiffness 
Magnetic resonance 
Non-invasive 
Systemic stiffness Waveform shape analysis 
Invasive     Aortic angiography 
 
 
Non-invasive assessment of arterial stiffness has been proposed for individual CV risk evaluation 
and early detection of vascular damage associated with hypertension and/or atherosclerosis [278, 279]. 
The CF-PWV has emerged as a gold standard due to its accuracy, reproducibility, relative easy 
measurement, and low costs. PWV has yielded prognostic value beyond and above traditional risk factors 
[279]. However, and in spite of its recognized value the evaluation of PWV in the clinical practice has 
been hampered among other factors by the absence of standardized methodologies of study and the lack 
of established normal/reference values for different populations [279, 280]. 
PWV assessment involves measuring the pulse wave transit time along the analyzed arterial segment 
and the distance between the pulse wave recording sites. Therefore, PWV values depend on both the path 
length measurement and the algorithm used to detect “the foot” of the analyzed waves [272]. The 
algorithms most frequently used are the intersecting tangent algorithm and the point of maximal upstroke 
during systole. The pathway can be the direct distance measured between the carotid and femoral 
measurement sites (Figure 6) [277], the sternal notch-femoral measurement site distance, or the distance 
obtained by subtracting the carotid-sternal notch distance from the sternal notch-femoral distance 
(subtracted distance) (Figure 7) [271].  
 
 
 
 
 
 
Figure 6: Pulse wave velocity determination. Transit time is estimated by the foot-to-foot method. The 
foot of the wave is defined at the end of diastole, when the steep rise of the waveform begins. The transit 
time (Δt) is the time of travel of the foot of the wave over a known distance. 
 
 
Foot of the wave 
Foot of the wave 
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Figure 7: Measuring Aortic PWV. Elements necessary to measure PWV if done by tonometry coupled 
with electrocardiography (EKG). Distance from sternal notch to carotid pulse site (red) and distance from 
sternal notch to umbilicus and then to groin (in blue) are measured as shown. The probe captures the 
wave form at the carotid and femoral sites, and the time elapsed between the tip of the QRS complex and 
the onset, or “foot,” of the pulse wav is calculated. Generally, 10 seconds worth of data are captured, 
yielding six to 11 beats, which are averaged for the elapsed time at the carotid and femoral sites. The 
distance divided by time generates the velocity. Because the distances are in millimeters and the times are 
in milliseconds, the “milli” cancels out, leaving units of m/s.  
 
Different algorithms applied to the same waves can lead to differences in PWV of 5–15%, while 
differences in path length alone can result in differences in PWV of up to 30%. When determining normal 
and/or reference values those technicality-related issues should be considered. Arterial stiffness also 
depends on BP levels and increases with age [272, 279]. The potential impact of several factors on PWV 
is no longer observed after correction for age. Reference values for PWV have been recently provided 
from data mainly derived from European populations [279]. Given the ethnic diversity in CV risk profile, 
the dissimilar risk associations, and the differences in genetic-environmental interactions among 
populations, studies performed in a given population may not be directly applied to another different 
population. Then, considering the value of the vascular evaluation in CV risk stratification and diagnosis 
it is necessary to determine normal/reference levels for different vascular parameters taking into account 
the differences among populations [281]. 
The largest amount of evidence regards aortic stiffness, measured through CF-PWV. Aortic stiffness 
has independent predictive value for all-cause and CV mortality, CV disease, fatal and nonfatal coronary 
events and fatal strokes in patients with various levels of CV risk, including very high risk, as in ESRD 
[269, 275], high risk as in diabetes [282], medium risk (uncomplicated essential hypertension) [283] and 
low risk (general population) [284, 285] as well as in healthy elderly subjects [286, 287]. Aortic stiffness 
retains its predictive value for CV events after adjustment either to classical risk factors [286, 287]: 
brachial pulse pressure [288], Framingham risk score [288] or carotid intima-media thickness [286]. This 
indicates that aortic stiffness has a better predictive value than each of these factors [289]. 
PWV can be viewed mathematically or pragmatically. 
From a mathematical point-of-view, the Moens-Korteweg equation relates PWV to a function of 
elastic modulus, viscosity, and vessel diameter, where V is wave speed, E is Young's elastic modulus in 
the circumferential direction (this modulus is a ratio of stress/strain, i.e., a way to represent the effects of 
force [stress] on shape [strain]), h is the wall thickness, ρ is the density of the fluid, and R is the radius of 
the vessel [271]. 
 
V = √ (Eh / 2pR) 
 
From a pragmatical point-of-view, the velocity is simply how fast the pulse wave travels a specified 
distance of the vascular bed. This has been the clinical approach to measuring PWV in recent times. The 
steps involved in the actual technique are described later in this text. 
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Certain clinical conditions, such as advanced age, obesity, hypertension, DM, coronary artery 
disease, myocardial infarction, CKD and other factors unfavorably alter ventricular/vascular coupling, 
and impact on aortic PWV [290-294]. 
 
Genes: Aortic PWV is a heritable trait, according to Framingham data [295]. Several genetic 
polymorphisms have been reported to influence PWV, including those for the AT1 receptor [296], 
fibrillin-1 [297], metalloproteinases [298], and the endothelin pathway [299]. 
 
Vessel Wall Proteins: Stiffness is also related to the relative amounts of elastin and collagen in the 
vessel wall. The more proximal parts of the aorta, which have slower velocities, contain relatively greater 
proportions of elastin compared with collagen. As one proceeds distally, this ratio changes [300]. 
Collagen also accumulates (relative to elastin) in the aorta with age and comorbidities such as 
hypertension, diabetes, and cigarette use. Excessive intramural build-up of other proteins, such as 
integrins, fibronectin, and desmin, also increase vascular stiffness [301]. 
 
Age: Age has one of the strongest effects on aortic PWV. Even in otherwise healthy individuals, 
aging results in an alteration of elastic wall components that generates an increase in stiffness[302]. Years 
of cyclic pulsatile stress lead to fragmentation of vascular elastin elements and accumulation of load-
bearing collagen with a loss of stretch and increase in stiffness reflected by a steadily increasing systolic 
pressure [303]. 
 
Systolic and Pulse Pressures: These age-related changes enhance the magnitude of the pulsatile 
component of the stress and strain placed on the vessel with each heartbeat [304]. The level of BP creates 
an initial “loading” condition that regulates pressure wave conductance in the aorta. Increasing the BP 
acutely in a healthy individual will increase the PWV [305].  
 
Calcification: Vascular calcification increases aortic stiffness [306]. Low bone turnover rates 
coupled with vitamin D and calcium salt therapies may be a “perfect storm” setting for deposition of 
calcium in the aorta [307]. Aortic calcium loads as evidenced on lateral lumbar x-rays are directly related 
to aortic PWV [308]. 
 
Sodium Intake: Although salt intake may be naturally linked to an increase in systolic BP and thus 
stiffness, there are clear instances in models of hypertension in which aortic stiffness results from 
increased salt intake independent of BP changes [309]. 
 
Kidney Failure: Some of the most impressive data on CV outcomes in patients with stiff aortas 
have come from the ESRD population. Aortic PWV is increased in ESRD. Debate continues as to 
whether this is independent of shared risk factors. The search for specific mechanisms related to kidney 
failure apart from those covered already are areas of active investigation. Arterial stiffening has been 
linked to the rate of decline of kidney function, although this finding has not been replicated (Figure 8) 
[310].  
 
 
 
 
Figure 8: Aortic PWV and eGFR for 2564 participants in the CKD cohort study (P<0.001) 
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DM: Diabetes adds to the aortic PWV independent of other comorbidities or pathophysiologies, 
such systolic BP, kidney failure, and aging [275, 311]. Diabetes has long been thought of as a model of 
accelerated aging [312], and the build-up of inelastic matrix materials similar to that of aging in vessel 
walls and their subsequent glycation is a principal mechanism of the effects of diabetes on aortic PWV 
[313]. 
 
Aortic Pulse Wave Analysis (Ao PWA) 
PWA uses a high-fidelity tonometer to capture electronically the shape of a peripheral arterial pulse. 
The tonometer probe is ‘applanated’ (applied so as to flatten, but not occlude an artery) at a convenient 
site such as the radial artery. The shape of the peripheral pulse wave obtained is then calibrated with the 
brachial systolic and diastolic BP (measured in the traditional manner with an inflated cuff at the brachial 
artery) to derive the shape and dimensions of the central aortic pressure wave [314]. 
 
The SphygmoCor system converts the peripheral waveform to a central waveform using a 
proprietary algorithm (‘general transfer functions) [315, 316]. PWA permits the non-invasive 
measurement of three main indices of CV function: augmentation index adjusted to a heart rate of 75 
beats per minute (AIX@75), subendocardial viability ratio (SEVR; or Buckberg index %), and the 
ejection duration index (ED %) [314]. The derivation of these indices is described below and shown 
schematically in (Figure 9) [317] and (Figure 10) [318]. 
 
Figure 9: Central aortic waveform (C) is the result of the overlap between Forward waveform (A) and Reflected 
waveform (B). In this case the central aortic summation waveform is the result of early reflection in a patient with 
stiff arteries. Thus Augmentation Index = augmentation pressure / pulse pressure. 
 
 
 
 
Figure 10: Types of the pulse waveforms. Type “C” is defined by a dominant initial pressure peak with an 
inflection on the pressure waveform downstroke, whereas type “A” is defined by a dominant late systolic peak and a 
shoulder with inflection on the upstroke. Type “B” is intermediate, with no obvious inflection. Augmentation index 
(AIX) is calculated by the ratio of the difference between the pressure at the respective peaks or inflections 
(augmentation pressure, P2 − P1) divided by the pulse pressure (Systolic BP − Diastolic BP). Tension-time index 
(TTI) is the pressure-time integral during systole, and diastolic pressure-time index (DPTI) is the corresponding 
integral in diastole. Subendocardial viability is the ratio of DPTI to TTI. Schematic for dP/dtmax is shown.  
P1, inflection point 
P2, inflection point 
Augmentation Index (%) = (P2 – P1) / PP 
Subendocardial Viability Ratio (SEVR, Buckberg Index) (%) = DPTT / TTI 
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Augmentation index (AIX) adjusted to a heart rate of 75 (AIX@75) 
 In the peripheral arteries the outgoing systolic pulse wave is reflected back towards the heart and 
adds to (‘augments’) the central aortic pressure in late systole [315, 319, 320]. The amount by which the 
aortic pressure is increased by this phenomenon is the ‘augmentation pressure’. AIX is this aortic 
augmentation pressure expressed as a percentage of the aortic ‘pulse pressure’ [319, 320]. AIX 
(augmentation pressure/pulse pressure) indicates the combined influence of large artery PWV, peripheral 
pulse wave reflection and vascular function [320, 321]. AIX is the most widely researched index of PWA, 
with several studies indicating that AIX is independently predictive of adverse cardiac events [293, 322]. 
Since AIX varies with heart rate it is commonly adjusted to a ‘standard heart rate’ of 75 beats per minute 
(AIX@75) [323]. 
The AIX is also associated with survival and it is a composite measure of the reflective properties of 
peripheral arteries and the elastic property of the large arteries [272]. Increased aortic stiffness is 
identified by an increase in the AIX and augmentation pressure.  
 
Subendocardial viability ratio (SEVR; or Buckberg Index) % 
The ‘area under the curve’ (AUC) of the systolic and diastolic portions of the central aortic pulse 
wave can be measured using PWA. Blood flow within the coronary arteries occurs mainly during diastole 
and the diastolic-AUC indicates myocardial perfusion (‘supply of oxygen’) [314, 324].The systolic-AUC 
indicates myocardial contraction (‘demand for oxygen’). The subendocardial viability ratio (SEVR %), 
also known as the Buckberg index, is a ‘supply to demand’ ratio of the diastolic-AUC divided by the 
systolic-AUC [314, 325]. The SEVR is a noninvasive estimate of myocardial perfusion relative to cardiac 
workload. Subendocardial ischemia occurs when SEVR% falls below 50% which is mainly due to 
reduction in diastolic perfusion times [326]. 
 
Ejection duration index (ED %) 
The duration of LV systolic ejection; systolic time interval in milliseconds, can be measured using 
PWA. The ratio of the duration of systolic ejection to the total duration of a cardiac cycle is the ejection 
duration index (ED %). Patients with systolic dysfunction have a higher ED % than those with diastolic 
dysfunction [314]. 
 
Repeatability of PWA indices 
It is important that clinical innovations, such as PWA, are carefully evaluated before their 
widespread introduction into routine clinical practice. The diffusion of previous medical innovations into 
medical practice has not always produced the benefits anticipated for patients [327]. For PWA to be 
clinically useful it must be a clinically reproducible technique [328]. Previous studies have demonstrated 
high levels of repeatability of AIX@75 and SEVR% [329, 330] and further studies have estimated the 
repeatability of SEVR% [331, 332], although one of these studies only addressed between-observer 
repeatability. No previous studies have reported on the repeatability of ED % [314]. Thus, we focused our 
study in AIX@75 and SEVR%. 
 
There is an ample observational evidence of the involvement of inflammation as a determinant of 
outcomes in CKD. However, this evidence has translated neither into the adoption of novel biomarkers in 
routine clinical practice nor into specific therapeutic options or improved outcomes for the CKD 
population. Identification of key biomarkers as well as accumulating experience with biologicals targeting 
these biomarkers in non-CKD populations may provide the rational basis for novel therapeutic 
approaches to the dismal outcome of ESRD patients. The same situation regarding the application of the 
noninvasive screening methods of vascular stiffness for high CV risk patients in the daily clinical 
practice; looking for better quality of life and improving the long term outcome for those patients. We 
have started a prospective study assessing the impact of these novel biomarkers on outcomes and 
response to therapy. We now present the information gathered at the baseline visit in a cross-sectional 
analysis assessing predictors of biomarker levels and altered pulse wave parameters.   
 36 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
HYPOTHESIS 
AND 
OBJECTIVES 
 
 
 37 
 
 
 
Hypothesis 
 
 
The study of biomarkers and the pulse wave assessment will provide insights into the pathogenesis and 
monitoring of CVD in diabetic CKD patients that may eventually lead to improve outcomes. 
 
 
 
Objectives 
 
 
The general objective of this thesis is to characterize potential markers of vascular injury in patients with 
CKD which help understand the pathogenesis of vascular injury in CKD in order to develop novel 
therapeutic approaches, as well as to develop novel monitoring instruments. 
 
 
1. To study the distribution of plasma values and the correlates of novel plasma biomarkers in 
diabetic non-dialysis CKD patients. 
 
 
2. To study the prevalence and correlates of vascular injury as assessed by pulse wave assessment 
in hypertensive and CKD patients. 
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The study was performed in Fundación Jiménez Díaz University Hospital – Autonomous University 
of Madrid. The study was approved by the IIS-Fundacion Jimenez Diaz Ethics Committee. Before 
enrollment, the study was fully explained to all participating patients and an informed consent was signed. 
Patients attending the CKD, diabetic nephropathy and hypertension clinics not on dialysis were 
offered to participate. No prior limits were provided for eGFR or albuminuria, although the nature of the 
clinics resulted in an overrepresentation of patients with some degree of albuminuria or decreased eGFR.   
Exclusion criteria were: less than 18 years old, Hepatitis C Virus (HCV), Hepatitis B Virus surface 
Antigen (HbsAg) and Human Immunodeficiency Virus (HIV) positive serology patients, being on 
dialysis or transplantation or refusal to sign an informed consent. 
 
Study design: This cross-sectional observational study assessed baseline data from the following 
two prospective cohorts of patients (Figure 11). 
· A “biomarker” cohort included 134 diabetic patients with CKD. In these patients the novel 
plasma biomarkers CXCL16 and PCSK9 were assessed. Additionally, biomarkers were 
assessed in 3 non-diabetic CKD patients and in 4 healthy controls. 
· A “Pulse Wave Assessment” cohort included 191 individuals. Of these, 153 were CKD 
patients and 38 non-CKD patients with hypertension or high cardiovascular risk. In these 
patients pulse wave assessment was performed. 
Both cohorts had in common 54 CKD patients, for whom both Pulse Wave Assessment and 
biomarkers data were available. 
Additionally, outside the main study, biomarkers were assessed in 3 non-diabetic CKD patients and 
in 4 healthy individuals. These patients didn’t belong to the analyzed biomarkers cohort and these results 
were not part of the main statistical analysis. However, they provided a guidance on the performance of 
the ELISA assay used. 
 
 
 
Figure 11: Cohort Study Groups 
 
Discrepancies in patient consents (Pulse Wave Assessment consent vs. Biobanking consent) 
accounted for the existence of two, partially overlapping cohorts. Those were in part due to the logistic 
constraints intrinsic to the organization of the outpatient clinics.  
 
1. Clinical History 
 
Clinical history was obtained on the base of the following data: 
1. Etiology of CKD, divided in 2 principal groups; DKD and non-diabetic CKD. 
 
 
 
 
 
Biomarkers 
group  
(Diabetic CKD) 
N.= 134 
Pulse Wave Assessment 
group  
N.= 191 
Biomarker + 
Pulse Wave 
Assessment
group 
N.=54 
N. = 3 N. = 4 
Biomarkers 
Non- diabetic CKD 
Biomarkers 
Healthy individuals 
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2. Age, gender and BMI 
3. Social habits: 
a. Smoking: the patients were classified into active smoker (consuming tobacco in regular or 
sporadic form), Ex-smoker (more than one year without smoking) and non smoker (never 
smoked). 
b. Alcohol intake: the patients were classified into active consumer (consuming alcohol in 
regular or sporadic form), Ex-consumer (more than one year without alcohol intake) and non-
consumer (never drink alcohol). 
4. Presence of CVD: 
a. Cardiac history: angina, myocardial infarction, heart failure, valvuloapthy, cardiac 
arrhythmias, coronary artery disease, systolic dysfunction, or diastolic dysfunction. 
b. Peripheral vascular disease: Intermittent Claudication  
c. Active pharmacological treatment considering: 
· Antidiabetics: oral hypoglycemic agents or injection therapy (Insulin) 
· Antihypertensives: ACEIs, ARBs, beta-blockers, calcium channels blockers, alpha-
blockers, alpha-beta blockers and diuretics. 
· Lipid lowering agents: Statins, Fibrates, Ezetimibe and Omega-3-fatty acids 
· Anti-platelet agents: acetylsalicylic acid, clopidogrel, ticlopidine and triflusal. 
· Iron supplementations and Erythropoiesis Stimulating Agents (ESA) and proton pump 
inhibitors 
· Calcium and Vitamin D supplementations 
· Potassium chelator (Calcium polystyrene sulfonate; resin calcium) and Phosphorus 
binders including calcium based (calcium acetate and calcium carbonate) and non 
calcium based (sevelamer, lanthanum and aluminum). 
· Cinacalcet 
 
2. Blood and urine analysis 
 
Blood and urine were assessed for biochemical parameters at the clinical laboratory of IIS-
Fundacion Jimenez Diaz. 
1. Plasma PCSK9 and plasma CXCL16 were assessed by ELISA R&D Systems (Minneapolis, 
USA) at the research laboratory of nephrology. 
2. Parameters of kidney functions: serum creatinine and eGFR; calculated by the 4 parameter 
MDRD formula [333]. 
3. Parameters of anemia and iron saturation: Hemoglobin (Hb), Iron, total iron binding capacity 
(TIBC), Ferritin and transferrin. 
4. Parameters of bone and mineral metabolism: calcium, phosphorus, magnesium, alkaline 
phosphatase and lactate dehydrogenase (LDH). ELISA was used to measure intact  
parathyroid hormone (PTH) (second generation immunoradiometric assay (IRMA) (CA-PTH 
duo; Scantibodies Laboratory Inc), 25 hydroxyvitamin D {25(OH)D} and 1,25 
dihydroxivitamin D {1,25(OH)2D}(radioimmunoassay, DiaSorin). 
5. Lipid profile: Serum cholesterol (Total, LDL and HDL) and Triglycerides (TG). 
6. Uric acid level. 
7. Parameters of inflammation: hsCRP. 
8. Parameters of nutritional status: Serum albumin and prealbumin. 
9. Parameters of glucose control: HbA1c, random blood glucose and glycosuria. 
10. Vasoactive hormones: renin activity (ng/ml/h); [normal level: (orthostatic: 1.3-4) and (supine: 
0.2-2.3)] and aldosterone (pg/ml); [normal level: (orthostatic: 40-300) and (supine: 17-130)]. 
These measures have been recorded in the morning hours (10.00-12.00 h).  
11. Ions: sodium and potassium were measured in the same day of the vasoactive hormones. In 
addition, blood CO2 was measured by autoanalyzer.  
12. Thyroid profile: TSH, Free T3, Free T4. 
13. Vitamins: Serum Vitamins A, E, B12 and folic acid levels. 
14. Urine examination; including: 
· 24 hours creatinine clearance. 
· Spot urinary creatinine, protein and microalbumin. 
· UACR and UPCR. 
· Spot urinary excretion of sodium and potassium, calcium, phosphorus and magnesium. 
· 24 hours excretion of creatinine, protein, phosphorus and magnesium. 
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3. Complementary cardiac investigations  
 
1. Basal Electrocardiogram. 
2. Transthoracic Echocardiogram to evaluate: All the following data have been specified and 
provided by the cardiologist. 
· LV diameter,  
· Left atrio-ventricular septum diameter,  
· Ejection fraction, 
· Altered ventricular relaxation pattern: grade I diastolic dysfunction; altered mitral valve 
flow. 
· LVH: Normal thickness of the LV myocardium is from 6 to 11 mm measured at the very 
end of diastole. The diagnosis of LVH was made, if the myocardium is more than 
11 mm thick [334]. 
· Cardiomyopathy (absence, hypertrophic or dilated): 
a. The hypertrophic cardiomyopathy was diagnosed based on the echocardiographic 
criteria which included; asymmetrical septal hypertrophy, systolic anterior motion of 
the mitral valve, a small LV cavity, septal immobility, and premature closure of the 
aortic valve. LV thickness, evaluated at septum and free wall level, is considered 
abnormal when ≥ 15 mm, and defined asymmetrical in presence of a septal to free wall 
thickness ratio between 1.3 and 1.5 [335]. 
b. The dilated cardiomyopathy was identified by the presence of LV dilatation and LV 
systolic dysfunction with normal LV wall thickness, diagnosis was made with 2-
dimensional echocardiography [336, 337]. 
· Valvular calcification (absence or presence), 
· Pericardial effusion (absence, mild, moderate or severe) 
 
4. Pulse Wave assessment 
 
The assessment of arterial wave reflection characteristics was performed noninvasively using the 
SphygmoCor CV Management System (CvMS) 2010 software version 9 (AtCor Medical, Sydney, 
Australia). High-fidelity carotid and femoral arteries pressure waveforms were recorded by applanation 
‘pencil type’ tonometry (SPT-304) of the carotid and femoral pulses. The best high-quality recordings; 
defined as an in-device quality control (operator index) of over 75%, was used for analysis. The operator 
index was derived from an algorithm including average pulse height variation, diastolic variation (<5%), 
and the maximum rate of rise of the peripheral waveform.  
A brachial BP measurement was taken using an automatic sphygmomanometer. The patient was 
sitting or lying comfortably and allowed to rest approximately 5 minutes prior to taking the brachial BP 
measurement to ensure stable hemodynamics. At least 2 minutes elapsed between taking the brachial BP 
and recording a pressure waveform using the tonometer. Then, diastolic and systolic BP, height, weight 
and BMI were entered in the corresponding fields on the Study Screen. In general, pressure waveforms 
were gated with simultaneous electrocardiographs recording. 
 
Aortic (Carotid-Femoral) Pulse Wave Velocity 
The standard method of measuring PWV is to record a proximal (located toward the centre of the 
body) and a distal (located far from the centre of the body) pressure waves at two different sites on the 
arterial tree. The Aortic PWV is recorded from simultaneous measurement of the pressure wave 
propagation from the carotid artery (proximal) to the femoral artery (distal). Foot-to-foot PWV was 
calculated by determining the delay between the appearance of the pressure waveform foot in the carotid 
and femoral sites (Δt; transit time). The measurement of the tonometry transit distance (TTD) was made 
using a measuring tape on the surface of the body connecting the carotid measuring site with the femoral 
measuring site then multiplying the value by a factor of (0.8) [338]. Then the device software 
automatically estimated the CF-PWV (m/sec). The results displayed compared to age-based reference 
range (Figure 12). 
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Figure 12: CF-PWV record data of one of our patient as obtained by SphygmoCor device 
 
 
The Delta PWV was calculated as follows= (measured PWV) - (Upper limit of the age-adjusted 
PWV values for the general population). The PWV values for the general population have been obtained 
from data of 16 867 subjects and patients from 13 different centers across eight European countries [279]. 
All patients with positive values were considered to have an abnormally high PWV for their age, while 
those Within the normal limits were assigned a value of zero. All patients were included in the delta PWV 
statistical analysis. 
 
Aortic Pulse wave analysis (PWA) 
The aortic pressure waveform was derived non-invasively from the carotid femoral pulse wave 
using applanation tonometry. Central pressure values were estimated from carotid measurements using 
the software's mathematical transfer function. The following PWA parameters related to the amplification 
and temporal characteristics of the reflecting wave were used as independent variables in the present 
study (Figure 13): 
· Aortic Systolic pressure (mmHg) 
· Aortic Pulse Pressure (mmHg), calculated by the difference between aortic systolic and diastolic 
BP; [Aortic pulse pressure = Aortic systolic BP – Aortic diastolic BP] 
· Aortic Augmentation Pressure (mmHg); the pressure wave created by left ventricular contraction 
propagates forward until meeting sites of resistance that reflect the wave backward; thus, stiffer 
artery walls result in earlier wave reflection. When the reflected wave returns during systole 
rather than diastole, systolic pressure is increased or “augmented.” Augmentation Pressure is 
calculated by the difference between the reflected wave (P2) and forward wave (P1) 
(Augmentation Pressure=P2-P1) is a measure of how much the early reflected wave contributes 
to central systolic pressure.  
Tonometry waveform for 
femoral measurement 
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Figure 13: Aortic PWA record data of one of our patients as obtained by the SphygmoCor device 
 
· Aortic Augmentation Index (AIX) represents the level of augmentation measured and is 
expressed as a percentage of the pulse pressure (Aortic AIX = Aortic Augmentation Pressure / 
Aortic Pulse Pressure). 
· Normalized Aortic Augmentation Index AIX@75; expressed as a percentage (%) defined as AIX 
normalized to a fixed heart rate of 75 beats per minute. 
· Subendocardial viability ratio (SEVR) or Buckberg Index; is a tonometric noninvasive measure 
of myocardial perfusion (as coronary artery perfusion takes place primarily during diastole) 
relative to cardiac workload (myocardial contraction). SEVR is measured as the ratio of diastolic 
pressure time index (DPTI) to tension time index (TTI); [DPRI/TTI] and is expressed as a 
percentage (%). 
 
5. Statistical Methodology 
 
Data analyses were performed using statistical software R version 3.0.1. Quantitative variables were 
described by mean and standard deviation or by median and inter-quartile ranges (IQR); 25% percentile 
and 75% percentile. Qualitative variables were described by frequency tables and contingency tables. 
Associations between quantitative and qualitative variables were assessed using Student’s t test or Mann-
Whitney test when comparing two groups, and ANOVA or Kruskal-Wallis test when comparing three or 
more groups. Correlations between quantitative variables were evaluated using Spearman correlation 
coefficient. Scatter plots and box plots were used to describe associations between variables. In order to 
identify potential predictors of quantitative outcomes, multivariable linear regression models were fitted. 
Models were built using forward stepwise procedures in order to maximize R-Squared with the smallest 
Derived parameters taken 
from the aortic waveform 
 
 
 
A 9 seconds of captured carotid waveform and corresponding derived aortic waveform. 
B average of the captured carotid waveforms 
C average of the derived aortic waveforms 
A 
B C 
Aortic and carotid blood pressure 
(recorded by the device) 
Operator index reflecting the quality of the record 
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number of predictor variables. The statistical significance of variables in the models was assessed by 
ANOVA test.  
 
The significance level was set as the following:  
· P value <0.01 = highly Significant 
· P value <0.05 = Significant 
· P value >0.05 and <0.1= trend towards association 
 
Univariate and multivariable analyses were performed with plasma PCSK9, plasma CXCL16, 
cfPWV, Aortic AIX@75, and SEVR as dependent variables. In order not to overload the results section, 
only statistically significant results are presented.  
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RESULTS 
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We performed a cross-sectional analysis of baseline data from two partially overlapping prospective 
cohorts (Figure 11).  
One cohort, that we will term the “Biomarker” cohort, included patients with diabetic CKD not on 
dialysis on regular follow up visits in the diabetic nephropathy clinic at Fundación Jiménez Díaz 
University Hospital. In this cohort of diabetic CKD patients (n.=134) biomarkers (plasma PCSK9 and 
CXCL16) were assessed.  
A second cohort, that we will term the “Pulse Wave Assessment” cohort, included 191 individuals. 
Of these, 153 were CKD patients and 38 non-CKD patients with hypertension or high cardiovascular risk. 
Both cohorts had in common 54 diabetic CKD patients, for whom both pulse wave assessment and 
biomarkers data were available. These shared patients were analyzed together with the rest of patients 
from their respective cohorts.  
 
1. Biomarkers cohort 
 
The biomarker cohort consisted of 134 subjects; all of them were diabetic and had CKD. Most 
patients were in CKD stage 3 (49/134, 37%). Mean±SD  (standard deviation) of age was 67.9±13.9 years 
and most of the patients were males (92/134, 69%). This population was borderline obese with mean BMI 
29.7±4.2 kg/m2.   
Main patient characteristics (Table 5) and pulse wave characteristics (Table 6) were summarized 
below. 
 
Table 5:  Main characteristics of patients in the biomarkers cohort (n=134) 
 
Variable Value 
Total patients n (%) 134 (100) 
DM n (%) 134 (100) 
Hypertension n (%) 128 (95.5) 
CVD n (%) 35 (26) 
Non CKD (control) 0 
DM 122 (91) 
Vascular 12 (9) 
Glomerulonephritis 0 
CKD Etiology  
n (%) 
Unknown 0 
Non CKD (control) 0 (0) 
Stage 1 11 (8.2) 
Stage 2 40 (29.9) 
Stage 3A 14 (10.4) 
Stage 3B 35 (26.1) 
Stage 4 34 (25.4) 
CKD Stages 
n (%) 
Stage 5 0 
Non smoker 62 (46.3) 
Active smoker 25 (18.7) Cigarette smoking n (%) 
Ex-smoker 47 (35.1) 
Non consumer 82 (61.2) 
Active consumer 41 (30.6) 
Alcohol 
consumption 
n (%) Ex-consumer 11 (8.2) 
Age (years) 67.9±13.9 
Males 92 (68.7) Gender 
n (%) Females 42 (31.3) 
Height (cm) 165.1±10.3 
Weight (kg) 81.0±14.9 
Body Mass Index (kg/m2) 29.7±4.2 
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Table 6: Pulse Wave characteristics of patients in the biomarkers cohort (n=134) 
 
Variable Value 
Total patients n (%) 134  (100) 
Systolic Blood Pressure (mmHg) 143.1±17.8 
Diastolic Blood Pressure (mmHg) 75.2±11.8 
Mean Blood Pressure (mmHg) 100.1±12.4 
Pulse Pressure (mmHg) 67.9±17.1 
Mean PWV (m/sec) 11.8±3.3 
 SD PWV (m/sec) 1.3±0.7 
CF-PTT (SD) (%) 10.5±4.4 
within normal 26 (48.1) 
high normal 5 (9.3) 
PWV Reference 
Range   
n (%) above normal 23 (42.6) 
Normal values for age (m/sec) 12.5±2.4 
Delta PWV (m/sec) 1.1±2.0 
Aortic Systolic pressure (mmHg) 140.7±18.4 
Aortic Pulse Pressure(mmHg) 63.0±16.6   
 Aortic AIx@75 (%)   24.1±14.1 
SEVR; Buckberg Index (%) 143.5±27 
             
            (CF-PTT: Carotid Femoral Pulse Transit Time) 
 
Mean eGFR was 56.3±23.0 ml/min/1.73m2 and the median (IQR) UACR was 123.6 (27.1, 386.7). 
Regarding the UACR, 35 patients (26%), 56 patients (42%), 26 patients (19%) and 17 patients (13%) had 
UACR of < 30, 30 to 299, 300 to 1000 and > 1000 mg /g respectively.  
 
The baseline urinalysis parameters (Table 7), distribution of UACR (Table 8), serum analysis 
parameters (Table 9) and echocardiograms (Table 10) . 
 
 
Table 7: Urinalysis parameters of the biomarkers cohort (134 diabetic CKD patients) 
 
Urinalysis parameters / (n. of patients) Value 
Total patients 134 
Creatinine Clearance (ml/min) / (136) 66.9±34.1 
Diuresis (ml/24h) / (136) 1892.4±554.3 
Total Proteinuria (mg/24h) / (134) 320.0 (135.0, 683.5) 
Glycosuria (mg/dl) / (136) 38.4±58.1 
Spot Proteinuria (mg/dl) / (136) 17.7 (7.6, 38.0) 
UPCR (mg/g) / (136) 261.2 (127.9, 698.5) 
Total Microalbuminuria (mg/24h) / (78) 207.4 (36.5, 518.6) 
UACR (mg/g) / (137) 123.6 (27.1, 386.7) 
Spot  Creatinuria (mg/dl) / (137) 69.0±42.1 
Urinary Sodium (mmol/L) / (135) 86.0±35.3 
Urinary Potassium  (mmol/L) / (135) 34.3±15.0 
Urinary Magnesium (mg/dl) / (135) 3.9±2.1 
Urinary Magnesium (mg/24h) / (135) 71.3±35.7 
Urinary Magnesium (mg/g Cr.) / (135) 0.063± 0.030 
FEMg (%) / (135) 6.6 ±4.3 
Urinary Calcium (mg/dl) / (135) 5.1±7.2 
Phosphaturia (mg/dl) / (135) 34.2±14.1 
Phosphaturia (mg/24h) / (135) 620.9±257.2 
Phosphaturia (mg/mg Cr.) / (135) 0.546±0.200 
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Table 8: Distribution of UACR in the biomarkers cohort (134 diabetic CKD patients) 
 
UACR (mg/g) Number of patients (%) 
<30 35 (26.1) 
30-299 56 (41.8) 
300-1000 26 (19.4) 
>1000 17 (12.7) 
Total 134 (100) 
 
Table 9: Serum analysis parameters of the biomarkers cohort (134 diabetic CKD patients) 
 
Serum analysis parameters / (Number of patients) Biomarkers cohort 
Total patients 134 
Serum Creatinine (mg/dl) / (137) 1.4±0.6  
GFR (MDRD) (ml/min/1.73 m2) / (137) 56.3±23.0 
Serum Glucose (mg/dl) / (137) 141.9±50.2  
Serum Uric Acid (mg/dl) / (137) 6.5±1.7  
Serum HbA1C (%) / (137) 7.5±1.2  
Haemoglobin (g/dl) / (137) 13.6±1.7 
Serum Albumin (g/dl) / (137) 4.1±0.4  
Serum hsCRP (mg/dl) / (65) 1.2±3.3  
Serum Prealbumin (mg/dl) / (116) 27.3±6.7 
Serum Transferrin (mg/dl) / (137) 251.9±52.3  
Serum Ferritin (ng/ml) / (137) 84.5 (45.3, 176.3) 
Serum Total Cholesterol (mg/dl) / (137) 154.4±32.6 
Serum LDL Cholesterol (mg/dl) / (137) 82.8±26.1 
Serum HDL Cholesterol (mg/dl) / (137) 44.8±13.8  
Serum Triglycerides (mg/dl) / (137) 136.5±84.0 
Plasma Renin (ng/ml/hr) / (115) 6.8 (1.8, 28.0) 
Plasma Aldosterone (pg/ml) / (123) 97.7 (70.9, 144.0) 
Serum CO2 (mEq/L) / (130) 27.4±3.6 
Serum LDH (IU/l) / (137) 398.3±102.5 
Serum Sodium (mmol/l) / (137) 139.8±2.8  
Serum Potassium (mmol/l) / (137) 4.6±0.5 
Serum Magnesium (mg/dl) / (135) 1.9±0.3 
Serum Calcium (mg/dl) / (137) 9.5±0.5 
Serum Phosphorus (mg/dl) / (137) 3.5±0.6 
Serum Alkaline Phosphatase (IU/l) / (137) 84.0±32.6 
Serum Iron (μg/dl) / (137) 73.8±25.1 
Serum TIBC (μg/dl) / (137) 320.6±67.6 
Serum intact PTH (pg/ml) / (134) 52.7 (35.0, 93.6) 
Serum 25(OH)D (ng/ml) / (134) 20.1±10.3 
Serum 1,25(OH)2D (pg/ml) / (89) 30.1±12.3 
Serum Vitamin B12 (pg/ml) / (124) 427.7±204.6 
Serum Folic Acid (ng/ml) / (123) 7.8±3.7 
Serum TSH (μIU/ml) / (127) 2.2±1.2 
Serum Free T3 (pg/ml) / (121) 3.1±0.6 
Serum Free T4 (ng/dl) / (128) 1.2±0.3 
Serum Vitamin A (mg/l) / (107) 0.7±0.3 
Serum Vitamin E (μg/ml) / (107) 14.5±5.0 
Plasma PCSK9 (ng/ml) / (134) 309.8±113.9 
Plasma CXCL16 (ng/ml) / (134) 4.0±0.9 
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Table 10: Echocardiograms for biomarkers cohorts 
 
Variable Value 
Total Patients n (%) 113 (100) 
Ejection Fraction (%)  58.9±7.8 
Left Ventricular Diameter (mm) 43.4±5.8 
Interventricular septum (mm) 10.2±1.4 
Left Ventricular Hypertrophy n (%) 48 (42.5) 
Altered Relaxation n (%) 80 (70.8) 
None 100 (88.5) 
Hypertrophic  11 (9.7) Cardiomyopathy          n (%) 
Dilated 2 (1.8) 
Valvular Calcification n (%) 19 (16.8) 
Pericardial Effusion n (%) 2 (1.8) 
 
 
The majority of the patients were receiving antidiabetic; oral hypoglycemic agents (84/134, 63%) 
and Insulin (90/134, 67%) or antihypertensive (134/134, 100%) medications. As well as 113/134 (84%) 
were on lipid lowering therapy. Over 67% of the patients were taking anti-platelet therapy. A minority of 
patients were receiving vitamin D supplementation (48/134, 36%), phosphate binders (12/134, 9%), or 
ESAs (7/134, 5%). Patients’ medications (Table 11) and dosage for selected medications (Table 12) were 
summarized below. 
 
Additionally to the study of the diabetic CKD cohort, biomarkers were assessed in 4 healthy subjects 
and 3 non-diabetic CKD patients. This was for the purpose of assessing the performance of the ELISA 
assay (technique control) and these biomarker results were not used for the main statistical analysis. 
 
For the healthy subjects; mean age was 36.8±8.9 years, most of them were males (3, 75%), mean 
plasma PCSK9 was 261±76 ng/ml and mean plasma CXCL16 was 3.1±0.3 ng/ml (Annex I). 
 
For the non-diabetic CKD patients; mean age was 71.0±8.5 years, most of them were males (2, 
66.7%), mean plasma PCSK9 was 341±106 ng/ml and mean plasma CXCL16 was 5.3±0.6 ng/ml. Mean 
eGFR was 25.0±11.8 and mean UACR was 704.4±421.6 (Annex I). Further characteristics for the non-
diabetic CKD control patients, laboratory parameters, medications and echocardiograms are available in 
Annex II. 
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Table 11:  Medications of the patients in the biomarkers cohorts. 
 
Medication Number of patients (%) 
Total patients 134 (100) 
Any vitamin D or VDR activator 48 (35.8) 
Paricalcitol (mcg/w) 16 (11.9) 
Calcifediol (IU/w) 42 (31.3 
Calcitriol (mcg/w) 4 (3) 
Cinacalcet (mg/w) 1 (0.7) 
Any phosphate binder 12 (9) 
Lanthanum 1 (0.7) 
Sevelamer 4 (3) 
Aluminium- based phosphate binders 6 (4.5) 
Calcium-based phosphate binders 3 (2.2) 
Calcium Supplement 5 (3.7) 
Calcium Polystyrene Sulfonate  (Potassium chelator) 10 (7.5) 
Iron supplement 33 (24.6) 
ESAs 7 (5.2) 
Oral hypoglycemic agents 84 (62.7) 
Insulin 90 (67.2) 
Any lipid lowering agent 113 (84.3) 
Statin 110 (82.1) 
Fibrate 18 (13.4) 
Ezetimibe 14 (10.4) 
Omega 3-Fatty Acids 14 (10.4) 
Any anti-hypertensive * 134 (100) 
Any RAAS blocker 131 (97.8) 
ACEIs 60 (44.8) 
ARBs 95 (70.9) 
Spironolactone 4 (3) 
Calcium Channel Blockers 79 (59) 
Beta Blockers 37 (27.6) 
Alpha Blockers 30 (22.4) 
Alpha & Beta Blockers 1 (0.7) 
Diuretics 94 (70.1) 
Proton Pump Inhibitors 54 (40.3) 
Anti-platelets 90 (67.2) 
 
* Including RAAS blockers, calcium channel blockers, beta blockers, alpha & beta blockers and diuretics 
 
 
 
Table 12: Dosage for selected medications; only patients received the medications were analyzed. 
                  
Medication Mean±SD or Median (IQR) 
Paricalcitol (mcg/w) 3.0±2.2 
Calcifediol (UI/w) 2160 (1440, 2880) 
Calcitriol (mcg/w) 0.75 (0.70, 18.00) 
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Plasma PCSK9 
 
In the cohort of diabetic CKD patients, the mean±SD of the plasma PCSK9 level were 309.8 ± 113.9 
ng/ml. We explored the association of plasma PCSK9 levels with clinical, echocardiogram, therapeutic 
and laboratory parameters. Plasma PCSK9 values according to CKD stages (Figure 14), UACR (Figure 
15) and lipid lowering therapy (Figure 16) are shown below. 
 
 
Figure 14: Plasma PCSK9 values according to CKD stages 
 
 
 
 
Figure 15: Plasma PCSK9 values according to UACR 
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Figure 16: Plasma PCSK9 values according to lipid lowering therapy categories. * p < 0.05, ** p < 0.01 vs 
none 
 
 
The univariate analysis of plasma PCSK9 (ng/ml) with other qualitative variables (Table 13) and 
quantitative variables (Table 14), showed that PCSK9 had a significant positive correlation with lipid 
lowering therapy (statin, fibrate or both together), serum TIBC, vitamin E, plasma renin and phosphaturia 
(Figure 17). Also there was a trend towards a positive correlation with total serum cholesterol.  
 
Table 13: Correlations between plasma PCSK9 (ng/ml) and qualitative variables in univariate analysis.  
Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1) are shown. 
 
Variable N Mean SD P value 
Statin 
No 
Yes 
 
24 
110 
 
264.62 
319.62 
 
73.3 
118.92 
 
 
0.0050 
Fibrate 
No 
Yes 
 
116 
18 
 
296.16 
397.28 
 
106.69 
122.79 
 
 
0.0004 
Statin + Fibrate 
No 
Yes 
 
118 
16 
 
297.17 
402.69 
 
106.68 
125.5 
 
 
0.0004 
 
 
 
Table 14: Correlations between plasma PCSK9 (ng/ml) and quantitative variables in univariate analysis. 
Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N Coefficient P value 
Plasma Renin (ng/ml/hr) 113 0.1986 0.0350 
Phosphaturia (mg/mg Cr.) 132 0.2565 0.0030 
Serum TIBC (µg/dl) 134 0.2087 0.0155 
Serum Vitamin-E (µg/ml) 105 0.2132 0.0290 
Serum Total Cholesterol (mg/dl) 134 0.1566 0.0708 
 
Figure 20. PCSK9 levels according to lipid lowering therapy 
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Figure 17: Statistically significant correlations with PCSK9 
 
 
In multivariate models, the only parameters that remained independently significantly positively 
correlated with plasma PCSK9 were therapy with fibrate alone or fibrate with statin, serum TIBC, Log 
Renin and phosphaturia. In general, the multivariate models (Table 15) explain very little of the PCSK9 
variability. The best R squared obtained was 0.20. 
 
Table 15: Different multivariate models for predictors of PCSK9 (ng/ml) levels 
 
Model A 
 Coefficient 95% CI p value 
Intercept -16.41 -224.9 192.1 0.8760 
Statin 31.99 -23.54 87.53 0.2553 
Serum Total Cholesterol (mg/dl) 0.638 -0.154 1.43 0.1130 
Phosphaturia (mg/mg Cr) 85.83 -38.56 210.2 0.1737 
Serum TIBC (µg/dl) 0.521 0.185 0.858 0.0028 
Log Renin (ng/ml/h) 8.529 -3.557 20.62 0.1642 
Log Vitamin-E (µg/ml) -10.25 -99.15 78.64 0.8192 
R squared = 0.1551 
     
 
 
Phosphaturia (mg/mg) 
(r= 0.2565, p= 0.0030) 
TIBC (µg /dl) 
(r= 0.2087, p= 0.0155) 
  (p= 0.0004)  (p= 0.0004) 
Yes No Yes No 
Log Renin (ng/ml/hr) 
(r= 0.1986, p= 0.0350) 
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Model B 
 Coefficient 95% CI p value 
Intercept 123.717 -102.984 350.419 0.2810 
Statin + Fibrate 99.25 25.049 1 73.451 0.0093 
Serum Total Cholesterol (mg/dl) 0.519 -0.252 1.29 0.1845 
Phosphaturia (mg/mg Cr) 94.581 -26.109 215.27 0.1229 
Serum TIBC (µg/dl) 0.339 -0.017 0.694 0.0616 
Log Renin (ng/ml/h) 12.571 0.692 24.45 0.0383 
Log Vitamin-E (µg/ml) -33.944 -122.191 54.302 0.4466 
R squared = 0.2074 
 
Plasma CXCL16 
  
In the cohort of diabetic CKD patients, the mean±SD of the plasma CXCL16 levels were 4.0±0.9 
ng/ml. We explored the association of plasma CXCL16 levels with clinical, echocardiogram, therapeutic 
and laboratory parameters. Plasma CXCL16 values according to CKD stages (Figure 18) and UACR 
(Figure 19) are shown below. 
 
Figure 18: Plasma CXCL16 values according to CKD stages. *  p < 0.05; ** p < 0.01 vs  stage 1 
 
0
1
2
3
4
5
6
< 30 30 - 299 300 - 1000 > 1000
 
 
UACR (mg/g) 
 
Figure 19: Plasma CXCL16 values according to UACR. * p < 0.01 vs UACR< 30 mg/g 
 
0
1
2
3
4
5
6
7
1 2 3A 3B 4 & 5
   (N.= 11) (N.= 40)     (N.= 35) (N.= 35)    (N.= 16) 
CKD stages 
** 
* 
  
C
X
C
L1
6 
(n
g/
m
l) 
C
X
C
L1
6 
(n
g/
m
l) 
(N= 35) (N= 56) (N= 28) (N= 18) 
* 
 55 
The univariate analysis of plasma CXCL16 (ng/ml) with other qualitative variables (Table 16) and 
quantitative variables (Table 17), showed a significant positive correlation between CXCL16 and history 
of CVD or treatment with paricalcitol, calcifediol, sevelamer, aluminum containing phosphate binders, 
potassium chelation therapy with calcium polystyrene sulfonate (resin calcium), iron supplementation, 
ESAs, oral hypoglycemic agents and beta blockers.  
 
 
Table 16: Correlations between plasma CXCL16 (ng/ml) and qualitative variables in univariate analysis. 
Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1)] are shown. 
 
 
Variable N Mean SD P value 
DM 134 4.001 0.927 0.0200 
CVD 
No 
Yes 
 
99 
35 
 
3.88 
4.33 
 
0.86 
1.03 
 
 
0.0132 
Paricalcitol 
No 
Yes 
 
118 
16 
 
3.91 
4.65 
 
0.85 
1.19 
 
 
0.0024 
Calcifediol 
No 
Yes 
 
92 
42 
 
3.84 
4.35 
 
0.83 
1.03 
 
 
0.0027 
Sevelamer 
No 
Yes 
 
130 
4 
 
3.950 
5.752 
 
0.874 
0.584 
 
 
0.0000 
Aluminum-Based Phosphate 
binders 
No 
Yes 
 
128 
6 
 
3.978 
5.150 
 
0.916 
0.760 
 
 
0.0025 
Calcium polystyrene sulfonate 
No 
Yes 
 
124 
10 
 
3.966 
4.683 
 
0.940 
0.638 
 
 
0.0110 
Iron supplement 
No 
Yes 
 
101 
33 
 
3.894 
4.423 
 
0.769 
1.245 
 
 
0.0225 
ESAs 
No 
Yes 
 
 
127 
7 
 
 
3.954 
5.244 
 
 
0.898 
0.763 
 
 
 
0.0001 
Oral hypoglycemic agents 
No 
1 drug 
2 drugs 
3 drugs 
 
50 
46 
29 
9 
 
4.208 
4.154 
3.706 
3.380 
 
0.901 
0.976 
0.895 
0.595 
 
 
 
 
0.0135 
Beta Blockers 
No 
Yes 
 
97 
37 
 
3.929 
4.291 
 
0.861 
1.084 
 
 
0.0427 
Ezetimibe 
No 
Yes 
 
120 
14 
 
3.979 
4.473 
 
0.933 
0.898 
 
 
0.0616 
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Table 17: Correlations between plasma CXCL16 (ng/ml) and quantitative variables in univariate 
analysis. Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N. Coefficient P value 
Age (years) 134 0.1942 0.0246 
Diastolic BP (mmHg) 134 - 0.2089 0.0154 
Pulse Pressure (mmHg) 134 0.1865 0.0310 
Paricalcitol dosage (mcg/w) 134 0.2221 0.0099 
Calcifediol dosage (IU/w) 134 0.2222 0.0099 
GFR (MDRD) (ml/min/1.73 m2) 134 - 0.5116 0.0000 
Total Proteinuria (mg/24h) 134 0.3226 0.0001 
UACR (mg/g) 134 0.3024 0.0004 
Hemoglobin (g/dl) 134 - .03017 0.0004 
Serum Albumin (g/dl) 134 - 0.3520 0.0000 
Serum CO2 (mEq/l) 127 - 0.1911 0.0314 
FEMg (%) 132 0.3256 0.0001 
Serum Calcium (mg/dl) 134 - 0.2284 0.0079 
Serum Phosphorus (mg/dl) 134 0.2230 0.0096 
Serum Alkaline phosphatase (IU/l) 134 0.2929 0.0006 
Serum TIBC (µg/dl) 134 - 0.2399 0.0052 
Serum intact PTH (pg/ml) 131 0.3612 0.0000 
Serum 1,25 (OH)2D (pg/ml) 87 - 0.2172 0.0433 
Serum Folic acid (ng/ml) 121 - 0.1992 0.0285 
Interventricular septum (mm) 113 0.1748 0.0641 
SEVR; Buckberg index (%) 54 - 0.2487 0.0697 
 
 
In addition, positive correlations were found between CXCL16 and age, pulse pressure, 24-hour 
urinary protein, UACR, fractional excretion of magnesium (FEMg), serum phosphorus, alkaline 
phosphatase and intact PTH. CXCL16 had a negative correlation with diastolic BP, eGFR (MDRD), Hb, 
serum TIBC, serum albumin, CO2, serum calcium, 1,25(OH)2D and folic acid (Figure 20).  
 
There was also a trend towards a positive correlation between CXCL16 and ezetimibe intake and 
interventricular septum thickness and a trend towards a negative correlation with SEVR.  
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Figure 20: Statistically significant correlations with CXCL16 
 
Several multivariate models (Table 18) showed that GFR and serum albumin remained 
independently significantly negatively correlated with plasma CXCL16, while UACR and serum alkaline 
phosphatase were independently positively correlated with plasma CXCL16. In addition, there was a 
trend towards a negative correlation with Log 1,25(OH)2D and a trend towards a positive correlation with 
serum phosphorus. The best R squared obtained was 0.34. 
 
Table 18: Different multivariate models for predictors of CXCL16 (ng/ml) levels 
 
Model A 
 Coefficient 95% CI p value 
Intercept 3.302 0.578 6.026 0.0181 
GFR (MDRD) (ml/min/1.73 m2) -0.019 -0.027 -0.010 0.0000 
Log UACR (mg/g) 0.098 -0.012 0.208 0.0792 
Serum Phosphorus (mg/dl) 0.181 -0.130 0.492 0.2501 
Log Alkaline phosphatase (IU/l) 0.380 -0.164 0.924 0.1684 
Log 1,25 (OH)2D ( pg/ml) -0.311 -0.755 0.132 0.1661 
R squared = 0.347 
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Model B 
 Coefficient 95% CI p value 
Intercept 6.289  1.867  10.711 0.0059 
Age (years) -0.007 -0.022  0.008 0.3472 
GFR (MDRD) (ml/min/1.73 m2) -0.023 -0.034 -0.013 0.0000 
FEMg (%) 0.001 -0.048  0.050 0.9621 
Serum Calcium (mg/dl) -0.147 -0.523  0.229 0.4384 
Serum Phosphorus (mg/dl) 0.240 -0.089  0.570 0.1499 
Serum Alkaline phosphatase (IU/l) 0.005  0.000  0.014 0.0393 
Serum intact PTH (pg/ml) -0.002 -0.004  0.001 0.1309 
Serum 1,25 (OH)2D (pg/ml) -0.014 -0.029  0.001 0.0691 
R squared = 0.3426 
Model C 
 Coefficient 95% CI p value 
Intercept 6.282  1.778  10.787 0.0069 
Age (years) -0.008 -0.023  0.008 0.3336 
GFR (MDRD) (ml/min/1.73 m2) -0.024 -0.034 -0.013 0.0000 
Calcifediol dosage (IU/w) 0.000 -0.000  0.000 0.7468 
Paricalcitol dosage (mcg/w) -0.015 -0.135  0.104 0.7985 
FEMg (%) 0.002 -0.048  0.053 0.9263 
Serum Calcium (mg/dl) -0.141 -0.525  0.243 0.4662 
Serum Phosphorus (mg/dl) 0.239 -0.095  0.572 0.1579 
Serum Alkaline phosphatase (IU/l) 0.007 -0.000  0.014 0.0505 
Serum intact PTH (pg/ml) -0.002 -0.004  0.001 0.1342 
Serum 1,25 (OH)2D (pg/ml) -0.014 -0.030  0.001 0.0666 
R squared = 0.3267 
Model D 
 Coefficient 95% CI p value 
Intercept 8.000 6.505 9.495 0.0000 
GFR (MDRD) (ml/min/1.73 m2) -0.016 -0.022 -0.010 0.0000 
Serum Albumin (g/dl) -0.751 -1.126 -0.376 0.0001 
R squared = 0.3002 
Model E 
 Coefficient 95% CI p value 
Intercept 8.075 5.727 10.424 0.0000 
Age (years) -0.008 -0.019 0.003 0.1498 
GFR (MDRD) (ml/min/1.73 m2) -0.018 -0.025 -0.011 0.0000 
Log UACR (mg/g) 0.048 -0.035 0.131 0.2587 
Serum Albumin (g/dl) -0.700 -1.136 -0.263 0.0019 
Serum TIBC (µg/dl) 0.001 -0.002 0.003 0.6179 
R squared = 0.3049 
Model F 
 Coefficient 95% CI p value 
Intercept 2.250 0.337 4.163 0.0215 
GFR (MDRD) (ml/min/1.7m2) -0.016 -0.022 -0.010 0.0000 
UACR (mg/g) 0.081 0.005 0.156 0.0359 
Serum Phosphorus (mg/dl) 0.195 -0.055 0.445 0.1251 
Serum Alkaline phosphatase (IU/l) 0.370 -0.021 0.761 0.0638 
R squared = 0.2865 
Model G 
 Coefficient 95% CI p value 
Intercept 5.108 4.061 6.156 0.0000 
Age (years) -0.004 -0.015 0.008 0.5322 
GFR (MDRD) (ml/min/1.7m2) -0.018 -0.025 -0.011 0.0000 
UACR (mg/g) 0.000 0.000 0.001 0.0029 
R squared = 0.2675 
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Model H 
 Coefficient 95% CI p value 
Intercept 6.176  2.686  9.666 0.0006 
Age (years) -0.005 -0.017  0.007 0.4203 
GFR (MDRD) (ml/min/1.7m2) -0.018 -0.026 -0.009 0.0000 
FEMg (%) 0.014 -0.026  0.054 0.4919 
Serum Calcium (mg/dl) -0.223 -0.544  0.099 0.1728 
Serum Phosphorus (mg/dl) 0.239 -0.030  0.507 0.0811 
Serum Alkaline phosphatase (IU/l) 0.005  0.000  0.009 0.0495 
Serum intact PTH (pg/ml) -0.001 -0.003  0.001 0.4272 
R squared = 0.2725 
 
 
2. Pulse Wave Assessment cohort 
 
The Pulse Wave Assessment cohort consisted of 191 subjects. Most of them were diabetic (153/191, 
80%) and had CKD (153/191, 80%). DM was the main cause of the CKD (134/191, 70%). This cohort 
included 38/191 (20%) non-CKD patients with high CV risk. Most CKD patients were in CKD stage 3 
(80/191, 42%). Mean age was 61.2±12.9 years and most of the patients were males (140/191, 73%). This 
population was borderline obese with mean BMI 29.6±5.2 kg/m2 and cfPWV was above normal levels for 
age in 85/191 (44.5%).  
 
Main patient characteristics (Table 19) and pulse wave characteristics (Table 20) were summarized 
below. 
 
Table 19:  Main characteristics of patients in the pulse wave assessment cohort (n=191) 
 
Total patients n (%) 191 (100) 
DM n (%) 153 (80.1) 
Hypertension n (%) 167 (87.4) 
CVD n (%) 41 (21.5) 
Non CKD (control) 38 (19.9) 
DM 134 (70.2) 
Vascular 16 (8.4) 
Glomerulonephritis 1 (0.5) 
CKD Etiology 
n (%) 
Unknown 2 (1) 
Non CKD (control) 38 (19.9) 
Stage 1 16 (8.4) 
Stage 2 49 (25.7) 
Stage 3A 47 (24.6)  
Stage 3B 33 (17.3) 
Stage 4 7 (3.7) 
CKD Stages 
n (%) 
Stage 5 1 (0.5) 
Non smoker 77 (40) 
Active smoker  49 (26) Cigarette smoking n (%) 
Ex-smoker 65 (34) 
Non consumer 126 (66) 
Active consumer 57 (30) 
Alcohol 
consumption 
n (%) Ex-consumer 8 (4) 
Age (years) 61.2±12.9 
Males 140 (73) Gender n (%) 
Females 51 (27) 
Height (cm) 168.0±9.4 
Weight (kg) 83.8±17.1 
Body Mass Index (kg/m2) 29.6±5.2 
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Table 20:  Pulse Wave characteristics of patients in the pulse wave assessment cohort (n=191) 
 
Variable Value 
Systolic Blood Pressure (mmHg) 141.2±18.8 
Diastolic Blood Pressure (mmHg) 78.7±12.9 
Mean Blood Pressure (mmHg) 103.1±14.0 
Pulse Pressure (mmHg) 62.5±16.8 
Mean PWV (m/sec) 10.9±3.1 
 SD PWV (m/sec) 1.2±0.7 
CF-PTT (SD) (%) 10.5±4.4 
within normal 92 (48.2) 
high normal 14 (7.3) 
PWV Reference 
Range  
n (%) above normal 85 (44.5) 
Normal values for age (m/sec) 12.0±2.4 
Delta PWV (m/sec) 0.8±1.6 
Aortic Systolic pressure (mmHg) 139.9±19.3 
Aortic Pulse Pressure(mmHg) 60.9±17.6 
 Aortic AIx@75 (%) 24.6±18.7 
SEVR (%) 141.1±30.0 
 
 
Mean eGFR was 64±21.7 ml/min/1.73m2 and the median (IQR) UACR was 97.2 (23.3, 348). 
Regarding the UACR, 68 patients (35.6%), 72 patients (37.7%), 33 patients (17.3%) and 18 patients 
(9.4%) had UACR of < 30, 30 to 299, 300 to 1000 and > 1000 mg /g respectively.  
 
The baseline urinalysis parameters (Table 21), distribution of albuminuria (Table 22), serum 
analysis parameters (Table 23) and echocardiograms (Table 24) for the pulse wave assessment cohort 
were summarized below. 
 
Table 21: Urinalysis parameters of the pulse wave assessment cohort (n=191) 
 
Urinalysis Parameters / (Number of patients) Pulse Wave Assessment cohort 
Total patients 191 
Creatinine Clearance (ml/min) / (158) 74.1±33.6 
Diuresis (ml/24h) / (158) 1894.0±584.8 
Total Proteinuria (mg/24h) / (153) 275 (137, 670) 
Glycosuria (mg/dl) / (167) 81.8 ± 230.2 
Spot Proteinuria (mg/dl) / (157) 17.7 ( 8.2, 36.5) 
UPCR (mg/g) / (156) 240.3 (120.0, 562.3) 
Total Microalbuminuria (mg/24h) / (54) 152.4 (38.4, 336.0) 
UACR (mg/g) / (175) 97.2 (23.3, 348.0) 
Spot  Creatinuria (mg/dl) / (175) 85.7±52.1 
Urinary Sodium (mmol/L) / (146) 91.9±38.3 
Urinary Potassium  (mmol/L) / (146) 37.3±14.6 
Urinary Magnesium (mg/dl) / (130) 4.1±2.2 
Urinary Magnesium (mg/24h) / (130) 71.7±34.6 
Urinary Magnesium (mg/g Cr.) / (130) 0.059±0.030 
FEMg (%) / (130) 5.6±3.2 
Urinary Calcium (mg/dl) / (132) 4.9±4.5 
Phosphaturia (mg/dl) / (131) 35.8±14.9 
Phosphaturia (mg/24h) / (131) 644.7±256.1 
Phosphaturia (mg/mg Cr.) / (131) 0.514±0.160 
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Table 22: Distribution of UACR among the pulse wave assessment cohort (n=191) 
 
UACR (mg/g) Number of patients (%) 
<30 68 (35.6) 
30-299 72 (37.7) 
300-1000 33 (17.3) 
>1000 18 (9.4) 
Total 191 (100) 
 
Table 23: Serum analysis parameters of the pulse wave assessment cohort (n=191) 
 
Laboratory Parameters / (Number of patients) Pulse Wave Assessment cohort 
Total patients 191 
Serum Creatinine (mg/dl) / (191) 1.2±0.5 
GFR (MDRD) (ml/min/1.73 m2) / (191) 64.0±21.7 
Serum Glucose (mg/dl) / (140) 140.2±56.5 
Serum Uric Acid (mg/dl) / (185) 6.6±1.8 
Serum HbA1C (%) / (185) 7.3±1.5 
Haemoglobin (g/dl) / (191) 14.0±1.6 
Serum Albumin (g/dl) / (179) 4.3±0.3 
hsCRP (mg/dl) / (90) 0.8±1.8 
Serum Prealbumin (mg/dl) / (118) 28.9±6.8 
Serum Transferrin (mg/dl) / (177) 255.4±50.1 
Serum Ferritin (ng/ml) / (182) 109.5 (53.3, 192.8) 
Serum Total Cholesterol (mg/dl) / (191) 163.1±37.5 
Serum LDL Cholesterol (mg/dl) / (188) 89.6±30.1 
Serum HDL Cholesterol (mg/dl) / (188) 44.3±13.2 
Serum Triglycerides (mg/dl) / (191) 147.6±89.1 
Plasma Renin (ng/ml/hr) / (98) 2.95 (1.30, 7.20) 
Plasma Aldosterone (pg/ml) / (111) 91.0 (64.6, 129.5) 
Serum CO2 (mEq/L) / (145) 28.0±3.4 
Serum LDH (IU/l) / (188) 374.5±89.9 
Serum Sodium (mmol/l) / (189) 140.2±2.7 
Serum Potassium (mmol/l) / (189) 4.6±0.5 
Serum Magnesium (mg/dl) / (148) 1.9±0.2 
Serum Calcium (mg/dl) / (184) 9.5±0.4 
Serum Phosphorus (mg/dl) / (180) 3.4±0.6 
Serum Alkaline Phosphatase (IU/l) / (187) 77.9±25.3 
Serum Iron (μg/dl) / (183) 75.8±26.5 
Serum TIBC (μg/dl) / (182) 325.4±60.3 
Serum intact PTH (pg/ml) / (164) 51.6 (38.1, 87.1) 
Serum 25(OH)D (ng/ml) / (164) 20.2±10.5 
Serum 1,25(OH)2D (pg/ml) / (66) 34.9±14.4 
Serum Vitamin B12 (pg/ml) / (167) 416.7±156.3 
Serum Folic Acid (ng/ml) / (159) 8.8±4.3 
Serum TSH (μIU/ml) / (178) 2.4±1.4 
Serum Free T3 (pg/ml) / (133) 3.1±0.5 
Serum Free T4 (ng/dl) / (153) 1.2±0.2 
Serum Vitamin A (mg/l) / (96) 0.7±0.2 
Serum Vitamin E (μg/ml) / (96) 14.2±4.3 
Plasma PCSK9 (ng/ml) / (54) 296.0±102.1 
Plasma CXCL16 (ng/ml) / (54) 3.9±0.8 
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Table 24: Echocardiograms for pulse wave assessment cohorts (n=191) 
 
Variable Value 
Total  Patients n (%) 140 (100) 
Ejection Fraction (%)  59.9±6.0 
Left Ventricular Diameter (mm) 43.2±4.8 
Interventricular septum (mm)  10.2±1.4 
Left Ventricular Hypertrophy n (%) 56 (40) 
Altered Relaxation n (%) 91 (65) 
None 126 (87.1) 
Hypertrophic  16 (11.4) Cardiomyopathy n (%) 
Dilated 2 (1.4) 
Valvular Calcification n (%) 23 (16.4) 
Pericardial Effusion n (%) 3 (2.1) 
 
 
The majority of the patients were receiving antidiabetic; oral hypoglycemic agents; 90/191, 47% and 
Insulin; 100/191, 52%) or antihypertensive (168/191, 88%) medications. Lipid lowering therapy was 
prescribed to 145/191 (76%). Over 50 % of the patients were taking anti-platelet therapy. A minority of 
patients were receiving vitamin D supplementation (49/191, 26%), phosphate binders (9/191, 5%), or 
ESAs (3/191, 2%). Patients’ medications (Table 25) and dosage for selected medications (Table 26) were 
summarizes below.  
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Table 25: Medications of the patients in the Pulse Wave Assessment cohort; only patients received the 
medications were analyzed. 
 
Medication Number of patients (%) 
Total patients 191 (100) 
Any vitamin D or VDR activator 49 (25.7) 
Paricalcitol (mcg/w) 17 (8.9) 
Calcifediol (IU/w) 37 (19.4) 
Calcitriol (mcg/w) 3 (1.6) 
Cinacalcet (mg/w) 0 
Any phosphate binder 9 (4.7) 
Lanthanum 1 (0.5) 
Sevelamer 1 (0.5) 
Aluminium- based phosphate binders 1 (0.5) 
Calcium-based phosphate binders 6 (3.1) 
Calcium Supplement 3 (1.6) 
Calcium Polystyrene Sulfonate  (Potassium chelator) 9 (4.7) 
Iron supplement 23 (12) 
ESAs 3 (1.6) 
Oral hypoglycemic agents 90 (47.1) 
Insulin 100 (52.4) 
Any lipid lowering agent 145 (75.9) 
Statin 132 (69.1) 
Fibrate 28 (14.7) 
Ezetimibe 16 (8.4) 
Omega 3-Fatty Acids 15 (7.9) 
Any anti-hypertensive * 168 (88) 
Any RAAS blocker 166 (86.9) 
ACEIs 84 (44) 
ARBs 103 (53.9) 
Spironolactone 11 (5.8) 
Calcium Channel Blockers 97 (50.8) 
Beta Blockers 45 (23.6) 
Alpha Blockers 35 (18.3) 
Alpha & Beta Blockers 2 (1) 
Diuretics 107 (56) 
Proton Pump Inhibitors 69 (36.1) 
Anti-platelets 101 (52.9) 
 
* Including RAAS blockers, calcium channel blockers, beta blockers, alpha & beta blockers and diuretics 
 
Table 26: Dosage for selected medications; only patients received the medications were analyzed. 
 
Medication Mean±SD or Median (IQR) 
Paricalcitol (mcg/w) 4.1±2.1 
Calcifediol (UI/w) 2160 (1440, 4000) 
Calcitriol (mcg/w) 0.6±0.3 
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Mean Pulse Wave Velocity 
 
In Pulse Wave Assessment cohort the mean±SD of the PWV were 10.9±3.1 m/sec. In the whole 
cohort 85/191 (44.5%) of patients had mean PWV above normal values for their age (Table 17).  Among 
CKD patients 73/153 (47.7%) had mean PWV above normal values for their age, with mean PWV 
13.6±2.6 m/sec. Among non-CKD patients 12/38 (31.6%) had mean PWV above normal values for their 
age, with mean PWV 10.8±2.3 m/sec.  
 
We explored the association of mean PWV with clinical, echocardiogram, therapeutic and 
laboratory parameters.  
 
The univariate analysis of mean PWV (m/sec) with other quantitative variables (Table 27) and 
qualitative variables (Table 28), showed a significant positive correlations between mean PWV and DM, 
hypertension, history of CVD, male gender and treatment with calcium containing phosphate binders, 
resin calcium, iron supplement, statin, ezetimibe, ARBs, diuretics, alpha blockers, proton pump 
inhibitors, anti-platelets. In addition, PWV positively correlated with age, systolic BP, pulse pressure, 
ejection fraction, UACR, serum uric acid, glucose and HbA1c. Also mean PWV was significantly 
negatively correlated with GFR, total serum cholesterol, LDL cholesterol, 1,25(OH)2D and SEVR 
(Figures 21). Mean PWV had a trend towards a positive correlation with altered ventricular relaxation and 
serum potassium, while there was a trend towards a negative correlation with serum 25(OH)D and free T3  
 
 
Table 27: Correlations between mean PWV (m/sec) and quantitative variables in univariate analysis. 
Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1)] are shown. 
 
 
Variable N Coefficient P value 
Age (years) 191 0.4533 0.0000 
Systolic Blood Pressure (mmHg) 191 0.4207 0.0000 
Pulse Pressure (mmHg) 191 0.4692 0.0000 
Ejection Fraction (%) 140 0.1964 0.0201 
GFR (MDRD) (ml/min/1.73 m2) 190 -0.2890 0.0001 
UACR (mg/g) 175 0.1574 0.0375 
Serum uric acid (mg/dl) 185 0.2928 0.0001 
Serum glucose (mg/dl) 190 0.1542 0.0336 
HbA1c (%) 185 0.2588 0.0004 
Serum Total cholesterol (mg/dl) 190 -0.2281 0.0015 
Serum LDL cholesterol (mg/dl) 188 -0.2387 0.0010 
Serum Potassium (mmol/l) 189 0.1425 0.0504 
Serum 25(OH)D (ng/ml) 164 -0.1347 0.0854 
Serum 1,25 (OH)2D ( pg/ml) 66 -0.3363 0.0058 
Serum Free T3 (pg/ml) 133 -0.1703 0.0500 
SEVR or Buckberg Index (%) 183 -0.3742 0.0000 
 
 65 
 
 
Table 28: Correlations between mean PWV (m/sec) and qualitative variables in univariate analysis.  
Only statistically significant (p < 0.05) results or trends (p > 0.05 to p < 0.1)] are shown. 
 
 
Variable N Mean SD P value 
DM 
No 
Yes 
 
38 
153 
 
8.74 
11.47 
 
2.19 
3.01 
 
 
0.0000 
HTN 
No 
Yes 
 
24 
167 
 
8.36 
11.3 
 
2.41 
2.97 
 
 
0.0000 
CVD 
No 
Yes 
 
150 
41 
 
10.66 
11.91 
 
2.94 
3.33 
 
 
0.0199 
Gender 
Females 
Males 
 
51 
140 
 
9.95 
11.29 
 
2.85 
3.07 
 
 
0.0072 
Calcium-Based Phosphate Binders 
No 
Yes 
 
185 
6 
 
10.83 
13.92 
 
3 
3.6 
 
 
0.0147 
Calcium polystyrene sulfonate 
No 
Yes 
 
182 
9 
 
10.72 
15.11 
 
2.93 
2.65 
 
 
0.0000 
Iron supplement 
No 
Yes 
 
168 
23 
 
10.73 
12.37 
 
2.93 
3.67 
 
 
0.0160 
Statin 
No 
Yes 
 
59 
132 
 
9.98 
11.35 
 
2.79 
3.09 
 
 
0.0040 
Ezetimibe 
No 
Yes 
 
175 
16 
 
10.78 
12.6 
 
3.04 
2.89 
 
 
0.0221 
ARBs 
No 
Yes 
 
88 
103 
 
10.07 
11.67 
 
2.73 
3.15 
 
 
0.0003 
Alpha blockers 
No 
Yes 
 
156 
35 
 
10.69 
12.01 
 
2.98 
3.21 
 
 
0.0202 
Diuretics 
No 
Yes 
 
84 
107 
 
10.2 
11.5 
 
2.88 
3.09 
 
 
0.0032 
Proton Pump Inhibitors 
No 
Yes 
 
122 
69 
 
10.39 
11.88 
 
2.81 
3.27 
 
 
0.0011 
Anti-Platelets 
No 
Yes 
 
90 
101 
 
9.88 
11.87 
 
2.79 
3.00 
 
 
0.0000 
Altered ventricular relaxation 
No 
Yes 
 
49 
91 
 
10.69 
11.65 
 
2.64 
3.29 
 
 
0.0794 
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Figure 21: Statistically significant correlations with Mean PWV 
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Different multivariate models (Table 29) showed that advanced age, systolic BP, DM, serum uric 
acid, UACR and resin calcium therapy were independently positively correlated with the mean PWV. The 
best R squared obtained was 0.335.  
 
Table 29:  Different multivariate models for predictors of mean PWV (m/sec) 
 
Model A 
 Coefficient 95% CI p value 
Intercept -1.015 -4.156 2.125 0.5243 
DM 1.287 0.296 2.279 0.0112 
Age (years) 0.062 0.031 0.092 0.0001 
Serum Uric acid (mg/dl) 0.288 0.076 0.501 0.0080 
Systolic Blood Pressure (mmHg) 0.036 0.016 0.057 0.0006 
Calcium polystyrene sulfonate 2.968 1.258 4.679 0.0008 
R squared= 0.3354 
Model B 
 Coefficient 95% CI p value 
Intercept -0.209 -3.775 3.357 0.9079 
Gender (male) 1.043 0.197 1.890 0.0160 
DM  1.250 0.251 2.250 0.0145 
Age (years) 0.066 0.033 0.099 0.0001 
Systolic Blood Pressure (mmHg) 0.026 -0.005 0.057 0.0948 
Pulse Pressure (mmHg) 0.026 -0.012 0.065 0.1732 
R squared = 0.3109 
Model C 
 Coefficient 95% CI p value 
Intercept -1.618 -4.830 1.595 0.3217 
DM 1.380 0.361 2.399 0.0082 
Age (years) 0.070 0.039 0.101 0.0000 
Serum Uric Acid (mg/dl) 0.309 0.091 0.528 0.0057 
Systolic Blood Pressure (mmHg) 0.036 0.015 0.057 0.0008 
R squared = 0.2958 
Model D 
 Coefficient 95% CI p value 
Intercept  4.627  1.465 7.790 0.0044 
DM  1.101 -0.162 2.364 0.0870 
CVD -0.134 -1.134 0.867 0.7925 
Gender (male)  0.784 -0.157 1.724 0.1017 
Age (years)  0.086  0.050 0.123 0.0000 
GFR (MDRD) (ml/min/1.73 m2) -0.008 -0.029 0.013 0.4332 
UACR (mg/g)  0.001  0.000 0.001 0.0348 
R squared = 0.2036 
 
Delta above upper limit of normal PWV (Delta PWV)  
 
Since the PWV increases with age and indeed we found a very significant correlation between PWV 
and age (Figure 22), we next explored parameters associated with the absolute increase in PWV over the 
higher expected normal limit of the age-adjusted PWV in the general population. Thus, the Delta PWV 
parameter was calculated as follows= (measured PWV) - (Upper limit of the age-adjusted PWV values 
for the general population).  
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Figure 22: Statistically significant correlations with Delta PWV 
 
The mean±SD of the Delta PWV were 0.8±1.6 m/sec. That is, as a mean, the PWV was 0.8 m/sec 
higher than the expected PWV for the patient’s age. We explored the association of delta PWV with 
clinical, echocardiogram, therapeutic and laboratory parameters.  
 
The univariate analysis of delta PWV with other qualitative (Table 30) and quantitative (Table 31) 
variables, showed that delta PWV was significantly positively correlated with DM, active smoking and 
use of resin calcium or ARBs. In addition, delta PWV was significantly positively correlated with systolic 
BP, diastolic BP, mean BP, UACR and HbA1c. On the other hand, delta PWV had significant negative 
correlations with age, SEVR, valvular calcification, use of calcium supplementation or beta blockers, 
serum CO2, serum sodium, urinary potassium and phosphaturia. The delta PWV had a trend towards a 
positive correlation with serum phosphorus and plasma CXCL16, and a trend towards a negative 
correlation with serum free T4 and creatinuria. 
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Table 30: Correlations between delta PWV (m/sec) and qualitative variables in univariate analysis.  
Only statistically significant results (p < 0.05) or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N Mean SD P value 
DM 
No 
Yes 
 
38 
153 
 
0.27 
0.89 
 
0.68 
1.74 
 
 
0.0008 
Smoking 
Non-smoker 
Active smoker 
Ex-smoker 
 
77 
49 
65 
 
0.43 
1.36 
0.72 
 
0.96 
2.25 
1.53 
 
 
 
0.0188 
Valvular calcification 
No 
Yes 
 
117 
23 
 
0.91 
0.38 
 
1.82 
0.63 
 
 
0.0148 
Pericardial effusion 
No 
Yes 
 
137 
3 
 
0.84 
0.07 
 
1.71 
0.12 
 
 
0.0000 
Calcium supplement 
No 
Yes 
 
188 
3 
 
0.78 
0.00 
 
1.61 
0.00 
 
 
0.0000 
Calcium polystyrene sulfonate 
No 
Yes 
 
182 
9 
 
0.69 
2.23 
 
1.54 
2.18 
 
 
0.0046 
ARBs 
No 
Yes 
 
88 
103 
 
0.45 
1.03 
 
1.08 
1.91 
 
 
0.0087 
Beta blockers 
No 
Yes 
 
146 
45 
 
0.95 
0.18 
 
1.78 
0.40 
 
 
0.0000 
 
 
Table 31: Correlations between delta PWV (m/sec) and quantitative variables in univariate analysis. Only 
statistically significant results (p < 0.05) or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N Coefficient P value 
Age (years) 191 - 0.2338 0.0011 
Systolic Blood Pressure (mmHg) 191 0.2215 0.0021 
Diastolic Blood Pressure (mmHg) 191 0.1649 0.0226 
Mean Blood Pressure (mmHg) 191 0.2004 0.0054 
SEVR or Buckberg index (%) 183 - 0.2874 0.0001 
UACR (mg/g) 175 0.1774 0.0188 
Urinary Creatinine (mg/dl) 175 - 0.1399 0.0648 
HbA1c (%) 185 0.1667 0.0233 
Serum CO2 (mEq/l) 145 - 0.1986 0.0166 
Serum sodium (mmol/l) 189 - 0.1557 0.0324 
Serum phosphorus (mmol/l) 180 0.1395 0.0618 
Urinary phosphorus (mg/dl) 131 - 0.1812 0.0384 
Urinary potassium (mmol/l) 146 - 0.3225 0.0001 
Serum Free T4 (mg/dl) 153 - 0.1551 0.0556 
Plasma CXCL16 (ng/ml) 54 0.2376 0.0836 
 
 
In the multivariate analysis (Table 32), systolic BP, active smoking and resin calcium therapy 
remained independently positively correlated with delta PWV, while age, urinary potassium and beta 
blocker therapy were independently negatively correlated with delta PWV. The multivariate model 
explain a little of the delta PWV variability with R squared of 0.27. 
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Table 32:  Multivariate analysis model for predictors of delta PWV (m/sec) 
 
 Coefficient 95% CI p value 
Intercept 0.970 - 1.679 3618 0.4703 
DM 0.437 - 0.844 1.718 0.5007 
Gender (Male) 0.023 - 0.626 0.672 0.9442 
Age (years) - 0.038 0.060 - 0.015 0.0014 
Smoking 
    Active smoker 
    Ex-smoker 
 
1.036 
0.409 
 
0.331 
- 0.234 
 
1.742 
1.053 
 
 
0.0152 
Calcium polystyrene sulfonate 1.278 0.193 2.362 0.0212 
Beta blockers - 0.971 - 1.554 - 0.388 0.0013 
Systolic Blood Pressure (mmHg) 0.019 0.005 0.033 0.0092 
Urinary potassium (mmol/l) - 0.029 - 0.047 - 0.011 0.0015 
R squared = 0.2729 
 
 
Aortic Augmentation Index adjusted by heart rate (Aortic AIX@75)  
 
The mean±SD of the Aortic AIX@75 was 24.6±18.7 %. We explored the association of Aortic 
AIX@75 with clinical, echocardiogram, therapeutic and laboratory parameters.  
The univariate analysis of the Aortic AIX@75 with other qualitative (Table 33) and quantitative 
(Table 34) variables, showed significant positive correlations between Aortic AIX@75 and systolic BP, 
Mean BP, pulse pressure, UACR and therapy with statin, beta blockers, anti-platelets or calcifediol. 
Aortic AIX@75 had significant negative correlations with male gender, height, weight and ejection 
fraction (Figure 23). A trend towards a positive correlation was found between Aortic AIX@75 and 
CVD, diuretic therapy and serum sodium and LDH, while a trend towards a negative correlation was 
found with paricalcitol therapy, serum magnesium and Hb. 
 
 
Figure 23: Statistically Significant Correlations with Aortic AIX@75 
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Table 33:  Correlations between Aortic AIX@75 (%) and qualitative variables in univariate analysis. 
Only statistically significant results (p < 0.05) or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N Mean SD P value 
CVD 
No 
Yes 
 
142 
39 
 
22.81 
27.25 
 
15.24 
13.15 
 
 
0.0995 
Gender 
Females 
Males 
 
47 
134 
 
30.15 
21.53 
 
12.73 
14.99 
 
 
0.0005 
Oral hypoglycemic agent 
No 
1 drug 
2 drugs 
3 drugs 
 
92 
48 
25 
16 
 
24.48 
20.06 
31.64 
18.48 
 
14.62 
15.11 
9.63 
17.89 
 
 
0.0060 
Statin 
No 
Yes 
 
54 
127 
 
20.39 
25.20 
 
16.99 
13.73 
 
 
0.0464 
Beta blockers 
No 
Yes 
 
138 
43 
 
22.14 
28.98 
 
15.72 
10.36 
 
 
0.0013 
Diuretics 
No 
Yes 
 
78 
103 
 
21.19 
25.71 
 
16.88 
12.93 
 
 
0.0510 
Anti-Platelets 
No 
Yes 
 
83 
98 
 
20.88 
26.21 
 
16.82 
12.61 
 
 
0.0188 
Calcifediol 
No 
Yes 
 
146 
35 
 
20.20 
30.31 
 
15.30 
10.98 
 
 
0.0006 
 
 
Table 34: Correlations between Aortic AIX@75 (%) and quantitative variables in univariate analysis. 
Only statistically significant results (p < 0.05) or trends (p > 0.05 to p < 0.1)] are shown. 
 
Variable N Coefficient P value 
Height (cm) 181 - 0.2637 0.0003 
Weight (kg) 181 - 0.2340 0.0015 
Systolic Blood Pressure (mmHg) 181 0.1847 0.0128 
Mean Blood Pressure (mmHg) 181 0.2015 0.0065 
Pulse Pressure (mmHg) 181 0.1576 0.0341 
Ejection Fraction (%) 136 - 0.2216 0.0095 
Paricalcitol dosage (mcg/w) 181 - 0.1279 0.0862 
Calcifediol dosage  (UI/w) 181 0.2124 0.0041 
UACR (mg/g) 168 0.2377 0.0019 
Haemoglobin (g/dl) 180 - 0.1300 0.0821 
Serum LDH (IU/l) 179 0.1280 0.0877 
Serum Sodium (mmol/l) 180 0.1241 0.0969 
Serum magnesium (mg/dl) 142 - 0.1612 0.0553 
 
 
In the multivariate analysis (Table 35). , mean BP and age independently positively correlated with 
Aortic AIX@75, while male gender and ejection fraction were independently negatively correlated with 
Aortic AIX@75. Age was added to the multivariate analysis despite not being significant in the univariate 
analysis because of its strong effect on arterial stiffness. The multivariate model explain a little of the 
Aortic AIX@75 variability with R squared of 0.20. 
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Table 35:  Multivariate regression analysis for predictors of Aortic AIX@75 
 
 Coefficient 95% CI p value 
Intercept 12.002 -20.703 44.706 0.4690 
Age (years) 0.246 0.047 0.444 0.0156 
Gender (Male) -11.759 -17.308 -6.211 0.0001 
Mean Blood Pressure (mmHg) 0.311 0.135 0.488 0.0007 
Ejection Fraction (%) -0.517 -0.892 -0.142 0.0073 
UACR (mg/g) 1.028 -0.247 2.303 0.1130 
R squared = 0.2252 
 
Subendocardial viability ratio (SEVR; or Buckberg Index) 
 
The mean±SD of the SEVR was 141.1±30.0 %. We explored the association of SEVR with clinical, 
echocardiogram, therapeutic and laboratory parameters.  
The univariate analysis of SEVR with other qualitative (Table 36) and quantitative (Table 37) 
variables, showed significant positive correlations between SEVR and male gender, beta blockers therapy 
as well as between SEVR and serum Hb, sodium and 25(OH)D. SEVR had significant negative 
correlations with DM, systolic BP, mean BP, pulse pressure or therapy with iron supplementation, 
ezetimibe or proton pump inhibitors. In addition, SEVR had significant negative correlations with mean 
PWV, ejection fraction, serum glucose, HbA1c, hsCRP, LDH, potassium, phosphorus and vitamin B12 
(Figure 24). A trend towards a positive correlation was found between SEVR and serum CO2 and free T3, 
while a trend towards a negative correlation was found with plasma CXCL16 and serum TIBC. 
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Table 36: Correlations between Subendocardial Viability Ratio (SEVR; Buckberg Index) (%) and 
qualitative variables in univariate analysis. Only statistically significant results (p < 0.05) or trends (p > 
0.05 to p < 0.1) are shown . 
 
 
Variable N Mean SD P value 
DM 
No 
Yes 
 
35 
148 
 
150.37 
138.93 
 
25.72 
26.87 
 
 
0.0236 
Gender 
Females 
Males 
 
47 
136 
 
129.21 
145.24 
 
24.03 
26.78 
 
 
0.0004 
Iron Supplement 
No 
Yes 
 
160 
23 
 
143.16 
126.96 
 
26.93 
23.10 
 
 
0.0067 
Ezetimibe 
No 
Yes 
 
168 
15 
 
142.41 
126.67 
 
26.93 
23.58 
 
 
0.0299 
Beta blockers 
No 
Yes 
 
139 
44 
 
138.65 
148.93 
 
25.05 
31.33 
 
 
0.0271 
Proton Pump Inhibitors 
No 
Yes 
 
115 
68 
 
144.72 
135.03 
 
29.04 
21.91 
 
 
0.0115 
 
 
 
 
Table 37: Correlations between Subendocardial Viability Ratio (SEVR; Buckberg Index) (%) and 
quantitative variables in univariate analysis. Only statistically significant results (p < 0.05) or trends (p > 
0.05 to p < 0.1) are shown. 
 
 
Variable N Coefficient P value 
Systolic Blood Pressure (mmHg) 183 - 0.2897 0.0001 
Mean Blood Pressure (mmHg) 183 - 0.1488 0.0444 
Pulse Pressure (mmHg) 183 - 0.3174 0.0000 
Mean PWV (m/sec) 183 - 0.3742 0.0000 
Ejection Fraction (%) 135 - 0.2025 0.0185 
Serum glucose (mg/dl) 182 - 0.1872 0.0114 
HbA1c (%) 178 - 0.2045 0.0062 
Haemoglobin (g/dl) 182 0.1827 0.0136 
hsCRP (mg/dl) 84 - 0.2618 0.0162 
Serum LDH (IU/l) 181 - 0.1799 0.0154 
Serum Sodium (mmol/l) 182 0.1634 0.0275 
Serum potassium (mmol/l) 182 - 0.1682 0.0233 
Serum phosphorus (mg/dl) 173 - 0.1539 0.0432 
Serum 25 (OH) Vitamin-D (ng/ml) 159 0.3136 0.0001 
Serum Vitamin-B12 (pg/ml) 160 - 0.1560 0.0489 
Serum Free T3 (pg/ml) 128 0.1583 0.0742 
Plasma CXCL16 (ng/ml) 54 - 0.2487 0.0697 
Serum CO2 (mEq/l) 140 0.1513 0.0743 
Serum TIBC (µg/dl) 176 - 0.1412 0.0615 
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Figure 24: Statistically Significant Correlations with SEVR or Buckberg Index 
 
Age (years) 
(r= -0.0033, p= 0.9648) 
Pulse pressure (mmHg) 
(r= -0.3174, p= 0.0000) 
Mean PWV (m/sec) 
(r= -0.3742, p= 0.0000) 
Log 25(OH)D (ng/ml) 
(r= 0.3136, p= 0.0001) 
B
u
c
k
b
e
r
g 
B
u
c
k
b
e
r
g 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
B
uc
kb
er
g 
In
de
x 
(%
) 
Male 
Proton pump inhibitors 
(p= 0.0115) 
Beta blockers 
(p= 0.0271) 
Female No Yes 
No Yes 
Gender 
(p= 0.0004) 
 75 
 
In the multivariate analysis (Table 38), beta blocker therapy and log 25(OH)D independently 
positively correlated with SEVR, while age, female gender, pulse pressure, mean PWV and proton pump 
inhibitor therapy were independently negatively correlated with SEVR. Age was added to the multivariate 
analysis despite not being significant in the univariate analysis because of the strong effect of advanced 
age on arterial stiffness and cardiac performance. The multivariate model explains little of the SEVR 
variability with the highest R squared obtained being 0.39. 
 
Table 38: Multivariate regression analysis for predictors of Subendocardial Viability Ratio [SEVR] (%) 
 
 Coefficient 95% CI p value 
Intercept 129.4 100.7 158.0 0.0000 
Age (years) 0.522 0.191 0.853 0.0022 
Gender (Male) 16.58 8.58 24.57 0.0001 
Pulse Pressure (mmHg) -0.389 -0.633 -0.146 0.0019 
Mean PWV (m/sec) -3.295 -4.631 -1.958 0.0000 
Log 25 (OH) Vitamin-D 25 10.21 3.62 16.81 0.0026 
Proton Pump Inhibitor -8.155 -15.650 -0.662 0.0331 
Beta Blockers 8.43 0.080 16.78 0.0478 
R squared = 0.3898 
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DISCUSSION 
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The main findings from this study may be summarized as follows:  
1. Plasma PCSK9 values in diabetic CKD patients are very variable and the factors underlying this 
variability are unclear. However, the use of lipid lowering therapies containing fibrates appears to be a 
key contributor. We may speculate that increased PCSK9 levels may contribute to "scape" from the lipid 
lowering effect of lipid lowering therapies. No effects of renal function or albuminuria on PCSK9 levels 
were noted. Despite PCSK9 been a potential determinant of serum cholesterol levels, no relationship to 
cardiovascular disease was observed in this cohort. 
2. By contrast to PCSK9, plasma CXCL16 correlated with renal function and albuminuria as well as 
with parameters of bone mineral metabolism. The present observational study does not provide clues as to 
cause-effect relationships. Increased CXCL16 levels may represent an aspect of the systemic 
inflammation associated with uremia. Alternatively, higher CXCL16 levels may contribute to kidney 
injury or the presentation of CKD related Mineral Bone Disease (CKD-MBD). Follow-up of the cohort 
will provide information on the prognostic value of the assessment of this parameter. Despite 
inflammation been a potential contributor to cardiovascular disease, no relationship of CXCL16 with 
cardiovascular disease was observed in this cohort. 
3. The analysis of modifiable determinants of PWV, a measure of arterial stiffness, identified serum 
uric acid, UACR and resin calcium therapy as independently and positively correlated with the mean 
PWV, while analysis of values of PWV above the age-expected normal range further identified active 
smoking as associated with higher delta PWV. By contrast, urinary potassium and beta blocker therapy 
were independently negatively correlated with delta PWV. These data identify a potential relationship 
between uric acid and potassium metabolism with arterial stiffness. 
4. Among modifiable factors, beta blocker therapy and 25(OH)D levels independently positively 
correlated with subendocardial viability ratio (SEVR), suggesting that they are associated with improved 
myocardial perfusion. By contrast, proton pump inhibitor therapy was independently negatively 
correlated with SEVR. 
Several aspects merit further discussion. 
 
Plasma PCSK9  
 
Mean plasma PCSK9 levels in diabetic CKD patients were 310±114 ng/ml. These represent 
relatively high levels. However, reported values in the general population and controls are very variable. 
Thus, previously reported mean values include 100±7 ng/ml for the general population [339], 177±13 
ng/ml in 112 healthy controls [225] and 327±131 ng/ml in 178 controls [248].. These differences may 
relate to the type of ELISA used, and genetic or environmental factors. In our small group of 4 healthy 
individuals PCSK9 values were 261±76 ng/ml while in 3 non-diabetic CKD patients they were 341 ±106 
ng/ml. Thus, diabetic CKD patients have PCSK9 values not very different from our small group of 
controls for the technique and are also similar to values reported previously for CKD patients on 
hemodialysis (276±110 ng/ml) for [248] and for type 2 DM patients (270±59 ng/ml) [340]. However, 
PCSK9 in hemodialysis patients was reported to be lower than in controls (276±110 ng/ml vs 327±131 
ng/ml) [341], while  Plasma PCSK9 was described as increased in proteinuric CKD subjects when 
compared to controls (213 [161-314] vs. 143 [113-190] ng/mL)  [342]. 
 Our regression analysis showed that the independent predictors of PCSK9 were combined statin-
fibrate lipid lowering therapy, serum TIBC and plasma renin.  
Lipid lowering therapy has been reported to increase plasma PCSK9 [343, 344]. This may be one of 
the mechanisms of resistance or poor therapy to these drugs and is specially interesting because of the 
expected availability of specific therapy in the near future. Recent clinical trials have reported a lipid 
lowering effect of monoclonal antibodies targeting PCSK9 in 160 statin-intolerant patients [345] and 631 
subjects with hypercholesterolemia receiving background therapy with statin [346]. 
A meta-analysis indicated a significant elevation of circulating PCSK9 concentrations following 
fibrate therapy (95% CI: 11.04-109.71; p=0.02). The PCSK9-elevating effect of fibrates remained 
significant after comparison with a control group receiving either placebo or a statin (95% CI: 5.68-42.26; 
p=0.01). Meta-regression analysis indicated that the effect size of fibrates in modulating circulating 
PCSK9 levels is not dependent to the duration of treatment [343]. In an open randomized study using 400 
mg bezafibrate or 200 mg fenofibrate on 14 patients with dyslipidemia with impaired glucose tolerance or 
type 2 DM, fibrates significantly increased plasma PCSK9 concentrations (+40% for bezafibrate and 
+67% for fenofibrate, p<0.001) [340]. In another study 12 weeks of fenofibrate 200 mg/day significantly 
increased serum PCSK9 levels by 25% in 22 patients with dyslipidemia and HbA1C<8% [339]. Fibrates 
stimulate a specific nuclear receptor designated as peroxisome proliferator-activated receptor alpha 
(PPAR-α) [341, 347, 348]. As PPAR-α agonists, fibrates improve triglyceride and HDL-Cholesterol 
concentrations by enhancing-oxidation of fatty acids and lipoprotein lipase (LPL) activity, increasing 
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production of the components of HDL (apolipoproteins A1 and A2), and reducing production of the 
inhibitor of LPL activity (apolipoprotein C3) [349-353], while enhancing cholesterol efflux from the liver 
[354]. Several reports [339, 355, 356] suggest that these effects of PPAR-α on cholesterol and lipoprotein 
metabolism may lead indirectly to decrease hepatic intracellular cholesterol levels, and thus result in a 
secondary increase in PCSK9 expression and secretion. Fibrates show different binding properties against 
PPAR subtypes, which could cause different clinical effects on circulating PCSK9 levels [340].  
Statins have also been reported to impact on PCSK9 levels. A 34% significantly higher serum 
PCSK9 levels were observed after 16 weeks of atorvastatin 40 mg/d [344]. In another study the 55 
patients on atorvastatin and 27 patients on rosuvastatin had around 45% (P<0.001) higher plasma PCSK9 
and PCSK9 increased with increasing statin dose. When atorvastatin was increased from 5 to 80 mg, 
plasma PCSK9 levels increased from 109±33 to 142±35 ng/ml and for rosuvastatin from 5 to 40 mg, 
plasma PCSK9 increased from 123±23 to 168±84 ng/ml [236]. Statins increase PCSK9 mRNA 
expression, and increase the activity/nuclear translocation of SREBP-2, a transcription factor that 
activates both the LDLR and PCSK9 genes [226, 357]. Our univariate analysis showed the significant 
correlations between plasma PCSK9 and statin alone and fibrate alone therapy, but in the multivariate 
analysis only combined fibrate-statin therapy was independent predictor which had not been reported 
before in the literature. 
In 39 CKD patients (e-GFR 61±29 mL/min/1.73 m2 with proteinuria 1.9 [0.9-3.3] g/day), 19 of them 
on statins and none on fibrates, plasma PCSK9 was elevated in proteinuria but no independent correlation 
with lipid lowering therapy was found [342]. However, we did not find a relationship with UACR. 
There is no clear explanation for the correlation of serum TIBC with plasma PCSK9. TIBC is an 
indirect measure of serum transferrin concentration. Higher TIBC levels may represent iron deficiency or 
absence of factors that decrease transferrin, i.e. absence of inflammation or malnutrition or severe 
proteinuria. However, if the association between TIBC and PCSK9 represents an indirect measure of the 
presence or absence of any of these factors, it is unclear why no association was found with variables that 
more closely reflect iron status, malnutrition, inflammation or proteinuria. A common link between TIBC 
and PCSK9 is that they are both synthesized by hepatocytes.   
There is also no clear explanation for the association between plasma PCSK9 and log plasma renin. 
PPAR-α may contribute to expression of renin, as knocking out the gene for PPAR-α in mice reduced 
plasma renin [358]. However, it is highly unlikely that fibrate use explains the association between log 
plasma renin and PCSK9, since the association between renin and PCSK9 remained statistically 
significant when combined statin-fibrate therapy was included in the multivariate model. Furthermore, 
mean renin activity was 13.3±28.0 ng/ml/hr in patients on fibrate and 34.9±73.3 ng/ml/hr in patients not 
on fibrates. 
 
Plasma CXCL16 
 
Mean±SD of plasma CXCL16 levels were 4.0±0.9 ng/ml. This compares with previously reported 
mean values of 1.30±0.05 ng/ml for the general population, 2.65±0.11 ng/ml for CKD patients, 3.04±0.16 
ng/ml for DKD patients and 1.23±0.04 ng/ml for type 2 DM patients [190]. Our small group of healthy 
individuals had CXCL16 levels of 3.1±0.3 ng/ml. Thus, circulating CXCL16 levels appear to be increased 
in diabetic CKD patients. 
Our multiple regression analysis demonstrated that the independent predictors of high plasma 
CXCL16 were low eGFR, low serum albumin, high UACR and high serum alkaline phosphatase. There 
was a trend towards a positive association between CXCL16 levels and serum phosphorus, while there 
was a trend towards a negative association with serum 1,25(OH)2D.  Thus, a relationship was found 
between CXCL16 and parameters of renal function/renal injury (eGFR, UACR), nutrition (serum 
albumin, although there are other influences on serum albumin levels) and mineral bone metabolism 
(serum alkaline phosphatase, serum phosphorus, serum 1,25(OH)2D). The relationship with alkaline 
phosphatase remained significant in models that included eGFR, suggesting that this association is 
independent from renal function. 
eGFR, serum albumin and UACR may be interrelated. Thus, there was a positive correlation 
between eGFR and serum albumin (r2=0.03, p=0.0001) and a negative correlation between eGFR and 
UACR (r2=0.27, p=0.0029). However, in some models both serum albumin and UACR were independent 
predictors of plasma CXCL16 when adjusted for eGFR. 
A study of 146 CKD patients indicated that plasma CXCL16 levels were independently associated 
with eGFR (P<0.05) [189]. In 30 DKD patients showed that plasma CXCL16 levels were independently 
associated with eGFR and negatively correlated with blood albumin [190]. Plasma CXCL16 was 
positively correlated with 24-hour urine protein but negatively correlated with albumin in 50 active 
nephrotic syndrome patients [359]. The association between plasma CXCL16 and GFR may be related to 
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either a low clearance of CXCL16 when renal function deteriorates or to the presence of inflammation in 
CKD. In this regard, it is not known how CXCL16 is cleared from the circulation. The fact that CXCL16 
correlated with proteinuria in nephrotic syndrome suggests that circulating CXCL16 is no excreted in 
great amounts in urine or that synthesis is higher than potential urinary losses. 
The correlation between the plasma CXCL16 and serum alkaline phosphatase is of potential interest. 
Loss of GFR is associated with increase serum alkaline phosphatase which itself is a clinical sign 
associated with crude mortality and strong death risk [360]. A study included 313 normoalbuminuric type 
1 DM patients showed that alkaline phosphatase levels were significantly associated with eGFR 
(p ≤ 0.007) [361]. The influence of eGFR on both plasma CXCL16 and serum alkaline phosphatase might 
explain the positive correlation found in our cohort between plasma CXCL16 and serum alkaline 
phosphatase. However, alkaline phosphatase and eGFR were independent predictors of plasma CXCL16 
levels, and in our cohort there was no correlation between eGFR and alkaline phosphatase. Thus, an 
alternate explanation should be sought. Markers of systemic inflammation had been previously found to 
be associated with markers of CKD-MBD, including alkaline phosphatase levels in patients with CKD 
[173, 362-364]. Thus, our finding represented additional evidence supporting a link between systemic 
inflammation and CKD-MBD. In this regard, the trend towards the associations between plasma CXCL16 
and serum phosphorus and 1,25(OH)2D levels may be further evidence of the inflammation and CKD-
MBD link. 
In addition, loss of eGFR is associated with decreased phosphate clearance, high fibroblast growth 
factor-23 (FGF-23) and low soluble Klotho [365, 366]. A link of the association between CXCL16 and 
CKD-MBD parameters with these alterations may be hypothesized. Thus, inflammation decreases Klotho 
which has anti-inflammatory actions. High FGF-23 leads to decrease of serum 1,25(OH)2D [366-368], 
which may suggest that the negative trend we found between plasma CXCL16 and serum 1,25(OH)2D is 
related to loss of the eGFR. 
 
Mean Pulse Wave Velocity (PWV) 
 
Our results showed that 85 patients (44.5%) had PWV higher than normal for age with mean PWV 
10.9±3.1 m/sec. Stepwise multiple regression analyses revealed that the independent determinants of 
PWV included non-modifiable (age, male gender, presence of DM) and modifiable factors (serum uric 
acid, UACR and resin calcium therapy for hyperkalemia). 
These observations are concordant with previous studies that have also identified age, male gender, 
systolic BP, the presence of DM and UACR as determinants of higher PWV [310, 369-379]. Our 
observation that PWV increased to a greater extent with age in males vs. females is consistent with data 
from another study that identified male gender as an independent determinant of increased PWV in a 
large cohort of people with CKD [310, 371]. 
Increasing age was an independent predictor of PWV and arterial stiffness in most studies in healthy 
individuals [380] or CKD patients [371, 381]. In 1717 CKD stage 3 patients, age was the main predictor 
of PWV, while albuminuria was a weaker determinant and eGFR was not a determinant of PWV [371]. 
Even in ESRD on regular hemodialysis, age was an independent predictor of PWV and arterial stiffness 
[382]. Interestingly, some studies found that the carotid artery is more affected by the aging process than 
the femoral artery, even in healthy subjects. Local PWV and arterial distensibility have strong 
correlations with age at the carotid artery, but not with the femoral artery [383, 384]. The increase in 
arterial stiffness with age is proposed to be due to overproduction of abnormal collagen fibers and a loss 
of elastin from the extracellular matrix [385, 386]. It is not clear, however, whether this is a time 
dependant phenomenon directly related to chronological age or if it reflects exposure to other risk factors. 
Hypertension has long been recognized as a major determinant of arterial stiffness due to the associated 
medial hypertrophy [291]. The association between diabetes and arterial stiffness may be due to 
accumulation of AGE that provoke structural changes in the arterial wall [387] and the generation of 
reactive oxygen species that deactivate nitric oxide resulting in endothelial dysfunction [388]. 
Interestingly, UACR is independently associated with arterial stiffness assessed by PWV in subjects 
with DM and hypertension [379, 389, 390], as well as in a non-diabetic, non-hypertensive population 
[391], and the general population [19, 392, 393]. The association of albuminuria and vascular stiffness 
may represent the presence of endothelial injury leading to both phenomena [394], an effect of vascular 
stiffness on UACR or systemic consequences of albuminuria that may favor arterial stiffness. Functional 
animal studies are needed to answer this question. Meanwhile, renal doppler sonography calculation of 
the renal artery vascular resistance have demonstrated associations of a resistive index to proteinuria in 
CKD patients with and without DM [395], to albuminuria and also to a measure of aortic stiffness 
(brachial-ankle) in 150 patients with type 2 DM [396]. In patients with hypertension, a modest increase in 
renal resistive index was associated with a greater adjusted relative risk of albuminuria [397]. 
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There is a strong association between hyperuricemia and CV morbidity or mortality [398-404]. In 
our study serum uric acid level was an independent determinant of PWV. Prior studies had linked serum 
uric acid with arterial stiffness in diabetes and non-CKD patients. In 106 male diabetic non-CKD patients 
[405] and in 3772 non-diabetic non-CKD individuals [406] serum uric acid was an independent 
determinant of PWV and arterial stiffness. However, for the first time we link serum uric acid and PWV 
in diabetic CKD patients. Our results may be related to the observation that use of allopurinol was 
independently associated with lower PWV in diabetic CKD patients, despite absence of significant 
correlation with serum uric acid levels [407]. 
Potassium chelation therapy was an independent determinant of PWV in our study. The significance 
of this observation is unclear, but merits further investigation. Thus the effects of potassium chelation 
therapy may be related to the chelation agent itself, which is known to release calcium in the gut and may 
favor phosphate binder-induced alkalosis [408]. Resin calcium was the potassium chelator in our study, 
composed of calcium polystyrene sulfonate [409-411]. Indeed, in hemodialysis patients, dialysate calcium 
and acute changes in the serum ionized calcium, even within physiological range, were associated with 
detectable changes of arterial stiffness and PWV [412]. Both calcium load and alkalosis may favor 
vascular calcification. However, patients on  potassium chelation therapy had mean CO2 of 26.1±3.0 
mEq/l, while those patients who were not taking potassium chelation therapy had mean CO2 of 28.1±3.4 
mEq/l. Potassium chelation therapy may be a surrogate for hyperkalemia. Advanced CKD, DM, coronary 
artery disease, and peripheral vascular disease are independent predictors of hyperkalemia [413, 414]. 
Hyperkalemia is associated with increases in all-cause mortality and hospitalizations in those patients 
[415]. However, we did not encounter a significant correlation between the PWV and serum potassium, 
Furthermore, most of our patients were normokalemic. Conversely, potassium chelation therapy might be 
associated with intracellular potassium depletion. However, we do not have evidence pro or against this 
concept. Finally, the need for potassium chelation therapy may be a surrogate for medication increasing 
potassium levels or represent an underlying hormonal misbalance that impairs renal potassium excretion. 
In any case, there is some evidence for a relationship between potassium and arterial stiffness. 
Extracellular potassium has been reported to impact endothelial cell function and endothelial cell 
stiffness. An acute increase of potassium in the physiological range swells and softens the endothelial cell 
and increases the release of nitric oxide [416]. The relationship between endothelial stiffness and arterial 
stiffness is unclear. While a high-salt diet increases ambulatory arterial stiffness index, addition of 
potassium supplementation to the high-salt diet prevents the increase in ambulatory arterial stiffness index 
[417]. In a randomized, controlled trial a salt substitute (65% sodium chloride, 25% potassium chloride, 
10% magnesium sulfate) over 12 months decreased BP and PWV compared with regular salt (100% 
sodium chloride) [418]. However, it is unclear what was driving the effect: low sodium or supplemental 
potassium or magnesium In this regard, in a randomized controlled trial increased potassium intake from 
fruit and vegetables or supplements did not modify PWV [419]. 
 
Delta upper limit of normal PWV (Delta PWV) 
 
Delta PWV was calculated by subtracting the higher normal median PWV of healthy general 
population of the same age from the patient mean PWV (the difference between normal and abnormal 
PWV). All patients with positive values were considered to have an abnormally high PWV for their age, 
while those Within the normal limits were assigned a value of zero. All patients were included in the delta 
PWV statistical analysis. 
Smoking, high systolic BP, and potassium chelation therapy were independent determinants of the 
high Delta PWV, while advanced age, increase urinary potassium and beta blocker therapy were 
independent determinants of low Delta PWV. 
Previous studies showed that the systolic BP [369, 372, 375] and smoking were independent 
predictors of PWV in diabetic non-CKD patients [405] and in healthy individuals [420]. 
Our study disclosed that the potassium chelation therapy is an independent predictor of high delta 
PWV and low urinary potassium as an independent predictor of high delta PWV. This further information 
regarding the association of low urinary potassium does not add further light to the issue. Thus, low 
urinary potassium may represent whole body potassium depletion, an impaired ability to excrete urinary 
potassium, the consequence of the use of potassium chelators or the use of potassium sparing drugs. In 
this regard, the impact of potassium metabolism on arterial stiffness has been poorly documented in the 
literature.  
A correlation between beta blockers and the delta PWV was observed. Beta blockers, especially 
vasodilating beta blockers, the most widely prescribed in our study, have been shown to decrease PWV in 
humans. The beta blocker nebivolol 5mg/day for 15 days in 13 essential hypertension non-diabetic, non-
CKD patients significantly reduced central aortic pressure and PWV [421]. Nebivolol, but not atenolol, 
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acted directly on the arterial wall to increase arterial distensibility and was associated with reduced PWV 
[422, 423]. Nebivolol is a highly selective β1-blocker currently on clinical use. Nebivolol enantiomers 
have different pharmacologic properties; D-isomer providing the beta-blocking activity and both the D- 
and L-isomers have an endothelial NO-dependent vasodilating effect [424, 425]. Thus nebivolol may 
impact vascular structure and function either directly by reducing BP or indirectly by increasing the 
bioavailability of NO [425]. Carvedilol; a vasodilating nonselective beta blocker, reduced PWV in 
hypertensive patients during 24 weeks of treatment [426]. However, no studies have addressed the effects 
of beta blockers on arterial stiffness using PWV in diabetic CKD patients.  
 
Aortic Augmentation Index adjusted by heart rate (Aortic AIX@75) 
 
Our study revealed that advanced age, high mean BP, female gender and low cardiac ejection 
fraction were independent predictors of high Aortic AIX@75. This was in concordant with previous 
studies performed in CKD and ESRD patients which showed that age, gender and mean arterial BP were 
independent predictors of Aortic AIX@75 [427-430]. Studies on in ESRD patients on hemodialysis 
revealed that low fractional shortening is independent predictor of Aortic AIX [318, 319]. The only factor 
associated to Aortic AIX@75 in our study that is modifiable is BP. 
 
Subendocardial viability ratio (SEVR; or Buckberg Index) 
 
The mean±SD of the SEVR were 141.1±30.0 %. This high value means a good myocardial 
perfusion. The SEVR reflects myocardial oxygen supply and demand, with low values representing a 
lesser degree of myocardial perfusion [431]. The ratio of diastolic time index (pressure load during 
diastole) vs. tension time index (pressure load during systole), that is, the integral of pressure and time 
during diastole and systole, respectively, has been shown to correlate well with the ratio of subepicardial 
to subendocardial blood flow, and therefore represents an index of subendocardial viability [432]. The 
SEVR is an independent predictor of coronary flow reserve in patients with essential hypertension [433]. 
The myocardial oxygen demand slightly increases in relation to blood supply in untreated hypertensive 
patients [434]. 
Independent predictors of low SEVR (representing worse myocardial perfusion) were female 
gender, high pulse pressure, high mean PWV and proton pump inhibitor therapy, while advanced age, 
high 25(OH)D and beta blocker therapy were independent predictors of high SEVR.  
Our univariate analysis did not show a significant correlation between age and SEVR, however we 
included age in the multivariate regression analysis because of its relationship with arterial stiffness and 
cardiac performance. Low SEVR has been reported in several studies to be independently associated with 
old age [318, 427, 435, 436]. High SEVR was independently associated with old age in some multivariate 
models explaining about 30 % of the variability of SEVR. However, this was not the case in other 
models. 
The association of low SEVR with female gender had been previously described in type 1 DM [435] 
and healthy population [318], however the association with low serum 25(OH)D [437] had been 
previously described in healthy population.  
The observed positive correlation between beta blocker therapy and SEVR might have been related to the 
BP control. There were no significant differences in mean diastolic BP between patients on beta blocker 
therapy and those not on beta blockers, while systolic BP and pulse pressure were significantly higher in 
patients on beta blocker therapy (146.4±20.2 mmHg vs. 139.6±18.1 mmHg and 70.2±18.7 mmHg vs. 
60.1±15.5 mmHg, respectively) . However, beta blocker use was an independent predictor of SEVR when 
pulse pressure was on the same multivariate model and the fact that patients on beta blockers therapy had 
higher pulse pressure does not fit with the inverse association between SEVR and pulse pressure. The 
inverse association between SEVR and pulse pressure had been previously reported. SEVR tended to be 
lower in hypertensive patients with pulse pressure > 60 mmHg than in hypertensive patients with normal 
pulse pressure [438]. In a meta-analysis pulse pressure but not the mean BP was an independent predictor 
of CV complications and all-cause mortality in older hypertensive patients [439]. Pulse pressure is 
generated by the left ventricle during systole and is dampened by the compliance of the aorta. Loss of 
aortic compliance with age or CVD will lead to greater pulse pressure. In addition, hypertension increases 
the LV afterload thus increases LV workload and consequently myocardial oxygen demand, increasing 
the susceptibility for myocardial ischemia [432]. 
 
In this cohort, PWV was an independent predictor of SEVR. In 54 non-diabetic hemodialysis 
patients severe vascular calcification was associated with higher PWV and lower SEVR. Ultrafiltration 
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improved both PWV (mean reduction of 16%) and SEVR (increase of 13%) and the severity of vascular 
calcifications influenced the effect of ultrafiltration on these two parameters [440]. 
In our study use of proton pump inhibitors was associated with low SEVR. This finding is 
concordant with the result of a study of 387 ESRD hemodialysis patients which reported that long-term 
treatment with proton pump inhibitors, especially in the presence of warfarin treatment, was associated 
with vascular calcification [441]. Another study found that proton pump inhibitors use was associated 
with increased major adverse CV events in patients with unstable coronary syndromes [442]. Proton 
pump inhibitors inhibit the activity of DDAH, an enzyme necessary for CV health. DDAH metabolizes 
ADMA; a uremic toxin which is an endogenous and competitive inhibitor of NOS. By inhibiting 
endothelial NOS, ADMA may increase CV risk [442, 443]. 
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CONCLUSIONS 
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The present thesis allows to draw the following conclusions: 
 
1. Plasma PCSK9 values in diabetic CKD patients are very variable and the factors underlying this 
variability are unclear. The use of lipid lowering therapies containing fibrates is associated with higher 
plasma PCSK9. However, PCSK9 did not correlate with features of vascular injury.  
 
2. Plasma CXCL16 values in diabetic CKD patients increased with renal function deterioration and 
albuminuria and correlate with parameters of bone mineral metabolism, but not with features of vascular 
injury.  
 
3. Arterial stiffness was very prevalent in CKD patients. Among modifiable factors associated with 
arterial stiffness we found serum uric acid, albuminuria and potassium metabolism. 
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CONCLUSIONES 
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La presente tesis permite extraer las siguientes conclusiones: 
 
1. Los valores de PCSK9 plasmáticos en pacientes con ERC diabéticos son muy variables y los 
factores que subyacen a esta variabilidad no están claros. El uso de terapia hipolipemiante con fibratos se 
asocia con niveles de PCSK9 más altos. Sin embargo, PCSK9 no se relacionó con patología 
cardiovascular. 
 
2. Los valores de CXCL16 plasmáticos en pacientes diabéticos con ERC aumentan con el deterioro 
de la función renal y la albuminuria, y se correlacionaron con parámetros del metabolismo mineral óseo, 
pero no con patología cardiovascular.  
 
3. La rigidez arterial es muy frecuente en los pacientes con ERC. Entre los factores modificables 
asociados con la rigidez arterial se encuentran la uricemia, albuminuria y el metabolismo de potasio.  
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ANNEX I 
 
 
Biomarkers characteristics of healthy individuals   
 
 Age (years) Gender PCSK9 (ng/ml) CXCL16 (ng/ml) 
Control 1  31  Male 204 3.19 
Control 2  50  Male  221 3.33 
Control 3  32   Male 248 3.27 
Control 4  34  Female 372 2.65 
Mean ± SD 36.8±8.9 ---------- 261.2±76.2 3.1±0.3 
 
 
 
Biomarkers characteristics of non diabetic CKD patients 
 
 Age (years) Gender 
PCSK9 
(ng/ml) 
CXCL16 
(ng/ml) 
eGFR 
(ml/min/ 
1.73m2) 
UACR 
(mg/g) 
CKD 1 72 Female 230 5.33 28 1189.9 
CKD2 64 Male 352 5.87 12 430.9 
CKD 3 79 Male 441 4.61 35 492.3 
Mean ± SD 71.0±8.5 --------- 341.0±105.9 5.3±0.6 25.0±11.8 704.4±421.6 
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ANNEX II 
 
 
General Description of non diabetic CKD patients (with biomarkers) 
 
Variable Value 
Total number of patients   n (%) 3 (100) 
DM n (%) 0 
Hypertension n (%) 2 (66.7) 
CVD 1 (33.3) 
Vascular 1 (33.3) 
CKD Etiololgy n (%) 
Chronic interstitial nephritis 2 (66.7) 
Stage 3B 1 (33.3) 
Stage 4 1 (33.3) CKD Stages n (%) 
Stage 5 1 (33.3) 
Non smoker 2 (66.7) 
Active smoker 1 (33.3) Cigarette smoking n (%) 
Ex-smoker 0 
Alcohol consumption n (%) 0 
Age (years) 71.0±8.5 
Males 2 (66.7) 
Gender n (%) 
Females 1 (33.3) 
Height (cm) 159.5±4.9 
Weight (kg) 69.3±3.1 
Body Mass Index (kg/m2) 28.2±2.6 
Systolic Blood Pressure (mmHg) 143.3±12.3 
Diastolic Blood Pressure (mmHg) 81.3± 20.2 
Mean Blood Pressure (mmHg) 102.7±17.4 
Pulse Pressure (mmHg) 62.0±14.7 
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Medications of the non diabetic CKD patients (with biomarkers) 
 
Medication Number of patients (%) 
Total patients 3 (100) 
Paricalcitol (mcg/w) 3 (100) 
Calcifediol (IU/w) 3 (100) 
Calcitriol (mcg/w) 0 
Cinacalcet (mg/w) 1 (33.3) 
Lantanum 1 (33.3) 
Sevelamer 2 (66.7) 
Aluminium- based phosphate binders 0 
Calcium-based phosphate binders 0 
Calcium Supplement 0 
Calcium Polystyrene Sulfonate   
(Potassium chelator) 2 (66.7) 
Iron supplement 2 (66.7) 
ESAs 1 (33.3) 
Oral hypoglycemic agents 1 (33.3) 
Insulin 0 
Statin 2 (66.7) 
Fibrate 0 
Ezetimibe 0 
Omega 3-Fatty Acids 0 
ACEIs 1 (33.3) 
ARBs 0 
Spironolacatone 0 
Calcium Channel Blockers 2 (66.7) 
Beta Blockers 1 (33.3) 
Alpha Blockers 0 
Alpha & Beta Blockers 0 
Diuretics 0 
Proton Pump Inhibitors 2 (66.7) 
Antiplatelets 0 
 
 
 
Dosage for selected medications of non diabetic CKD patients (with biomarkers), Only patients received 
the medications were analyzed 
 
Medication Mean±SD 
Paricalcitol (mcg/w) 5.0±2.6 
Calcifediol (UI/w) 1680.0±415.7 
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Serum analysis parameters of non diabetic CKD patients (with biomarkers) 
 
Laboratory Parameters / (n. of patients) Non diabetic CKD control 
Total patients n (%) 3 (100) 
Serum Creatinine (mg/dl) / (3) 3.1±1.9 
GFR (MDRD) (ml/min/1.73 m2) / (3) 25.0±11.8 
Serum Glucose (mg/dl) / (3) 105.7±29.9 
Serum Uric Acid (mg/dl) / (3) 6.6±1.3 
Serum HbA1C (%) / (3) 6.0±0.6 
Haemoglobin (g/dl) / (3) 13.2±2.4 
Serum Albumin (g/dl) / (3) 3.9±0.6 
Serum hsCRP (mg/dl) / (2) 0.925±0.300 
Serum Prealbumin (mg/dl) / (2) 25.8±2.1 
Serum Transferrin (mg/dl) / (3) 252.7±51.7 
Serum Ferritin (ng/ml) / (3) 84.7±80.3 
Serum Total Cholesterol (mg/dl) / (3) 157.3±18.7 
Serum LDL Cholesterol (mg/dl) / (3) 71.0±9.6 
Serum HDL Cholesterol (mg/dl) / (3) 62.0±7.5 
Serum Triglycerides (mg/dl) / (3) 122.0±41.9 
Plasma Renin (ng/ml/hr) / (2) 31.55±18.90 
Plasma Aldosterone (pg/ml) / (2) 376.0±4.2 
Serum CO2 (mEq/L) / (3) 22.7±6.1 
Serum LDH (IU/l) / (3) 438.7±39.6 
Serum Sodium (mmol/l) / (3) 141.3±2.5 
Serum Potassium (mmol/l) / (3) 4.7±0.3 
Serum Magnesium (mg/dl) / (3) 2.1±0.3 
Serum Calcium (mg/dl) / (3) 9.4±0.3 
Serum Phosphorus (mg/dl) / (3) 3.90± 0.06 
Serum Alkaline Phosphatase (IU/l) / (3) 112.3±36.5 
Serum Iron (μg/dl) / (3) 70±42 
Serum TIBC (μg/dl) / (3) 320.7±65.5 
Serum intact PTH (pg/ml) / (3) 166.8±60.8 
Serum 25(OH)D (ng/ml) / (3) 31.4±4.8 
Serum 1,25(OH)2D (pg/ml) / (2) 23.0±1.4 
Serum Vitamin B12 (pg/ml) / (2) 504.0±11.3 
Serum Folic Acid (ng/ml) / (2) 6.1±2.1 
Serum TSH (μIU/ml) / (3) 2.7±1.3 
Serum Free T3 (pg/ml) / (3) 3.3±0.5 
Serum Free T4 (ng/dl) / (3) 1±0 
SerumVitamin E (mg/l) / (2) 0.685±0.200 
SerumVitamin E (μg/ml) / (2) 17.8±7.4 
Plasma PCSK9 (ng/ml) / (3) 341.0±105.9 
Plasma CXCL16 (ng/ml) / (3) 5.27±0.60 
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Urinalysis parameters of non diabetic CKD patients (with biomarkers) 
 
Laboratory Parameters / (n. of patients) Non diabetic CKD control 
Total patients n (%) 3 (100) 
Creatinine Clearance (ml/min) / (3) 19.3±5.9 
Diuresis (ml/24h) / (3) 2866.1±950.4 
Total Proteinuria (mg/24h) / (3) 2318 (1577, 3537) 
Glycosuria (mg/dl) / (3) 0 
Spot Proteinuria (mg/dl) / (3) 61.0 (52.5,112.5) 
UPCR (mg/g) / (3) 2006.5 (1567.4, 6193.2) 
Total Microalbuminuria (mg/24h) / (3) 154.7 (25.0, 326.1) 
UACR (mg/g) / (3) 95.4 (18.0, 273.7) 
Spot  Creatinuria (mg/dl) / (3) 28.4±11.7 
Urinary Sodium (mmol/L) / (3) 73.7±25.1 
Urinary Potassium  (mmol/L) / (3) 18.7±11.0 
Urinary Magnesium (mg/dl) / (3) 2.4±1.0 
Urinary Magnesium (mg/24h) / (3) 63.9±20.1 
Urinary Magnesium (mg/g Cr.) / (3) 0.085±0.010 
FEMg (%)/ (3) 17.0±7.2 
Urinary Calcium (mg/dl) / (3) 3.1±1.2 
Phosphaturia (mg/dl) / (3) 21.7±6.6 
Phosphaturia (mg/24h) / (3) 526.0 (474.7, 698.1) 
Phosphaturia (mg/mg Cr.) / (3) 0.796±0.100 
 
Distribution of UACR among the non diabetic CKD patients (with biomarkers) 
 
Non diabetic CKD control group  
UACR (mg/g) 
Number of patients (%) 
<30 0 
30-299 0 
300-1000 2 (66.7%) 
>1000 1 (33.3%) 
Total 3 (100) 
 
Echocardiograms of non diabetic CKD patients (with biomarkers) 
 
Variable  Value 
Total number of patients  n (%) 3 (100) 
Ejection Fraction (%)  60±0 
Left Ventricular Diameter (mm) 44.3±5.0 
Interventricular septum (mm) 11.2±1.0 
Left Ventricular Hypertrophy n (%) 2 (66.7) 
Alterered Relaxation n (%) 3 (100) 
Cardiomyopathy n (%) 0 
Valvular Calcification n (%) 1 (33.3) 
Pericardial Effusion n (%) 0 
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